Evaluation of GPR55 and GPR120 as novel therapeutic targets for the treatment of type 2 diabetes by Mc Closkey, Andrew
 Evaluation of GPR55 and GPR120 as 
novel therapeutic targets for the 
treatment of type 2 diabetes 
 
A thesis presented for the degree of 
Doctor of Philosophy 
in the 
School of Biomedical Sciences 
Faculty of Life & Health Sciences 
 
 
 
Andrew Gerard McCloskey, BSc (Hons). 
May 2019 
 
(I can confirm the word count for this thesis is less than 100,000 words) 
ii 
 
Contents 
 
Acknowledgments 
Summary 
Abbreviations  
Declaration  
Publications arising from Thesis 
 
Chapter 1: General Introduction 
1.1: Pancreas 
1.1.1: Insulin 
1.1.2: Glucagon 
1.1.3: Somatostatin 
1.1.4: Pancreatic polypeptide 
1.2: Gastrointestinal hormones 
1.2.1: Glucagon-like peptide 1 (GLP-1) 
1.2.2: Glucose-dependent insulinotropic polypeptide (GIP)  
1.2.3: Peptide YY (PYY)  
1.2.4: Cholecystokinin (CCK) 
1.2.5: Oxyntomodulin (OXM) 
1.3 Diabetes mellitus 
 1.3.1: Type 1 diabetes 
1.3.2: Gestational diabetes 
1.3.3: Type 2 diabetes 
1.3.3.1: Pancreatic beta cell dysfunction 
xv 
xvi 
xvii 
xxiii 
xxiv 
 
1 
2 
2 
4 
4 
5 
6 
6 
7 
8 
8 
9 
9 
11 
12 
13 
14 
iii 
 
1.3.3.2: Insulin resistance 
1.4: Current therapies for type 2 diabetes 
1.4.1: Alpha-glucosidase inhibitors 
1.4.2: Biguanides 
1.4.3: Sulphonylureas 
1.4.4: Meglitinides: 
1.4.5: Thiazolidinediones 
1.4.6: Sodium glucose co-transport 2 inhibitors 
1.4.7: Incretin mimetics 
1.4.8: DPP-IV inhibitors 
1.4.9: Combinational therapies 
 1.5: G-protein coupled receptors (GPCRs) 
  1.5.1: GPCR classifications 
  1.5.2 GPCR structure and signalling cascades 
1.5.3: GPCRs involved in energy homeostasis 
1.5.4: GLP-1 receptor 
1.5.5: GIP receptor 
1.5.6: Glucagon receptor 
1.5.7: Neuropeptide Y receptors 
1.6: Cannabinoid receptors 
1.6.1: CB1 receptor 
1.6.2: CB2 receptor 
1.6.3: GPR18 and GPR119 
1.6.4: GPR55 
 1.7: Free fatty acid receptors 
1.7.1: GPR40 
15 
16 
16 
17 
17 
18 
18 
19 
19 
20 
21 
22 
22 
24 
27 
27 
28 
29 
29 
30 
31 
31 
32 
33 
34 
34 
iv 
 
1.7.2: GPR41 
1.7.3: GPR43 
1.7.4: GPR120 
 1.8: Aims and objectives 
 
Chapter 2: Materials and Methods 
 2.1: Tissue Culture 
  2.1.1: Materials 
2.1.2: Culture of clonal BRIN-BD11 cells 
2.1.3: Culture of human 1.1B4 cells 
2.1.4: Culture of α-TC1.9 cells 
2.1.5: Acute insulin secretory tests in BRIN-BD11 and 1.1B4 
cells  
2.1.6: 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay 
2.2: Insulin Radioimmunoassay (RIA) 
2.2.1: Materials 
2.2.2: Preparation of iodinated insulin   
2.2.3: Determination of insulin by radioimmunoassay 
 2.3: Intracellular Ca2+ measurement 
  2.3.1: Materials 
2.3.2: Determination of intracellular Ca2+ in BRIN-BD11 cells 
 2.4: Cyclic AMP assay 
2.4.1: Materials 
2.4.2: Measurement of cAMP production in BRIN-BD11 cells 
35 
36 
36 
37 
 
45 
46 
46 
46 
47 
48 
 
49 
 
50 
50 
50 
51 
52 
53 
53 
53 
54 
54 
54 
 
  cells 
v 
 
2.5: Determination of BRIN-BD11 cell proliferation and apoptosis 
upon GPCR agonist treatment. 
2.5.1: Materials 
2.5.2 Measurement of cell proliferation and apoptosis 
2.6: Determination of mRNA expression in BRIN-BD11 cells and 
Swiss TO mouse pancreas 
 2.6.1: Materials 
2.6.2: mRNA extraction and conversion to cDNA 
2.6.3: Quantitative real-time PCR (qPCR) 
2.7: Protein expression in BRIN-BD11 cells using western blotting 
2.8: Histology 
2.8.1: Materials 
2.8.2: Immunofluorescence staining of BRIN-BD11 cells 
2.8.3: Tissue processing and immunofluorescence staining of 
pancreatic tissue 
2.9: Animal models 
2.9.1: Swiss TO mice 
2.9.2: Diet induced diabetic mice 
2.10: Acute in-vivo glucose tolerance tests 
2.10.1: Materials 
2.10.2: Glucose tolerance tests 
2.11: Chronic biological effects of ALA and Abn-CBD in high fat fed 
induced diabetic mice 
2.11.1: Materials  
2.11.2: Treatment procedure and parameters assessed 
2.11.3: Insulin sensitivity 
 
56 
56 
56 
 
57 
57 
57 
58 
59 
59 
59 
60 
 
60 
61 
62 
62 
62 
62 
63 
 
63 
63 
64 
64 
vi 
 
2.11.4: Dual energy X-ray absorption (DEXA) 
2.11.4: Measurement of plasma hormones and biomarkers 
2.11.5: Assessment of plasma lipid profiles 
2.11.6: Tissue extraction and immunofluorescence staining 
2.11.7: Pancreatic insulin content 
2.11.8: Measurement of Amylase activity 
2.12: DPP-IV assay 
2.12.1: Materials 
2.12.2: Measurement of plasma DPP-IV activity 
2.13: Enzyme-linked immunosorbent assay (ELISA) 
2.13.1: Materials 
2.13.2: Measurement of GLP-1 
2.13.3: Measurement of GIP 
2.13.4 Measurement of C-Reactive Protein 
2.14: Statistics 
 
Chapter 3: Evaluation of the effects of GPR120 activation on insulin 
secretion and islet cell function in-vitro 
3.1: Summary 
3.2: Introduction 
3.3: Materials and methods 
3.3.1: Materials 
3.3.2: Acute insulin secretion studies from pancreatic BRIN-
BD11 cells 
3.3.3: Determination of GPR120 mRNA expression in 
pancreatic BRIN-BD11 cells 
64 
65 
66 
66 
66 
67 
67 
67 
68 
69 
69 
69 
70 
71 
72 
 
 
84 
85 
86 
90 
90 
 
90 
 
91 
  BD11 cells 
vii 
 
3.3.4: Immunofluorescence staining of BRIN-BD11 cells 
3.3.5: Determination of cAMP production in pancreatic BRIN-
BD11 cells 
3.3.6: MAPK signalling and GPR120 expression analysis by 
western blotting in pancreatic BRIN-BD11 cells 
3.3.7: ERK1/2 signalling analysis by flow cytometry in 
pancreatic BRIN-BD11 cells 
3.3.8: Cellular viability and apoptosis studies on pancreatic 
BRIN-BD11 and α-TC1.9 cells 
3.4: Results 
3.4.1: Effect of GPR120 agonists on insulin secretion from 
clonal pancreatic BRIN-BD11 cells 
3.4.2: Effect of GPR120 agonists on insulin secretion from 
clonal human pancreatic 1.1B4 cells 
3.4.3: Effect of GPR120 antagonist (AH7614) and GPR40 
antagonist (GW1100) on Compound A and GSK137647 
induced insulin secretion from clonal pancreatic BRIN-BD11 
cells 
3.4.4: Expression and distribution of GPR120 and insulin in 
clonal pancreatic BRIN-BD11 cells 
3.4.5: Effects of GW9508, ALA, Compound A and 
GSK137647 on GPR120 expression in clonal pancreatic 
BRIN-BD11 cells 
3.4.6: Effect of GPR120 agonists on cAMP production and 
intracellular Ca2+ modulated insulin secretion from clonal 
pancreatic BRIN-BD11 cells 
91 
 
91 
 
92 
 
92 
 
93 
93 
 
93 
 
95 
 
 
 
96 
 
97 
 
 
97 
 
 
98 
viii 
 
 
3.4.7: Effect of GSK137647, GW9508, ALA and PMA on 
ERK1/2 (p44/42) signalling in clonal pancreatic BRIN-BD11 
cells 
3.4.8: Effect of GSK137647 on JNK, p38 and ERK1/2 MAPK 
signalling in clonal pancreatic BRIN-BD11 cells 
3.4.9: Effect of GW9508, ALA and GSK137647 on clonal 
pancreatic BRIN-BD11 cell viability and apoptosis 
3.4.10: Effect of GW9508, ALA and GSK137647 on clonal 
pancreatic α-TC1.9 cell viability and apoptosis 
3.5: Discussion 
 
Chapter 4: Investigating the effects of GPR55 on insulin secretion, 
downstream receptor signalling and islet cell regeneration in-vitro 
4.1: Summary 
4.2: Introduction 
4.3: Materials and methods 
4.3.1: Materials 
4.3.2: Acute insulin secretion studies from pancreatic BRIN-
BD11 cells 
4.3.3: Determination of GPR55 mRNA expression in 
pancreatic BRIN-BD11 cells 
4.3.4: Immunofluorescence staining of BRIN-BD11 cells 
4.3.5: Determination of cAMP production in pancreatic BRIN-
BD11 cells 
4.3.6: Intracellular Ca2+ measurement 
 
 
 
99 
 
99 
 
100 
 
100 
101 
 
 
135 
136 
137 
141 
141 
 
141 
 
141 
142 
 
142 
142 
ix 
 
 
4.3.7: MAPK signalling and GPR55 expression analysis by 
western blotting in pancreatic BRIN-BD11 cells 
4.3.8: ERK1/2 signalling analysis by flow cytometry in 
pancreatic BRIN-BD11 cells 
4.3.9: Cellular viability and apoptosis studies on pancreatic 
BRIN-BD11 cells and α-TC1.9 cells 
4.4: Results 
4.4.1: Effect of GPR55 agonists on insulin secretion from 
clonal pancreatic BRIN-BD11 cells 
4.4.2: Effect of GPR55 agonists on insulin secretion from 
clonal human pancreatic 1.1B4 cells 
4.4.3: Expression and distribution of GPR55 and insulin in 
clonal pancreatic BRIN-BD11 cells 
4.4.4: Effects of Abn-CBD and AM251 on GPR55 and insulin 
expression in clonal pancreatic BRIN-BD11 cells 
4.4.5: Effect of GPR55 agonists on intracellular Ca2+ and 
cAMP modulation in clonal pancreatic BRIN-BD11 cells 
4.4.6: Effect of Abn-CBD, AM251, OEA and PMA on 
ERK1/2 (p44/42) signalling in clonal pancreatic BRIN-BD11 
cells 
4.4.7: Effect of Abn-CBD on JNK, p38 and ERK1/2 MAPK 
signalling in clonal pancreatic BRIN-BD11 cells 
4.4.8: Effect of Abn-CBD, AM251 and O-1602 on clonal 
pancreatic BRIN-BD11 cell viability and apoptosis 
 
 
143 
 
143 
 
144 
145 
 
145 
 
146 
 
147 
 
148 
 
148 
 
 
149 
 
149 
 
150 
 
x 
 
3.4.9: Effect of Abn-CBD, AM251 and O-1602 on clonal 
pancreatic α-TC1.9 cell viability and apoptosis 
4.5: Discussion 
 
Chapter 5: Determining the specificity and pharmacological role of 
putative GPR55 and GPR120 agonists in islets using innovative 
CRISPR/Cas9 gene editing 
5.1: Summary 
5.2: Introduction 
5.3: Materials and methods 
5.3.1: Materials 
5.3.2: Constructs  
5.3.3: Dual-luciferase assay 
5.3.4: Construct transfection and FACS sorting 
5.3.5: Sequencing and determination of GPR55/GPR120 
knockout 
5.3.6: Insulin secretion from BRIN-BD11 cells 
5.3.7: Determination of cAMP production in pancreatic BRIN-
BD11 cells 
5.3.8: Intracellular Ca2+ measurement 
5.3.9: Gene expression analysis by qPCR 
5.3.10: Protein expression using western blotting 
5.4: Results 
5.4.1: Development of a GPR55 null BRIN-BD11 cell line 
using CRISPR/Cas9 gene editing 
 
150 
151 
 
 
 
179 
180 
181 
185 
185 
185 
186 
186 
 
187 
187 
 
188 
188 
188 
189 
190 
 
190 
 
  knockout 
xi 
 
5.4.2: Effects of GPR55 agonists on insulin secretion from 
wild type and GPR55 knockout BRIN-BD11 cells 
5.4.3: Effects of GPR55 agonists on intracellular Ca2+ and 
cAMP in wild type and GPR55 knockout BRIN-BD11 cells 
5.4.4: Effects of GPR55 agonists on insulin mRNA expression 
in wild type and GPR55 knockout BRIN-BD11 cells 
5.4.5: Development of GPR120 null BRIN-BD11 clonal cell 
lines using CRISPR/Cas9 gene editing 
5.4.6: Effects of GPR120 agonists on insulin secretion from 
wild type and GPR120 knockout BRIN-BD11 cells 
5.4.7: Effects of GPR120 agonists on intracellular Ca2+ in wild 
type and GPR120 knockout BRIN-BD11 cells 
5.5: Discussion 
 
Chapter 6: Investigating the metabolic actions of GPR120 agonist 
monotherapy and combinational therapy (Sitagliptin) on glycaemic 
control and lipid homeostasis in-vivo 
6.1: Summary 
6.2: Introduction 
6.3: Materials and methods 
6.4 Results 
6.4.1: Effect of a high fat fed diet for 4 months on glucose 
tolerance in Swiss TO mice 
6.4.2: Acute effect of GPR120 agonist monotherapy and 
combinational therapy (Sitagliptin) on glucose tolerance and 
insulin secretion in high fat fed diabetic mice 
 
191 
 
192 
 
192 
 
193 
 
194 
 
195 
195 
 
 
 
223 
224 
225 
229 
229 
 
229 
 
 
230 
xii 
 
6.4.3: Acute effect of GPR120 agonist monotherapy and 
combinational therapy (Sitagliptin) on incretin secretion and 
DPP-IV activity in high fat fed diabetic mice 
6.4.4: Chronic effect of once daily oral administration of ALA 
monotherapy and combinational therapy (Sitagliptin) on body 
weight, non-fasting plasma glucose, insulin, pancreatic insulin 
content, circulating incretin concentrations, DPP-IV activity 
and food intake 
6.4.5: Chronic effect of once daily oral administration of ALA 
monotherapy and combinational therapy (Sitagliptin) on 
glucose tolerance and insulin sensitivity 
6.4.6: Chronic effect of once daily oral administration of ALA 
monotherapy and combinational therapy (Sitagliptin) on 
DEXA measurements, lipid profile, plasma C-reactive protein 
and amylase activity 
6.4.7: Chronic effect of once daily oral administration of ALA 
monotherapy and combinational therapy (Sitagliptin) on islet 
morphology 
6.5: Discussion 
 
Chapter 7: Assessing the therapeutic actions of GPR55 agonist 
monotherapy and combinational therapy (Sitagliptin) on glucose 
intolerance, dyslipidaemia and bodyweight control in-vivo 
7.1: Summary 
7.2: Introduction 
7.3: Materials and methods 
 
 
231 
 
 
 
 
231 
 
 
233 
 
 
 
233 
 
 
235 
236 
 
 
 
274 
275 
276 
280 
xiii 
 
7.4: Results 
7.4.1: Effect of four-month high fat fed diet on glucose 
tolerance in Swiss TO mice 
7.4.2: Acute effect of GPR55 agonist monotherapy and 
combinational therapy (Sitagliptin) on glucose tolerance and 
insulin secretion in high fat fed mice 
7.4.3: Acute effect of GPR55 agonist monotherapy and 
combinational therapy (Sitagliptin) on incretin secretion and 
DPP-IV activity in high fat fed mice 
7.4.4: Chronic effect of once daily oral administration of Abn-
CBD monotherapy and combinational therapy (Sitagliptin) on 
body weight, non-fasting plasma glucose, insulin, pancreatic 
inulin content, circulating incretin concentrations, DPP-IV 
activity and food intake 
7.4.5: Chronic effect of once daily oral administration of Abn-
CBD monotherapy and combinational therapy (Sitagliptin) on 
glucose tolerance and insulin sensitivity 
7.4.6: Chronic effect of once daily oral administration of Abn-
CBD monotherapy and combinational therapy (Sitagliptin) on 
DEXA measurements, lipid profile, plasma C-reactive protein 
and amylase activity 
7.4.7: Chronic effect of once daily oral administration of Abn-
CBD monotherapy and combinational therapy (Sitagliptin) on 
islet morphology 
7.5: Discussion 
 
280 
 
280 
 
 
281 
 
 
281 
 
 
 
 
282 
 
 
283 
 
 
 
284 
 
 
285 
286 
 
xiv 
 
Chapter 8: General Discussion 
8.1: Limitations of current anti-diabetic therapeutics 
8.2: GPCR targeting therapeutics 
8.3: Activation of GPR120 in pancreatic islets 
8.4: Activation of GPR55 in pancreatic islets 
8.5: Specificity of putative GPR120 and GPR55 agonists in islets 
8.6: Biological effect of GPR55/GPR120 agonist monotherapy and 
combinational therapy 
8.7: Future studies 
 
Chapter 9: References 
320 
321 
322 
324 
326 
328 
 
330 
332 
 
336 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
Acknowledgments 
 
Firstly, I would like to express my sincere gratitude to my PhD supervisor Prof. Aine 
McKillop for her invaluable advice, guidance and continued support throughout my 
studies. I would like to thank Prof. Peter Flatt for his scientific advice and insightful 
recommendations during my research. 
I would like to thank all past and present members of the Diabetes Research Group for 
their support and friendship during my PhD. Thanks to Michael, Chris, Ryan, Shruti and 
Neil for being great friends and for making my time at Ulster University most enjoyable.   
I would also like to thank all my family and friends, especially my parents and brothers 
for their never-ending support. Finally, special thanks to Kate for her help, enthusiasm 
and constant encouragement throughout my PhD. 
 
 
 
 
 
 
 
 
 
xvi 
 
Summary 
G-protein coupled receptors (GPCRs) are expressed in the gut-brain-pancreatic axis and 
regulate energy metabolism through a range of cellular responses, including hormone 
release, cell proliferation, neurological signalling and immune responses. Novel therapies 
that maintain glucose homeostasis and enhance islet cell proliferation are required with 
research focusing on cannabinoid and free fatty acid receptors. This research study aims 
to evaluate the therapeutic potential of two GPCRs, namely GPR55 and GPR120.   
BRIN-BD11 cells were used to assess the effects of endogenous and synthetic GPR55 
and GPR120 agonists on insulin release, cell proliferation and cytotoxicity, followed by 
GPCR expression and intracellular signalling analysis. CRISPR/Cas9 gene editing was 
utilised to assess agonist specificity. Metabolic effects of GPCR agonist therapies in-vivo 
were explored in high fat fed (HFF) induced diabetic mice. GPR55 and GPR120 
activation exhibited insulinotropic and proliferative effects on pancreatic BRIN-BD11 
cells, with modulations in intracellular Ca2+ and MAPK signalling. Assessment of agonist 
specificity using knockout beta cell lines developed by CRISPR/Cas9 revealed that ALA 
(GPR120) and Abn-CBD (GPR55) were the most potent selective agonists. Expression 
and localisation of GPR55 and GPR120 were demonstrated in clonal beta cells and 
murine islets with areas of co-localisation observed with insulin. Orally administered 
GPR55/GPR120 agonists improved glucose tolerance and circulating insulin, GLP-1 and 
GIP in HFF mice, with further improvements in combination with DPP-IV inhibitor 
(Sitagliptin). Long term administration of ALA and Abn-CBD based therapies improved 
glycaemic control, bodyweight, insulin sensitivity and enhanced islet cell regeneration. 
Biochemical analysis revealed improvements towards circulating insulin, dyslipidaemia 
and CVD risk markers. Collectively, this study highlights GPR55 and GPR120 as novel 
therapeutic targets for the treatment of diabetes and obesity related diseases.     
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Chapter 1 
 
General Introduction 
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1.1: Pancreas 
 
The pancreas is a vital organ of gastrointestinal system that is located behind the stomach 
in the abdominal cavity and is composed of both endocrine and exocrine tissue (Bertelli 
& Bendayan 2005). The functionality of the pancreas includes the regulation of food 
digestion and energy metabolism (Roder et al. 2016). The exocrine pancreas releases 
digestive enzymes and pancreatic juice that facilitates the breakdown and absorption of 
nutrients in the gastrointestinal tract (Roder et al. 2016). Pancreatic juice contains 
bicarbonates which can neutralise the acidity of chyme, whilst the secretion of digestive 
enzymes can help breakdown proteins, lipids and carbohydrates (Lee & Kim 2000). 
The endocrine pancreas comprises 1-2% of total pancreatic mass and is referred to as the 
‘islets of Langerhans’ (Steiner et al. 2010).  Islets are arranged in small clusters and are 
comprised of 5 different cell types; insulin producing beta cells, glucagon secreting alpha 
cells, pancreatic polypeptide secreting PP cells, somatostatin secreting delta cells and 
ghrelin secreting epsilon cells (Steiner et al. 2010).  
 
1.1.1: Insulin 
Insulin is a peptide hormone that is produced, stored and secreted from the beta cells of 
the endocrine pancreas (Steiner et al. 2010). Insulin is released in response to hormones, 
glucose, neurotransmitters and other nutrients (Gerber & Rutter 2017). Upon release, 
insulin regulates the metabolism of glucose, complex carbohydrates, fats and proteins, 
whilst promoting the absorption of glucose from the circulatory system to peripheral 
tissues (i.e. muscle, adipose) (Gerber & Rutter 2017). Upon insulin signalling in 
peripheral tissues, glucose is absorbed then converted to glycogen and/or triglycerides via 
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glycogenesis and lipogenesis, respectively. Subsequently, insulin is considered the 
primary anabolic hormone of the body (Otero et al. 2014).  
Insulin is a 51 amino acid polypeptide that is synthesised within the ribosomes of the 
endoplasmic reticulum (ER) (Vargas & Sepulveda 2018). Insulin begins synthesis as a 
large biologically inactive precursor, known as preproinsulin, which is cleaved to form 
proinsulin within the ER, then transported to the Golgi apparatus (Vargas & Sepulveda 
2018). Prohormone convertase 1/3 (PC1/3) and prohormone convertase 2 (PC2) further 
cleave proinsulin into equal concentrations of both C-peptide and the biologically active 
insulin (Hoshino et al. 2011). Insulin is then densely stored in granules within pancreatic 
beta cells, prior to the stimulation of insulin release (Rorsman & Renstrom 2003). 
The release of insulin from pancreatic beta cells is primarily driven by circulating glucose 
concentrations (MacDonald et al. 2005). Glucose stimulated insulin secretion (GSIS) 
begins with the absorption of glucose into the pancreatic beta cell by glucose transporter 
2 (GLUT2) (MacDonald et al. 2005). During the anabolic glycolysis of glucose within 
the beta cells via the Schiff pathway, the ATP:ADP ratio is increased. Subsequently, 
potassium ATP (KATP) channels are closed within the cell resulting in cellular 
depolarisation (MacDonald et al. 2005). In response, voltage dependent Ca2+ channels 
are opened to re-polarise the cell, which results in insulin exocytosis from intracellular 
insulin storage granules through Ca2+ specific protein signalling (MacDonald et al. 2005).  
Circulating insulin secreted from the pancreas facilitates the absorption of glucose in 
peripheral tissues by binding to the insulin receptor which mediates the translocation of 
glucose transporter 4 (GLUT4), thus enabling glucose to enter the cell (Brewer et al. 
2014)   
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1.1.2: Glucagon 
Glucagon is 29 amino acid peptide hormone that is secreted from the alpha cells of the 
endocrine pancreas (Wewer-Albrechtsen et al. 2016). Alpha cells comprise 15-20% of 
islet mass and augment glucagon secretion in response to hypoglycaemic blood glucose 
concentrations (Baetens et al. 1979, Briant et al. 2017). Upon secretion, glucagon 
stimulates glycogenesis and gluconeogenesis in the liver, whilst also reducing lipogenesis 
and triglyceride production (Kalra & Gupta 2016). Glucagon is synthesised from a large 
precursor peptide called proglucagon (Dhanvantari et al. 1996). Proglucagon is 
differentially cleaved within various cell types to produce a diverse range of bioactive 
hormones (GLP-1, GLP-2, glicentin, oxyntomodulin, glucagon) (Dhanvantari et al. 
1996). Within the pancreatic alpha cell, proglucagon is cleaved by PC2 to form glucagon. 
Secretion of glucagon from alpha cells is mediated by voltage dependent Ca2+ channels, 
which augment glucagon exocytosis in response to low circulating glucose concentrations 
(Dhanvantari et al. 1996, Briant et al. 2016).  
 
1.1.3: Somatostatin 
Also known as growth hormone-inhibiting hormone (GHIH), somatostatin is secreted by 
the delta cells of the endocrine pancreas (Steiner et al. 2010). Upon secretion, 
somatostatin is a paracrine inhibitor of insulin, glucagon and PP secretion from pancreatic 
islet cells (Strowski et al. 2000, Henquin et al. 2017). The release of somatostatin from 
the pancreatic islet is triggered by hyperglycaemic glucose concentrations (Ribes et al. 
1987). In a similar manner to insulin release from beta cells, high glucose concentrations 
increase the ATP:ADP ratio and augments exocytotic somatostatin release by increasing 
intracellular Ca2+ concentrations (Gopel et al. 2000). Somatostatin regulates islet cell 
function through  six different specific somatostatin receptors (sstr), sstr1, sstr2A, sstr2B, 
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sstr3, sstr4, and sstr5 on the beta, alpha and PP cells, whilst the expression of somatostatin 
receptor is downregulated in type 2 diabetic islets (Portela-Gomes et al. 2010, Henquin 
et al. 2017). GPR120 activation was previously shown to inhibit somatostatin secretion 
from pancreatic delta cells (Stone et al. 2014). Aside from the inhibitory effects of 
somatostatin towards pancreatic hormone release, somatostatin also decreases the rate of 
gastric emptying, reduces intestinal motility and supresses the release of other 
gastrointestinal hormones, including gastrin, cholecystokinin (CCK), secretin, motilin 
and vasoactive intestinal peptide (VIP) (Krejs 1986, ElSayed & Bhimji 2018).  
 
1.1.4: Pancreatic polypeptide 
Pancreatic polypeptide (PP) is a 36 amino acid peptide that is secreted from islet PP cells, 
which account for approximately 2% of total islet cells and are primarily located at the 
head of the pancreas (Steiner et al. 2010). PP belongs to a family of peptides including 
neuropeptide Y (NPY) and peptide YY (PYY) (Holzer et al. 2013). PP is released 
postprandial and remains elevated for several hours in humans (Koska et al. 2004). 
Studies have revealed that PP reduces food intake, intestinal motility and decreases 
exocrine secretions (Koska et al. 2004, Schmidt et al. 2005). Interestingly, PP responses 
are blunted in obese children with Prader-Willi syndrome (Zipf et al. 1981). Moreover, 
circulating PP concentrations are greatly reduced in in both rodents and humans with 
obesity, whilst abnormal circulating concentrations are also associated with eating 
disorders (Reinehr et al. 2006, Yulyaningish et al. 2014). PP secretion is almost entirely 
dependent on the PP cells of the islet and is released via the Ca2+ and KATP channels (Liu 
et al. 1999).  
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1.2: Gastrointestinal hormones 
 
The gastrointestinal hormones are comprised by a group of hormones that are secreted by 
the enteroendocrine cells of the stomach and small intestine and purpose to regulate food 
digestion and energy homeostasis (Rehfeld 2014). Moreover, studies have also 
demonstrated that gut hormones such as secretin substance P and cholecystokinin can act 
as neuromodulators in both the central nervous system (CNS) and peripheral nervous 
system (PNS) (Wank et al. 1992, Madva & Granstein 2013). Several gut hormones are 
known to play a pivotal role in the maintenance of glucose homeostasis, including 
glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), 
peptide YY (PYY), oxyntomodulin (OXM), pancreatic polypeptide (PP) and ghrelin 
(Drucker 2007).    
 
1.2.1: Glucagon-like peptide 1 (GLP-1) 
Glucagon-like peptide 1 (GLP-1) is a gastrointestinal hormone secreted from the 
enteroendocrine L-cells of the duodenum and ileum (Sun et al. 2017). GLP-1 synthesised 
is derived from the proglucagon peptide that undergoes tissue specific posttranslational 
processing (Sandoval & D’Alessio 2015). The full-length product, produced by the L-
cells, is GLP-1 (1-37) that is highly susceptible to proteolytic cleavage and amination 
which results in the formation of two truncated yet bioactive peptides; GLP-1 (7-36) and 
GLP-1 (7-37) (Deacon 2004). The shorter bioactive forms of GLP-1 have potent 
insulinotropic properties in response to glucose (Deacon 2004). In addition, GLP-1 
inhibits glucose release, decreases food intake and delays gastric emptying (Gutzwiller et 
al. 1999).  The bioactive forms of GLP-1 play a key role in pancreatic beta cell function 
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and modulate insulin release through the adenylate cyclase pathway increasing cAMP 
through the phosphorylation of protein kinase A (PKA) (Leech et al. 2011). Moreover, 
GLP-1 increases beta cell mass and increases insulin synthesis whilst inducing 
cytoprotective effects towards beta cells (Vilsboll 2009, Vasu et al. 2014). Although the 
active forms of GLP-1 play a key role in pancreatic function, they are readily degraded 
by dipeptidyl peptidase IV (DPP-IV) to the biologically inactive GLP-1 (9-36) and GLP-
1 (9-37), which are subsequently excreted by the kidneys (Deacon 2004).   
 
1.2.2: Glucose-dependent insulinotropic polypeptide (GIP) 
Glucose-dependent insulinotropic polypeptide (GIP) is a 42 amino acid peptide that is 
secreted by the enteroendocrine K-cells of the jejunum and duodenum (Deacon 2004). 
The biologically active form of GIP (1-42) is derived from a 153 amino acid precursor 
proprotein encoded by the GIP gene (Inagaki et al. 1989). PC1/3 cleaves GIP proprotein 
within the endocrine K-cells to form the bioactive GIP molecule (Ugleholdt et al. 2006). 
Like GLP-1, GIP is also an incretin hormone and enhances GSIS within the pancreatic 
islet (Gault et al. 2003, Rehfeld 2014). In addition, GIP has been shown to play a role in 
islet cell regeneration through the reduction of beta cell apoptosis and the promotion of 
beta cell proliferation (Vasu et al. 2014). Similar to GLP-1, GIP also modulates insulin 
release through the adenylyl cyclase and cAMP pathway (McIntosh et al. 2012). Aside 
from effects towards insulin release, GIP is also a weak inhibitor of gastric acid secretin 
and has only minor effects on gastric emptying (Meier et al. 2006). The active form of 
GIP (1-42) is readily cleaved at the alanine residue at position two by DPP-IV to form the 
truncated and biologically inactive isoform GIP (3-42) (Deacon 2004).    
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1.2.3: Peptide YY (PYY) 
Peptide YY (PYY) is a short 36 amino acid peptide that is secreted by the L-cells of the 
colon and ileum postprandial (Ballantyne 2006).  The primary physiological function of 
PYY is to attenuate appetite and reduce food intake (Ballantyne 2006). The circulating 
concentration of PYY increases after food intake and lowers when fasting. There are two 
isoforms of PYY; PYY (1-36) and PYY (3-36). PYY (1-36) is directly secreted from the 
enteroendocrine cells of the gut then cleaved to form PYY (3-36) by DPP-IV (Batterham 
& Bloom 2003). Interestingly, the shorter isoform PYY (3-36) is the most biologically 
active form of PYY and activates the Y2 receptor to induce appetite suppression (Hung 
et al. 2004). In addition, PYY demonstrates effects in pancreatic beta cells within the 
endocrine pancreas (Lafferty et al. 2018). Although, PYY has no effect towards insulin 
release, it has been shown to increase beta cell proliferation and enhance beta cell mass 
(Lafferty et al. 2018). 
 
1.2.4: Cholecystokinin (CCK) 
Cholecystokinin (CCK) is a peptide hormone that is secreted from the I-cells of the gut 
and exhibits similar structure to the gastrointestinal hormone gastrin (Rehfeld et al. 2007). 
Gastrin and CCK share the same five amino acid residues at the C-terminus, however 
CCK can be composed of a various number of amino acids based on the posttranslational 
modification of the 150 amino acid CCK precursor, preprocholecystokinin (Rehfeld et al. 
2007). Resultingly, CCK can exist in several isoforms, including CCK5, CCK7, CCK8 
and CCK12 (Rehfeld 2017). In the gut, CCK has a range of physiological functions 
including satiety and digestion (Rehfeld 2017). Medium chain fatty acids are the most 
potent stimulators of CCK secretion from the mucosal lining of the small intestine, 
however, its half-life is very short when in circulation (McLaughlin et al. 1998). With 
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respect to the endocrine pancreas, CCK stimulates insulin release from pancreatic beta 
cells through the activation of phospholipase C (PLC) and protein kinase C (PKC) (Ning 
et al. 2015). 
 
1.2.5: Oxyntomodulin (OXM) 
Oxyntomodulin (OXM) is a short 37 amino acid peptide that is secreted from the 
enteroendocrine L-cells of the intestine, with synthesis deriving from the proglucagon 
precursor polypeptide (Pocai 2013). OXM is released from the gut in response to nutrient 
ingestion and is cleaved by DPP-IV for clearance (Yi et al. 2015). Although the 
mechanistic function of OXM is not fully understood, studies have shown it to bind to 
both the GLP-1 and glucagon receptors (Pocai 2013). OXM decreases body weight, 
increases energy expenditure, attenuates appetite and improves glucose tolerance in 
humans (Pocai 2013, Pathak et al. 2015). Interestingly, OXM stimulates weight loss 
beyond the capabilities of selective GLP-1 agonists (Pocai 2013).   
 
1.3 Diabetes mellitus 
 
Diabetes mellitus (DM) is a chronic metabolic disease that is associated with 
hyperglycaemic blood glucose concentrations over an extended period (Lebovitz 2001).  
Healthy, non-diabetic individuals maintain glucose homeostasis through glucose 
stimulated insulin secretion (GSIS) from the endocrine pancreas (Lebovitz 2001). Insulin 
secreted from pancreatic beta cells facilitates the absorption of circulating glucose to 
peripheral tissues (i.e. muscle and adipose tissue), thus lowering blood glucose 
concentrations (Briant et al. 2017). In diabetic patients, hyperglycaemic blood glucose 
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concentrations are a symptomatic result of pancreatic beta cell dysfunction resulting in 
insufficient insulin release and/or impaired insulin signalling in peripheral tissues, 
resulting in reduced glucose absorption (Cerf 2013).  
Common symptoms associated with diabetes include polyuria, polyphagia polydipsia, 
impaired eyesight and fatigue (Hharroubi & Darwish 2015). Moreover, various health 
complications may arise as the prognosis of the disease deteriorates. Acute complications 
most commonly linked with diabetes includes hypoglycaemia, hyperglycaemia 
hyperosmolar syndrome (HHS) and diabetic ketoacidosis (DKA) (Gosmanov et al. 2000). 
In addition, adverse chronic health complications can develop in severe circumstances, 
including chronic kidney failure, diabetic retinopathy, cardiovascular disease, stroke, 
amputations and foot ulcers (Hung et al. 2017).   
At present, diabetes is prevalent in all ethnical backgrounds and is associated with 
individuals of all ages (Zheng et al. 2018). Clinical studies have demonstrated that the 
incidence of diabetes is typically higher in African-Americans and Hispanic-Americans, 
when compared to Non-Hispanic Whites (Mercader & Florez 2017). Studies presenting 
these findings have indicated that genetic predisposition correlates with the incidence of 
the disease within ethnicities (Mercader & Florez 2017). However, studies have also 
indicated that the prevalence of diabetes in is strongly linked with dietary and lifestyle 
choices, which are typified by the consumption of high-sugar/high-fat food coupled with 
exceedingly low levels of exercise (Appuhamy et al. 2014).  
Diagnosis of a pre-diabetic individual can be identified by impaired glucose tolerance and 
impaired fasting blood glucose concentrations (Lebovitz 2001). In accordance to the 
American Diabetes Association (ADA), criteria used to diagnose the disease include a 
non-fasting blood glucose concertation >11.1 mmol/l, fasting blood glucose >7.0 mmol/l, 
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>11.1 mmol blood glucose post two-hour oral glucose tolerance test (OGTT) and >48 
mmol/l HbA1c (American Diabetes Association 2014).  
Recent figures demonstrate that diabetes is a global epidemic with 3.3 million sufferers 
diagnosed within the United Kingdom alone (Howells et al. 2016). Over the past two 
decades, data trends have documented the incidence of the disease to be increasing at an 
alarming rate, with a projection of 5 million patients with diabetes to be diagnosed within 
the United Kingdom by 2025 (Howells et al. 2016). Subsequent treatment costs cast a 
substantial financial burden towards government expenditure and the NHS (Elbich et al. 
2017). Although the onset of diabetes is not linked with one origin, factors including diet, 
exercise, genetic predisposition, general health and environmental factors greatly 
contribute (Fletcher et al. 2002).  
 
1.3.1: Type 1 diabetes 
Type 1 diabetes is characterised by hyperglycaemia and low circulating insulin 
concentrations due to auto-immune destruction of pancreatic beta cells which are 
responsible for the production and release of insulin (Paschou et al. 2018). Type 1A 
(autoimmune) and type 1B (idiopathic) are two further subdivisions of type 1 diabetes 
(Paschou et al. 2018). Type 1B diabetes involves destruction of pancreatic beta cells with 
no evidence of autoimmunity. This classification is due to genetic inheritance and is 
strongly linked associated with individuals of African and Asian descent (Paschou et al. 
2018). 
Type 1A diabetes is derived from autoimmune destruction of insulin-producing 
pancreatic beta cells (Michels & Gottlieb 2000). The onset of this disease can occur at 
any age; however, it is commonly diagnosed at early developmental stages. Globally, type 
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1 diabetes accounts for 5-10% of all diabetes (Michels & Gottlieb 2000). Two 
predominant antibodies are responsible for the autoimmune destruction of beta cells; anti-
insulin antibodies (IAA) and anti-islet cell antibodies (ICA) and are expressed in 50% 
and 70-80% of type 1A diabetic patients, respectfully (Michels & Gottlieb 2000).  
Current therapies for type 1 diabetes are limited and patients are typically required to 
frequently administer synthetic insulin to maintain glucose homeostasis (McCall & Farhy 
2013). Currently, the restoration of endocrine-pancreatic function, including the 
production of endogenous insulin in patients with type 1 diabetes requires pancreatic 
transplantation (Lerner 2008). The frequency and success rate of this method has 
improved drastically in recent years; however, the cost of the procedure and donor 
availability remain substantial limitations (Lerner 2008). 
 
1.3.2: Gestational diabetes 
Currently, gestational diabetes (GDM) is a metabolic disorder that affects 13.2% of 
pregnant woman worldwide (Melchior et al. 2017). Women that are genetically linked 
with the onset of diabetes and/or have previously experienced pregnancy complications 
are at an increased risk for the development of GDM (Melchior et al. 2017). Obesity, 
large foetal development and late-age pregnancies are factors that contribute to the 
pathophysiology of the disease, however, only 50% of pregnant woman display the 
predominant risk factors associated with GDM (Melchior et al. 2017). 
Due to the prevalence of GDM, women are typically screened for the disease at week 24 
of pregnancy for signs of impaired glucose tolerance (Rani & Begum 2016). Biochemical 
characteristics of GDM include hyperglycaemia, dyslipidaemia and hyperinsulinemia 
(Rani & Begum 2016). Following diagnosis, patients are typically treated with dietary 
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intervention rather than anti-diabetic medications (Hernandez et al. 2013). Nutritional 
plans ensure the preservation of maternal and neonatal health, whilst preventing the 
incidence of hyperglycaemia and ketosis (Hernandez et al. 2013). Patients that experience 
GDM are at a 4- to 7- fold greater risk of developing type 2 diabetes within 5-10 years 
prior diagnosis (Herath et al. 2017).       
 
1.3.3: Type 2 diabetes 
Type 2 diabetes is the most prevalent class of type of diabetes and accounts for 90-95% 
of all diabetes worldwide (American Diabetes Association 2009). Characteristics of type 
2 diabetes include hyperglycaemia, insulin resistance and increased hepatic glucose 
production (Petersen et al. 2017). Increased production of glucose from the liver 
accompanied with increased insulin resistance promotes the production of insulin form 
pancreatic beta cells (Cerf 2013). The production of insulin beyond normal physiological 
concentrations results in beta exhaustion after an extended period. Ultimately, pancreatic 
beta cell exhaustion leads to inadequate insulin production and hyperglycaemia (Cerf 
2013).  
Numerous studies have correlated prevalence of diabetes with other metabolic diseases, 
including obesity, cardiovascular disease (CVD) and kidney failure, with findings 
demonstrating 85% of patients with type 2 diabetes to be above the recommended body 
mass index (BMI) (Leon & Maddox 2015, Jerant et al. 2015). The link between diabetes 
and obesity has become an area of interest in the development of novel anti-diabetic 
therapeutics. Type 2 diabetics typically display other symptoms of metabolic syndrome 
including hypertension and dyslipidaemia, which greatly increases the risk of CVD (Leon 
& Maddox 2015).  
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Pre-diabetic and moderate cases of type 2 diabetes are commonly counteracted with 
dietary intervention and exercise (Senechal et al. 2014). However, anti-diabetic 
pharmaceuticals are often required to improve the prognosis of the disease (Rojas & 
Gomes 2013). At present, orally available biguanides are the first line of treatment, 
accompanied with dietary intervention (Rojas & Gomes 2013). In more severe 
circumstances, administration of synthetic insulin is often required, however, the 
frequency of the treatment and route of administration (parental) is undesirable for many 
patients (Swinnen et al. 2009).  
 
1.3.3.1: Pancreatic beta cell dysfunction 
Type 2 diabetes is typified by beta cell dysfunction reduced beta cell mass (Cerf 2013). 
Chronic exposure to hyperglycaemia directly affects beta cell function by impairing 
insulin synthesis and insulin secretion through the disruption of gene transcription and 
cell secretory mechanics (Cernea & Dobreanu 2013). Upon absorption into the beta cell 
via GLUT1/GLUT2, glucose undergoes anaerobic glycolysis and produces reactive 
oxygen species (ROS); a direct bi-product that impairs gene transcription at super-
physiological concentrations (Gerber & Rutter 2017). ROS and reactive nitrogen species 
(RNS) can induce DNA damage, form glycated end products and generate alternate ATP 
production in the beta cell, which can directly affect cellular insulin responses to glucose 
(Gerber & Rutter 2017). In addition, increased oxidative stress derived from 
hyperglycaemia causes increased intra-islet peroxide concentrations which overload the 
anti-oxidant capabilities of the pancreatic beta, resulting in beta cell failure (Robertson & 
Harmon 2007). Moreover, elevated intra-islet peroxide concentrations are correlated with 
defects in PDX-1 transcription; an essential factor for proinsulin processing (Robertson 
& Harmon 2007). 
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The multi-factorial process of beta cell dysfunction remains not fully understood; 
however, studies have demonstrated that increased oxidative stress, cytokines, free fatty 
acid (FFA), inflammation and cellular organelle stress play a key role in its onset (Cerf 
2013). Pro-inflammatory cytokines have been heavily linked with beta cell dysfunction 
and have been shown to potentiate defective insulin release and increase beta cell 
apoptosis, through the induction of mitochondrial stress (Nordmann et al. 2017). 
Chronic exposure to elevated circulating concentrations of FFA as a result of a high-
fat/high-sugar diet can directly disrupt the glycolysis pathway, thus impairing insulin 
biosynthesis, insulin secretion and cellular proliferation (Acosta-Montano & Garcia-
Gonzalez 2018).  Moreover, increased concentrations of exocrine and intra-islet fat 
deposits derived from FFAs can directly de-sensitise GSIS and increase islet 
inflammation and beta cell apoptosis (Murakami et al. 2017).   
 
1.3.3.2: Insulin resistance 
Insulin resistance in peripheral tissues is a predominant characteristic of type 2 diabetes, 
which results in reduced glucose absorption to peripheral tissues (muscle, adipose, liver) 
(Cerf 2013). In response to impaired glucose absorption, pancreatic beta cells produce 
additional concentrations of insulin to maintain glucose homeostasis, which can 
ultimately result in beta cell exhaustion (Cerf 2013). Circulating insulin binds to the 
insulin receptor on peripheral tissues, a tyrosine kinase receptor that stimulates an 
intracellular signalling cascade within the cell (Ijuin & Takenawa 2012). Upon activation, 
insulin receptor substrate 1 (IRS-1) is phosphorylated and mediates the translocation of 
glucose transporter 4 (GLUT4) (Ijuin & Takenawa 2012). The translocation of GLUT4 
from the cytosol to the cell surface involves the inactivation of intracellular Rab proteins, 
which function to withhold GLUT4 within the cytosol (Sano et al. 2003). Once 
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translocated to the cell membrane, GLUT4 facilitates the absorption of glucose from the 
bloodstream into the cell (Sano et al. 2003). In type 2 diabetes, the translocation of 
GLUT4 to the cell surface is reduced due to impaired insulin-receptor activation (Cerf 
2013). Although the exact pathophysiology of insulin resistance is not fully understood, 
high-fat/high-calorie diets, reduced physical activity and weight gain are correlated with 
its pathophysiology (Cerf 2013).  
 
1.4: Current therapies for type 2 diabetes 
 
Maintaining glucose homeostasis is the primary objective for all anti-diabetic 
therapeutics. The prognosis of type 2 diabetes can be improved with dietary intervention 
and lifestyle changes (Senechal et al. 2014). Studies have shown that calorie restriction 
diets and exercise can greatly improve the symptoms and onset of the disease (Senechal 
et al. 2014). However, in more severe instances, pharmaceuticals are required to maintain 
physiological glucose concentrations. At present, metformin (Glucophage) is the first line 
of treatment with diet and exercise (Rojas & Gomes 2013). Alternative types of treatment 
are then considered for non-responders or when adverse side effects are observed, 
including sulphonylureas, incretin mimetics and DPP-IV inhibitors (Figure 1.1).  
 
1.4.1: Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors are a range of oral anti-diabetic drugs that inhibit the 
digestion of complex carbohydrates and sugars into monosaccharides (Kalra 2014). 
Acarbose, Miglitol and Voglibose are approved examples of this drug classification that 
inhibit that action of the alpha-glucosidase enzymes of the small intestine, thus reducing 
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glucose elevations postprandial (Derosa & Maffioli 2012). Although considered safe, this 
drug class is not commonly prescribed for the treatment of type 2 diabetes. Common side 
effects of alpha-glucosidase inhibitors include abdominal bloating, flatulence and 
diarrhoea, whilst the risk of hypoglycaemia is also presented (Derosa & Maffioli 2012).  
 
1.4.2: Biguanides 
Biguanides including metformin (Glucophage), buphormin and phenformin are a class of 
anti-diabetic drugs that reduce hepatic glucose production, thus lowering blood glucose 
concentrations (Bailey 1992). At present, metformin is the first line of treatment for type 
2 diabetic patients accompanied with dietary intervention and exercise (Rojas & Gomes 
2013, American Diabetes Association 2014). In addition, biguanides enhance insulin 
sensitivity and lower the absorption rate of glucose, with beneficial effects also 
demonstrated towards macrovascular complications such as dyslipidaemia and CVD risk 
(Palumbo 1998). Although the exact mechanism of metformin remains elusive, the 
primary effect of this drug is to acutely decrease hepatic glucose production, 
predominately mediated through mild and transient inhibition of the mitochondrial 
respiratory-chain complex 1 (Viollet et al. 2012). Studies have demonstrated metformin 
to enhance insulin receptor activation and GLUT4 translocation in peripheral tissues (Lee 
et al. 2012). Further findings have also shown metformin to lower plasma DPP-IV activity 
and enhance exogenous GLP-1 action, thus indirectly enhancing GSIS and islet cell 
function.  
 Aside from potent antihyperglycaemic properties, metformin is also exhibits numerous 
additional beneficial effects including improvements in endothelial dysfunction, 
hemostasis and oxidative stress, insulin resistance, lipid profiles and fat redistribution 
18 
 
(Rojas & Gomes 2013). Metformin is typically prescribed as a monotherapy and omits 
the risk of hypoglycaemia (Rojas & Gomes 2013, Chaudhury et al. 2017). 
 
1.4.3: Sulphonylureas 
Sulphonylureas are a common class of anti-diabetic drug used to treat patients with 
chronic hyperglycaemia (Rendell 2004). Glipizide and Glimepiride are examples of 
sulphonylureas that target the sulphonylurea receptor (SUR) on pancreatic beta cells to 
stimulate insulin release (Rendell 2004).  Upon activation of the SUR receptor, KATP are 
closed which influences an influx of Ca2+ leading to insulin exocytosis from intracellular 
storage granules (Rendell 2004). Hypoglycaemia is the major risk factor associated with 
this class of pharmaceuticals as activation of the SUR receptor is not glucose dependent 
(Sola et al. 2015). In addition, a range of adverse side effects may also be displayed, 
including excessive weight gain, beta cell apoptosis and increased CVD risk (Sola et al. 
2015). 
 
1.4.4: Meglitinides: 
Functionally similar to sulphonylureas, meglitinides are a class of anti-diabetic drug that 
enhances insulin release from pancreatic beta cells through cellular depolarisation with 
the KATP channels (Black et al. 2007). Repaglinide (Prandin) and nateglinide (Starlix) are 
examples of meglitinides that present a decreased risk of hypoglycaemia due to a shorter 
circulating half-life of 4-6 hours (Black et al. 2007). Administration of meglitinides 
occurs pre-prandial to facilities the clearance of glucose from the bloodstream 
postprandial (Guardado-Mendoza et al. 2013). Side effects include weight gain and 
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gastrointestinal discomfort, whilst the onset of hypoglycaemia is also possible (Stein et 
al. 2013).  
 
1.4.5: Thiazolidinediones 
The glucose lowering effect of thiazolidinediones (TZDs), also known as Glitazones is 
derived from increased insulin sensitivity in peripheral tissues and decreased 
glycogenolysis in the liver (Diamant & Heine 2003). TZDs bind to the PPAR-gamma 
receptor which stimulates the activation of several genes that promote glucose uptake in 
peripheral cells, whilst reducing hepatic glucose production (Diamant & Heine 2003). 
Additional beneficial effects of this drug class include improved lipid profile and reduced 
hypertension (Barnett 2009). However, a range of adverse effects are also associated with 
TZDs, including water retention, weight gain and liver/kidney toxicity (Quinn et al. 
2008). 
 
1.4.6: Sodium glucose co-transport 2 inhibitors  
Sodium glucose co-transport 2 inhibitors (SGLT2 inhibitors) are used to treat type 2 
diabetes by reducing glucose reabsorption in the kidney (Hattersley & Thorens 2015). 
SGLT2 is highly expressed in the epithelial cells of the proximal tubule and depends on 
GLUT1/GLUT2 for glucose excretion. Inhibiting SGLT2 lowers blood glucose 
concentrations by increasing urinary glucose excretion (Hattersley & Thorens 2015). As 
this mechanism is insulin-independent, the risk of hypoglycaemia is very low (Monica-
Reddy & Inzucchi 2016). Currently, SGLT2 inhibitors such as Dapagliflozin and 
Canagliflozin are second- or third-line treatments for type 2 diabetes as other drugs (e.g. 
metformin) have longer safety records and are less expensive (Johnston et al. 2017). Side 
20 
 
effects of SGLT2 inhibitors include urinary tract infections, mycotic infections and 
osmotic diuresis (Singh & Kumar 2018). 
 
1.4.7: Incretin mimetics  
The endogenous GLP-1 and GIP enteroendocrine hormones play a pivotal role in the 
maintenance of glucose homeostasis by enhancing GSIS and reducing 
hyperglucagonemia (Green & Flatt 2007).  However, both peptides are readily cleaved 
by DPP-IV and have very short half-lives in circulation (Tarantola et al. 2012). Incretin 
mimetics, primarily GLP-1 analogues, have been designed to avoid enzymatic 
degradation, thus prolonging their circulating half-life and bioactivity (Green & Flatt 
2007). Liraglutide (Victoza) and exenatide (Byetta) are the two most common synthetic 
GLP-1 analogues currently available for the treatment of type 2 diabetes (Jackson et al. 
2010). Victoza has 97% sequence homology with the human GLP-1 sequence with an 
Arg34Lys amino acid replacement accompanied with a glutamic acid and C-16 free fatty 
acid linkage to Lys26. The structural design promotes non-covalent binding to albumin 
and prolongs the biological half-life so that only one dose daily is required (Jackson et al. 
2010). Byetta is derived from salivary glands of the Gila monster and displays 53% 
sequence homology with human GLP-1 sequence, with once daily administration 
required (Furman 2012). Longer acting analogues of exenatide and liraglutide are also 
available with once weekly administration (Christensen & Knop 2010). The major 
limitation associated with incretin mimetics is the route of administration (subcutaneous), 
which is unfavourable for many patients with diabetes. Aside from improving glucose 
homeostasis, GLP-1 mimetics have been also shown to improve weight loss and insulin 
sensitivity without the risk of hypoglycaemia (Green & Flatt 2007). However, adverse 
effects such as vomiting, nausea and gastrointestinal discomfort have been reported in 
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with GLP-1 mimetics (Gupta 2013). Recently, a once weekly dual GIP/GLP-1 agonist 
(LY3298176) has shown clinical promise in patients with type 2 diabetes and may emerge 
as a leading therapeutic (Frias et al. 2018).  
 
1.4.8: DPP-IV inhibitors 
DPP-IV inhibitors are a novel class of orally available anti-diabetic therapeutics that 
inhibit the function of DPP-IV. DPP-IV is involved in the degradation of several 
glucoregulatory hormones and is expressed in numerous tissues throughout the body 
(Tarantola et al. 2012). Inhibition of DPP-IV impairs the rapid degradation of the key 
incretin hormones GLP-1 and GIP. DPP-IV cleaves both GLP-1 (7-36) and GIP (1-42) at 
the Pro and Ala amino acids at the second position on the N-terminus, resulting in 
biologically inactive truncated peptides (Deacon 2004). Approved DPP-IV inhibitors 
such Sitagliptin, Vidagliptin and Saxagliptin are typically used as a second or third line 
of medication after metformin and sulphonylureas. In addition to the beneficial effects 
towards glycaemic control, DPP-IV inhibitors have been shown to enhance weight loss 
and induce appetite suppression without the risk of hypoglycaemia (Ahren 2009). Side 
effects associated with DPP-IV inhibitors include flu-like symptoms, skin reactions and 
gastrointestinal discomfort (Ahren 2009).  
 
1.4.9: Combinational therapies 
Due to the limitations of current therapies for the treatment of type 2 diabetes and 
complications associated with the disease, combinational therapies are often utilised to 
improve patient prognosis (American Diabetes Association 2018). Dual therapies are 
often considered to reduce the risk of major adverse cardiovascular events. Metformin in 
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combination with incretin mimetics and DPP-IV inhibitors are most commonly 
prescribed dual therapies as they are anti-hyperglycaemic agents that reduce the risk of 
hypoglycaemia and cardiovascular disease, whilst enhancing islet cell regeneration 
(American Diabetes Association 2018). In addition, dual and triple agonist therapies have 
also become a promising therapeutic approach with interest focusing on synergistic 
activation of the incretin receptors (Naylor et al. 2016, Frais et al. 2018).  
 
1.5: G-protein coupled receptors (GPCRs) 
G-protein coupled receptors (GPCRs), also known as seven transmembrane domain 
receptors (7TM) are the largest family of membrane bound receptors expressed within 
the human genome (Rosenbaum et al. 2009). In recent years, research has intensified on 
discovering the structure and function of novel GPCRs, mainly through GPCR 
sequencing and cloning. Findings from the Human Genome Project in 2001 revealed that 
the number of GPCRs expressed in humans was greatly underestimated (Takeda et al. 
2002). Subsequently, research investigating the biological function of orphan GPCRs was 
spurred. Due to the independent downstream signalling cascades stimulated upon 
receptor activation, GPCRs have been recognised as potential therapeutic targets (Fang 
et al. 2015). GPCRs play a key role at a cellular level and regulate a diverse range of 
physiological functions, including cell secretions, immune responses, neurological 
signalling and cellular growth (Fang et al. 2015). At present, GPCRs are the direct target 
of over 700 FDA approved drugs, which account for approximately 35% of all drugs 
currently prescribed (Sriram & Insel 2018). Non-olfactory GPCRs are primarily targeted 
by small molecule and peptide ligands, however, the biological function of numerous 
GPCRs remains largely unknown (Laschet et al. 2018). 
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1.5.1: GPCR classifications 
GPCRs can be divided into six separate classifications (A-F) based on their structure and 
biological function; rhodopsin-like (class A), secretin-like (class B), metabotropic 
glutamate (class C), pheromone (class D), cAMP (class E) and frizzled (class F) (Peng et 
al. 2010). Rhodopsin-like, secretin-like, metabotropic glutamate and frizzed GPCRs are 
expressed within mammalian systems, whilst pheromone and cAMP GPCRs are 
exclusively found in fungal species and amoeba (Dictyostelium discoideum), respectively 
(Peng et al. 2010). Further sub-divisions of GPCRs can be made within primary 
classifications based on ligand binding and biological functionalities (Peng et al. 2010).  
The rhodopsin-like (Class A) family represents the largest class of GPCRs expressed in 
mammalian organisms and is comprised of 701 independent receptors (Zhang et al. 
2015). These receptors are abundantly expressed in numerous tissues, particularly within 
sensory organs such as the eye (Palczewski 2006). Subsequently, rhodopsin-like GPCRs 
have been previously isolated from bovine retina and have been characterised with respect 
to structure more than the other GPCR classifications (Palczewski 2006). Moreover, 
rhodopsin-like GPCRs are the most structurally stable, enabling extensive 
characterisation through experimental endurance (Palczewski 2006).  
The secretin-like (Class B) family of GPCRs are typically activated by peptides and other 
large protein-based ligands leading to Gαq and Gαs signalling (Hollenstein et al. 2014). 
Class B receptors are involved in the detection of numerous pancreatic and 
gastrointestinal hormones, including glucagon, incretins (GLP-1, GIP), vasoactive 
intestinal hormone (VIP), secretin, parathyroid hormone and calcitonin (Nordstrom et al. 
2009). Secretin-like receptors are important regulators of energy metabolism and glucose 
homeostasis (Nordstrom et al. 2009).  
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Metabotropic glutamate (Class C) receptors function as neurotransmitters and are the 
family of GPCRs responsible for indirect metabotropic signalling, mediating through the 
associated glutamate residue (Wu et al. 2014). This family of GPCRs are abundantly 
expressed in pre-synaptic and post-synaptic neurons of the cerebral cortex, cerebellum 
and hippocampus (Niswender & Conn 2010). Subsequently, Class C GPCRs regulate 
responses within both the peripheral and central nervous systems with receptor activation 
controlling memory, learning, mood and pain sensitisation (Javitt et al. 2011). Studies 
have identified the pathophysiological role and therapeutic potential of metabotropic 
glutamate receptors in neurodegenerative diseases such as Parkinson’s disease, 
schizophrenia and generalised anxiety disorder (Chun et al. 2012). 
Frizzled (Class F) GPCRs are the family of receptors that modulate Wnt signal 
transduction that facilitates the transfer of cellular responses from cell surface receptors 
(Katanaev 2012). Frizzled receptors stimulated on the cell membrane activate the 
cytoplasmic dishevelled phosphoprotein through both canonical and non-canonical Wnt 
signalling pathways (Gonzalez-Sancho et al. 2004). Activation of frizzled receptor 
signalling can regulate a range of cellular responses, including gene transcription, 
intracellular calcium concentrations and cytoskeleton dynamics (Huang & Klein 2004). 
There are a total of 1265 GPCRs expressed in the human genome, however, the 
physiological function of only 800 is understood (Kobilka 2007, Insel et al. 2012). The 
endogenous ligands for many GPCRs remains elusive yet the number of orphan receptors 
is in constant decline due to progressing research utilising GPCR targeting therapeutics 
(Insel et al. 2012). Recent studies have suggested that the majority of human GPCRs act 
as olfactory receptors by inducing responses to taste, sight and smell. However, 
approximately 342 non-olfactory GPCRs are also expressed and have been recognised as 
potential therapeutic targets (Fredriksson et al. 2003).  
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1.5.2 GPCR structure and signalling cascades 
All GPCRs are comprised of 7 hydrophobic transmembrane domains accompanied with 
an intracellular carboxyl terminus and an extracellular amino terminus (Peng et al. 2010). 
The extracellular loops of the membrane bound receptor are stabilised by disulphide 
bonds formed between two cysteine amino acid residues (Rosenbaum et al. 2009). An 
intact G-protein comprised of three individual subunits (Gα, Gβ, Gγ) completes the 
intracellular portion of the receptor (Rosenbaum et al. 2009). The subunits of the G-
protein can be further subdivided with Gα containing 4 classes, Gβ containing 5 classes 
and Gγ containing 12 classes (Syrovatkina et al. 2016). Upon ligand binding and GPCR 
activation, receptor dependent G-protein subunits are phosphorylated, thus inducing the 
activation of downstream receptor signalling through secondary messenger pathways 
(Syrovatkina et al. 2016).  
The transmembrane domains within all classifications of GPCRs exhibit similar sequence 
homology, whilst variations are notably present in the extracellular amino terminus and 
in the TM5/TM6 loops of the intracellular carboxyl terminus (Kobilka 2007). Overall, the 
greatest degree of structural diversity between independent GPCRs exists in the 
extracellular amino terminus, with sequence length ranging from 10-600 amino acid 
residues (Kobilka 2007). Short 10-15 amino termini are typically associated with peptide 
and small molecule binding, whilst longer 350-600 amino acid termini are linked with 
glutamate and glycoprotein GPCRs (Kobilka 2007).   
Agonist binding typically stimulates downstream GPCR signalling, whilst constitutive 
phosphorylation of intracellular G-protein subunits may also occur in unbound receptors 
(Syrovatkina et al. 2016). In most cases, the downstream response induced by GPCR 
activation is directly proportional to the potency of the ligand at the receptor binding sites 
(Rozenfeld & Devi 2011). Numerous ligands can exist for the activation of an individual 
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GPCR; ligands inducing full activation of the receptor are referred to as ‘agonists’, whilst 
ligands that influence submaximal stimulation of a given receptor are known as ‘partial 
agonists’ (Basith et al. 2018). Contrastingly, antagonist binding inhibits receptor 
activation by competitively blocking receptor binding sites and demonstrates no effect 
towards basal activity (Basith et al. 2018). The downstream signalling cascade stimulated 
by a given receptor directly correlates to the efficacy of the bound ligand (Basith et al. 
2018).  
Upon agonist binding, receptor activation begins with a conformational change within the 
membrane bound G-protein that catalyses the generation of guanosine triphosphate (GTP) 
in exchange for guanosine diphosphate (GDP) (Yen et al. 2017). As a result of this 
exchange, the Gα subunit is dissociated from the intact G-protein at the cell membrane 
into the cytosol and stimulates the receptor dependent signalling cascade (Kobilka 2007).  
The four independent Gα subunits (Gαq, Gαs, Gαi, Gα12/13) determine the secondary 
messenger signalling pathway upon receptor activation (Figure 1.2) (Syrovatkina et al. 
2016).  
Activation of Gαq primarily couples to the beta isoform of phospholipase C (PLC), 
resulting in inositol trisphosphate (IP3) and diacylglycerol (DAG) secondary messenger 
signalling, which can lead to mitogen activation protein kinase (MAPK) phosphorylation 
and/or release of intracellular Ca2+ from the ER (Figure 1.4) (Zhang & Shi 2016). The 
Gα12/13 subunit generates no effects towards secondary messenger signalling pathways; 
instead activates RhoGEFs such as Rho-, Rac- and Cdc42-like GTPases (Figure 1.5) 
(Siehler 2009). The Gαs intracellular subunit directly stimulates adenylyl cyclase 
signalling, resulting in cAMP production and PKA activation (Billington & Penn 2003). 
In contrast, the Gαi subunit inhibits adenylyl cyclase leading to attenuated cAMP 
production (Billington & Penn 2003). Coupling to other secondary messenger molecules 
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including PLC and KATP is also linked with Gαi signalling (Billington & Penn 2003). 
Although lesser understood, the Gβ and Gγ subunits have also been shown to modulate 
PLC, PKA and adenylyl cyclase signalling (Syrovatkina et al. 2016). Following agonist 
dissociation and receptor deactivation, GTP is hydrolysed to GDP and the G-protein re-
associates to the cell membrane (Figure 1.3) (Yen et al. 2017). 
 
1.5.3: GPCRs involved in energy homeostasis 
Numerous GPCRs play a pivotal role in the maintenance of glucose homeostasis by 
controlling glucoregulatory and gastrointestinal hormone release (Moran et al. 2016). At 
present, 293 GPCRs have been identified in human islets with activation mediated by a 
wide range of structurally diverse ligands, including lipids, peptides, macromolecules and 
monatomic ions (Amisten et al. 2013). Activation of specific GPCRs on pancreatic islet 
cells can potentiate insulin, glucagon and somatostatin secretion, thus controlling 
circulating blood glucose concentrations (Amisten et al. 2013). In addition, GPCRs 
present on the enteroendocrine cells of the gut can regulate the release of incretins (GLP-
1, GIP) and other gastrointestinal hormones in response to the influx of carbohydrates, 
proteins and lipids (Moran et al. 2016).  
 
1.5.4: GLP-1 receptor  
The GLP-1 receptor (GLP1R) is a GPCR abundantly expressed in pancreatic islet cells. 
GLP1R is expressed on chromosome 6 of the human genome and encodes 463 amino 
acids upon translation (Lee & Lee 2017). With respect to receptor binding, GLP1R 
contains two binding domains; one transmembrane domain that binds to the N-terminal 
region of GLP-1 and one extracellular domain that binds to the C-terminal helix of GLP-
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1 (Dods & Donnelly 2015). Upon GLP1R agonism, the Gαs subunit is phosphorylated 
leading to cAMP production through the adenylyl cyclase pathway (Green et al. 2004). 
Pancreatic activation of GLP1R augments insulin release from beta cells whilst 
attenuating glucagon secretion from alpha cells (Green et al. 2004). Moreover, studies 
have shown that GLP-1 enhances beta cell proliferation and impairs beta cell apoptosis 
by upregulating pancreas duodenal homebox-1 (PDX-1) expression (Li et al. 2005). GLP-
1 mimetics exenatide and liraglutide are longer lasting analogues of GLP-1 that activate 
the GLP-1 receptor, whilst exendin (9-39) is an antagonist (Gupta 2013). GLP1R is 
expressed in numerous tissues including the intestines, brain, kidneys, nervous system 
and lungs (Muscogiuri et al. 2014). Interestingly, activation of the GLP1R promotes 
weight loss and exhibits neuroprotective effects in the brain (McIntyre et al. 2013, 
Muscogiuri et al. 2014). 
 
1.5.5: GIP receptor 
The GIP receptor (GIP-R) gene is expressed on chromosome 19 and encodes a 466 amino 
acid protein (Gremlich et al. 1995). Similar to the GLP-1 receptor, GIP agonism results 
in activation of Gαs signalling which increases cAMP production and PKA 
phosphorylation (Green et al. 2004). GIP-R is expressed in numerous tissues throughout 
the body including the pancreas, intestines brain, bone, heart, adipose and circulatory 
vasculature (Baggio & Drucker 2007). Activation of GIP-R in pancreatic beta cells 
augments insulin release, hence GIP is categorised as an incretin (Green et al. 2004). In 
patients with type 2 diabetes, the biological activity of GIP is greatly impaired with GIP-
R desensitisation suspected as the primary pathophysiological source (Knop et al. 2007). 
The native 42 amino acid GIP molecule exhibits an unfavourable pharmacokinetic profile 
due to its weak biological activity and effectiveness in the treatment of type 2 diabetes 
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(Irwin et al. 2006). Subsequently, longer acting GIP analogues with increased enzymatic 
stability have been synthesised to enhance the actions of the GIP receptor (Irwin et al. 
2006). GIP-R activation also plays a key role in fat deposition and lipid metabolism (Gault 
et al. 2003). Interestingly, antagonism of the GIP-R can alleviate obesity-associated 
metabolic impairments that are commonly linked with type 2 diabetes (McClean et al. 
2007). 
 
1.5.6: Glucagon receptor 
The glucagon receptor (GCGR) is a 477 amino acid protein that is expressed on 
chromosome 17 of the human genome (Menzel et al. 1994). Agonism of GCGR primarily 
stimulates activation of the Gαs intracellular G-protein, accompanied with Gαq activation 
to a lesser extent (Li & Zhuo 2007). Subsequently, glucagon binding stimulates cAMP 
production and PKA activation through the adenylyl cyclase pathway (Li & Zhuo 2007). 
Glucagon receptors are abundantly expressed within the endocrine-pancreas, liver and 
kidney (Brubaker & Drucker 2002). Lower expression is also found in intestine, heart, 
spleen, brain and adipose tissues (Brubaker & Drucker 2002). Hepatic GCGR activation 
result in PKA phosphorylation and augments glycogenolysis to increase blood glucose 
concentrations (Brubaker & Drucker 2002). Native glucagon is a full agonist for GCGR 
activation, whilst OXM acts as a partial-agonist (Kerr et al. 2010). Adomeglivant and L-
168,049 are potent GCGR antagonists and emit glucose-lowering effects in-vivo (Casieri 
at al. 1999).  
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1.5.7: Neuropeptide Y receptors 
Neuropeptide Y receptors including Y1, Y2, Y4 and Y5 are a family of receptors 
expressed in pancreatic islets that are activated by endogenous peptide hormones 
neuropeptide Y (NPY), PP and PYY (Amisten et al. 2013). In addition, the Y6 receptor 
expressed in primates contains a frameshift mutation producing a non-functional 
truncated gene (Starback et al. 2000). Activation of Y1, Y4 and Y5 induces Gαi 
signalling, thus inhibiting adenylyl cyclase and cAMP, whereas Y2 augments 
intracellular Ca2+ concentrations through Gαq signal transduction (Gao et al. 2004). 
Within the pancreatic islet, PYY has been shown to attenuate insulin release primarily 
through Y2 activation (Gao et al. 2004). NPY, PP and PYY (1-36) have been shown to 
activate all neuropeptide Y receptors (Lafferty et al. 2018). Interestingly, the DPP-IV 
cleaved isoform PYY (3-36) is selective for Y2 activation and induces appetite 
suppression and promotes beta cell proliferation (Lafferty et al. 2018). 
 
1.6: Cannabinoid receptors 
 
Cannabinoid receptors comprise part of the endocannabinoid system (ECS) and are 
responsible numerous physiological responses including pain sensitisation, appetite, 
memory and mood (Manzanares et al. 2006). Ligands that activate cannabinoid receptors 
can be grouped into three primary classifications; plant cannabinoids (e.g. cannabidiol), 
endocannabinoids and synthetic cannabinoids (Fine & Rosenfeld 2013). 
Endocannabinoids are produced naturally in mammalian systems whereas synthetic 
cannabinoids are typically structural analogues of existing cannabinoids (Fine & 
Rosenfeld 2013). CB1 and CB2 are the primary receptors of the ECS and are heavily 
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expressed in the CNS, liver and immune system (Mouslech & Valla 2009). The CB1 and 
CB2 subtypes are involved in the regulation of neurological signalling and the generation 
of immune responses (Mouslech & Valla 2009). Recently, previously considered orphan 
receptors GPR18, GPR55 and GPR119 have been shown to mediate the non-CB1/CB2 
effects of the endocannabinoid ligands (Irving et al. 2017). These novel receptors are 
linked with the regulation of energy metabolism, whilst exhibiting no psychoactive 
properties (Table 1.1) (Irving et al. 2017).  
 
1.6.1: CB1 receptor 
CB1 is a 472 amino acid protein encoded from chromosome 6 in the human genome and 
is one of the most abundantly expressed receptors in the brain (Laprairie et al. 2012). The 
natural endogenous ligands for CB1 activation are anandamide (AEA) and 2-
arachidonoylglycero (2-AG) (Laprairie et al. 2012). Activation of CB1 results in Gαi 
signalling, attenuating cAMP and PKC by inhibition of adenylyl cyclase (Howlett et al. 
2010). However, ion channel regulation and MAPK signalling are also associated with 
CB1 agonism (Howlett et al. 2010). Hepatic activation of CB1 has been shown to mediate 
lipogenesis, whilst activation in the nervous system modulates neurotransmitter release 
(Kunos et al. 2008). CB1 receptor knockout mice display numerous physiological 
alterations, including hypophagia, hypoalgesia and hypoactivity (Wiley et al. 2005). In 
addition, the psychoactive component of marijuana delta9-tetrahydrohydrocannabinol 
(THC) mediates through CB1 receptors by coupling to inhibitory G-protein subunits 
(Wiley et al. 2005). 
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1.6.2: CB2 receptor 
CB2 is 360 amino acid protein encoded from chromosome 1 of the human genome with 
high expression found in the peripheral nervous system and immune cells (Liu et al. 
2009). Activation of CB2 is primarily linked with anti-inflammatory and 
immunoregulatory responses whilst other studies have demonstrated its involvement in 
appetite control (Fine & Rosenfeld 2013). Similar to CB1, CB2 also couples to the 
intracellular Gαi subunit leading to adenylyl cyclase inhibition and cAMP attenuation 
(Kaminski 1998). In addition, the same endogenous ligands (AEA, 2-AG) are shared 
between CB1 and CB2 (Fine & Rosenfeld 2013). Interestingly, CB2 was previously 
targeted for the treatment of obesity with Rimonabant once used as an inverse agonist 
prior to its withdrawal due to mood altering side effects (Sam et al. 2011).  
 
1.6.3: GPR18 and GPR119 
Recently, GPR18 and GPR119 have been identified as endocannabinoid receptors (Irving 
et al. 2017). Although structurally dissimilar to CB1 and CB2, these receptors contain 
endocannabinoid binding sites within extracellular and transmembrane domains (Irving 
et al. 2017). The functionality of GPR18 remains largely unknown as it is still considered 
as an orphan receptor, although endogenous AEA metabolite N-arachidonoylglycine 
(NAGly) has been shown to upregulate intracellular Ca2+ concentrations in GPR18-
transfecrted cells (Burstein et al. 2011). GPR18 activation mediates both Gαi and Gαq 
signal transduction which can regulate cAMP and Ca2+ production intracellularly. In 
contrast, the biological function of GPR119 is further understood with studies revealing 
its role as a lipid biosensor. N-oleoylethanolamide (OEA) has been recognised as the 
primary endogenous ligand (Hassing et al. 2016). Upon activation, GPR119 couples to 
Gαs which stimulates cAMP production through adenylyl cyclase signalling (Hassing et 
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al. 2016). GPR119 is highly expressed in pancreatic beta cells and induces GSIS and 
incretin release upon activation (Moran et al. 2014). GPR119 agonist GSK-1292263 
(GlaxoSmithKline) has completed stage II clinical trials for the treatment of type 2 
diabetes (Polli et al. 2013). 
 
1.6.4: GPR55  
GPR55 is a 319 amino acid rhodopsin-like receptor that is expressed on chromosome 
2q36.3 in the human genome (Sharir & Abood 2010). Previously, GPR55 was considered 
an orphan receptor prior to research revealing its interactions with endocannabinoid 
ligands (Sharir & Abood 2010). GPR55 is abundantly expressed in the endocrine-
pancreas, intestines, CNS, adipose tissue and spleen (Simcocks et al. 2014). Interestingly, 
GPR55 displays limited sequence homology with other cannabinoid receptors, including 
CB1 and CB2. Whilst other GPCRs such as CCR4, GPR35 and GPR23 exhibit the closest 
structural similarities with GPR55 (Sharir & Abood 2010). Recently, studies have 
demonstrated that GPR55 activation modulates numerous responses involved in energy 
metabolism, including GSIS, insulin sensitivity, appetite, lipogenesis and gastric 
emptying (Tuduri et al. 2017). Downstream of GPR55 activation, Gαq and Gα12/13 
subunits are activated. Gαq augments intracellular Ca2+ concentrations and MAPK 
phosphorylation through PLC signalling, whereas Gα12/13 activation influences 
RhoGEFs signalling leading to Rho/ROCK, cdc42 and rac activation (Shi et al. 2017). 
At present, there are a wide range of endogenous and synthetic ligands available for the 
activation of GPR55. Moreover, several GPR55 endocannabinoids 
(lysophosphatidylinositol, palmitoylethanolamide, OEA, AEA, 2-AG) and synthetic 
cannabinoid ligands (Abn-CBD, AM251, O-1602) have been shown to induce 
insulinotropic and glucoregulatory effects in clonal pancreatic BRIN-BD11 cells and 
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diabetic mice (McKillop et al. 2013). In addition, naturally occurring cannabidiol have 
been previously used to antagonise GPR55 (McKillop et al. 2013). 
 
1.7: Free fatty acid receptors 
 
The free fatty acid family of GPCRs act as lipid biosensors to short, medium and long 
chain fatty acid molecules (Yonezawa et al. 2013). There are five subclasses of free fatty 
acid receptors that are differentiated based on the carbon length of their corresponding 
fatty acid ligands (Yonezawa et al. 2013). GPR41 (FFAR3) and GPR43 (FFAR2) sense 
short chain fatty acid (C2-C6) molecules, GPR84 is activated by medium fatty acids (C9-
C14), whereas GPR40 (FFAR1) and GPR120 (FFAR4) are long chain fatty acid (C15-
C22) sensing GPCRs (Yonezawa et al. 2013). Free fatty acid receptors are known to 
modulate numerous biological functions such as inflammatory responses and energy 
metabolism (Hara et al. 2013). Recently, research has intensified on the involvement of 
free fatty acid receptors in type 2 diabetes, with the GPR40 agonist Fasiglifam (TAK-
875) recently undergoing stage III clinical trials prior to its withdrawal due to signs of 
liver toxicity (Marcinak et al. 2017). In addition, long chain fatty molecules have been 
previously shown to regulate insulin and GLP-1 release from pancreatic and 
enteroendocrine cells, respectively (Table 1.1) (Martin et al. 2012).  
 
1.7.1: GPR40 
Free fatty acid receptor 1 (FFAR1), also known as GPR40 is a 300 amino acid membrane 
bound protein expressed on chromosome 19q13.1 that senses saturated and unsaturated 
long chain fatty acid (C12-C16) molecules (Vangaveti et al. 2010). GPR40 is expressed 
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on immune cells, regions of the brain and pancreatic islet cells and potentiates GSIS upon 
activation (Swaminath 2008). In addition, GPR40 is highly expressed in enteroendocrine 
I-, K, and L-cells of the gut with effects towards GLP-1, GIP and CCK secretion linked 
with receptor activation (Hauge et al. 2014). GPR40 primarily couples to Gαq which 
increases intracellular Ca2+ through PLC and IP3 signalling (Hauge et al. 2014). 
Currently, a range of naturally occurring (long chain carboxylic acids) and synthetic 
(GW9508, TAK-875, TUG-905) agonists exist for the activation of GPR40, whilst 
GW1100 is recognised as a potent antagonist (Milligan et al. 2015). The specificity of 
endogenous GPR40 agonists remain uncertain, however, several synthetic agonists such 
as TAK-875 and TUG-905 exhibit selectivity towards GPR40 (Hudson et al. 2013). 
Although GPR40 stimulates insulin release, GPR40 knockout mice are protected from 
hyperinsulinemia, hypertriglyceridemia, hyperglycaemia and increased hepatic glucose 
production (Stenenerg et al. 2005). However, overexpression of GPR40 in beta cells via 
the PDX-1 promoter improves insulin secretion and glucose tolerance (Nagasumi et al. 
2009).  
 
1.7.2: GPR41 
Free fatty acid receptor 3 (FFAR3), also referred to as GPR41 is expressed at chromosome 
19q13.1 which encodes a 346 amino acid protein (Vangaveti et al. 2010). GPR43 is 
activated by short chain fatty acid (C3-C5) molecules such as propanoic acid, pentanoic 
acid, butyric acid and 1-methylcyclopropanecarboxylic acid (Swaminath 2008, Vangaveti 
et al. 2010). Expression of GPR41 has been demonstrated in pancreatic islets, 
enteroendocrine L-cells, spleen, lymph nodes and bone marrow (Swaminath 2008). 
Studies have shown GPR41 to regulate inflammatory and immune responses, whilst other 
findings demonstrated GPR41 activation augment leptin production (Kim et al. 2014). 
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GPR41 knockout mice display increased fat mass, attenuated expression of PYY and 
impaired sympathetic nervous signalling to short chain fatty acids (Inoue et al. 2014). 
 
1.7.3: GPR43 
GPR43, also known as free fatty acid receptor 2 (FFAR2) is a 330 amino acid protein that 
is expressed on chromosome 19q13.1 likewise to GPR40 and GPR41 (Vangaveti et al. 
2010). Activation of GPR43 results in Gαq which generates an increase on intracellular 
Ca2+ concentrations through PLC and IP3 signalling (Talukdar et al. 2011). GPR43 is 
activated by a range of short chain fatty acids (C2-C3), including propanoic acid, acetic 
acid and butyric acid (Vangaveti et al. 2010). Endogenous acetic acid exhibits selectivity 
towards GPR43 over GPR41. In addition, synthetic GLPG0974 is a potent antagonist of 
GPR43 and displays the highest affinity for the receptor (Namour et al. 2016). GPR43 
has been shown to control inflammatory and immune responses, with GLPG0974 
undertaking stage II clinical trials for ulcerative colitis (Namour et al. 2016). GPR43 
knockout mice display reduced bodyweight, impaired insulin sensitivity and reduced 
gastrointestinal inflammation (Nakajima et al. 2017). 
 
1.7.4: GPR120 
GPR120, also known as free fatty acid receptor 4 (FFAR4) is expressed on chromosome 
10q23.33 and encodes a 377 rhodopsin-like receptor upon translation (Stone et al. 2014). 
Abundant expression of GPR120 have been identified in pro-inflammatory macrophages, 
intestines, endocrine-pancreas, lungs, spleen and adipose tissue (Miyauchi et al. 2009, 
Song et al. 2017). Moreover, GPR120 is heavily expressed in both human and rodent 
pancreatic beta and delta cells, with expression also demonstrated on pancreatic beta cell 
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lines such as BRIN-BD11, MIN6, INS-1 and RINm5f (Moran et al. 2014, Stone et al. 
2014). GPR120 is a long chain fatty acid receptor that senses endogenous omega 3 fatty 
acids (α-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid) and other 
structurally similar synthetic analogues (GW9508, GSK137647 and Compound A) 
(Sparks et al. 2014, Oh et al. 2014). AH-7614 is a potent antagonist for GPR120 and 
exhibits no affinity for the other free fatty acid receptors (Sparks et al. 2014). Many of 
the endogenous ligands for long chain fatty acid sensing receptors, such as omega 3 fatty 
acids DHA and ALA have previously demonstrated insulinotropic and anti-inflammatory 
properties that are of interest for the treatment of obesity and type 2 diabetes (Oh et al. 
2010, Moran et al. 2014). 
Upon agonist binding and receptor activation, GPR120 activates the intracellular Gαq 
subunit which modulates an increase in intracellular Ca2+ from the ER through PLC and 
IP3 signalling (Moran et al. 2014, Sanchez-Fernandez et al. 2014). The Gαq subunit can 
also augment MAPK (ERK1/2, p38 and JNK) phosphorylation through PKC activation 
(Sanchez-Fernandez et al. 2014). GPR120 activation plays a regulatory role in 
glucoregulatory hormone release from the endocrine-pancreas (insulin, somatostatin) and 
the enteroendocrine cells of the gut (GLP-1, CCK) (Martin et al. 2012, Moran et al. 2014). 
Aside from hormone release, GPR120 is also linked with anti-inflammatory responses 
and insulin sensitisation (Oh et al. 2014). Interestingly, GPR120 knockout mice 
demonstrated glucose intolerance and were more susceptible to the effects of a high fat 
diet, including obesity, fatty liver and increased lipogenesis (Ichimura et al. 2012). 
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1.8: Aims and objectives 
GPCRs are responsible for mediating the secretion of numerous glucoregulatory 
hormones from the pancreatic islet and enteroendocrine cells of the gut, including insulin, 
GLP-1 and GIP. Recently, novel GPCRs from the cannabinoid and free fatty acids 
families have been identified as potential therapeutic targets for the treatment of type 2 
diabetes and other obesity related complications. Namely, GPR55 and GPR120 have 
shown pre-clinical promise and may be utilised to counteract beta cell dysfunction, 
dyslipidaemia and obesity. The present study aims to investigate the specificity, 
mechanistic function and efficacy of GPCR agonists as novel therapeutic agents using in- 
vitro studies, CRISPR/Cas9 gene editing and diabetic mice studies. 
The primary aims of the thesis are as follows: 
 To investigate the expression and cellular localisation of GPR55 and GPR120 in 
clonal BRIN-BD11 cells and islets of lean and diabetic rodent models of diabetes 
as assessed by qPCR, western blotting and double immunofluorescent staining.  
 To determine the role of several GPR55 and GPR120 ligands on insulin and 
incretin (GLP-1, GIP) release using clonal BRIN-BD11 cells and high fat fed-
induced diabetic mice.  
 To examine the specificity of putative GPR55 and GPR120 ligands on beta cell 
function using CRISPR/Cas9 gene editing in clonal BRIN-BD11 cells. 
 To explore the intracellular signalling events of insulin secretion activated 
downstream of GPR55 and GPR120 agonism using western blotting, flow 
cytometry, ELISA and fluorometric assays. 
  To evaluate the chronic therapeutic effectiveness of GPCR agonist monotherapy 
and combinational therapy (DPP-IV inhibition) in high fat fed-induced diabetic 
mice. 
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Table 1.1: Biological function, agonists and signalling mechanism of cannabinoid 
and free fatty acid GPCRS. 
Family Receptor G-
protein 
Biological 
function 
Agonists 
 
 
 
 
 
Cannabinoid 
receptors 
CB1 Gαi Neurotransmitter 
release, anti-
inflammatory 
Anandamide, 2-
arachidonoylglycerol 
Cannabinol, Δ9-
tetrahydrocannabinol,  
CB2 Gαi Anti-
inflammatory, 
immune regulation 
AM7499, Δ9-
tetrahydrocannabinol, 
HU-210, APD371 
GPR18 Gαi 
Gαq 
- - 
GPR55 Gα12/13 
Gαq 
Insulin release, 
Anti-inflammatory 
Abn-CBD, O-1602, 
AM251, OEA, PEA 
GPR119 Gαs Insulin release, 
appetite 
suppression 
AS-1269574, 
PSN-375963, 
AR-231453 
 
 
 
 
 
Free fatty acid 
receptors 
GPR40 Gαq Glucose stimulated 
insulin secretion 
TAK-875, GW9508 
GPR41 Gαi Anti-
inflammatory, 
Leptin release 
Short chain fatty 
acids (C3-C5) 
GPR43 Gαi 
Gαq 
Immune response 
Attenuates 
lipolysis 
Short chain fatty 
acids (C2-C3) 
GPR84 Gαi Anti-inflammatory Medium chain fatty 
acids (C9-C14) 
GPR120 Gαq Anti-
inflammatory, 
insulin release 
ALA, DHA, EPA, 
GSK137647, 
Compound A 
 
(Adapted from Swaminath 2008, Amisten et al. 2013)
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Figure 1.1: Target organs and examples of current therapies for the treatment of type 2 diabetes. 
 
 
 
 
   
  
 
 
 
  
(Adapted from Evans et al. 2000) 
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Figure 1.2: Mechanism of GPCR activation upon agonist binding. 
 
 
 
 
(Adapted from Wettschureck & Offermanns 2005) 
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Figure 1.3: Intracellular G-protein signalling pathways (Gαq, Gαs, Gαi, Gα12/13) 
stimulated upon GPCR activation.  
 
 
(Adapted from Wu et al. 2012) 
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Figure 1.4: Gαq signalling upon GPCR activation (GPR55 and GPR120 signalling pathways) 
 
 
 
 
 
 
 
 
 
 
(Adapted from Mizuno & Itoh 2009, Sanchez-Fernandez et al. 2014) 
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Figure 1.5: Gα12/13 signalling upon GPCR activation (GPR55 signalling pathway) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from Siehler 2009) 
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Chapter 2 
 
Materials and Methods 
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2.1: Tissue Culture 
 
2.1.1: Materials 
RPMI 1640 medium, foetal bovine serum (FBS), penicillin/streptomycin (100 U/ml; 0.1 
mg/ml), trypsin/EDTA and Hanks Buffered Saline Solution (HBSS) were purchased 
from Gibco Life Technologies (Paisley, Strathclyde, UK). HEPES, sodium chloride 
(NaCl), potassium chloride (KCl), calcium chloride dihydrate (CaCl2.2H2O), sodium 
hydroxide (NaOH), dimethylsulphoxide (DMSO), bovine serum albumin (BSA) and 
hydrogen peroxide (H2O2) were sourced from Sigma-Aldrich (Poole, Dorset, UK). D-
glucose, hydrochloric acid (HCL), sodium bicarbonate (NaHCO3), magnesium sulphate 
(MgSO4.7H2O) and trypan blue were obtained from BDH Chemicals (Poole, Dorset, 
UK). Sterile 96-well, 24-well, 12-well and 6-well tissue culture plates were obtained 
from Nunclon (Roskilde, Denmark). 
 
2.1.2: Culture of clonal BRIN-BD11 cells 
Clonal pancreatic BRIN-BD11 cells were derived from the electrofusion of RINm5F 
cells with New England Deaconess Hospital (NEDH) rat pancreatic beta cells, as 
previously described (McClenaghan et al. 1996). BRIN-BD11 cell stocks, containing 1 
million cells, were cryopreserved in 1 ml of freezing medium (80% FBS (v/v), 10% 
RPMI-1640 (v/v), 10% DMSO (v/v)) and stored in 1.5 ml cryovials (Sterilin, Houslow, 
UK). Cryovials containing stocks were stored at -20˚C for 4 h, -80˚C for 24 h, followed 
by long-term storage in liquid nitrogen. BRIN-BD11 cells (passages 15-45) were 
cultured in RPMI-1640 media with 1% antibiotics (v/v), 10% FBS (v/v) at a glucose 
concentration of 11.1 mM. Cells were grown in 20 ml of media in 75 cm3 vented sterile 
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tissue culture flasks at 37˚C in 5% CO2 and 95% air inside a LEEC incubator 
(Laboratory Technical Engineering, Nottingham, UK).  
When the cells reached confluency (75-90%) they were harvested by washing with 10 
ml of HBSS then incubated with pre-warmed 0.025% (w/v) trypsin/EDTA at 37˚C for 5 
min. Confirmation of detachment was performed by visual inspection using a phase 
contrast microscope (Zeiss, Germany). Cells were resuspended in 10 ml of RPMI-1640 
media, transferred to a 50 ml sterilin tube (Sterilin, Houslow, UK) and centrifuged at 
900 rpm for 5 min using a bench centrifuge (MSE Mistral 200, RHYS International, 
Manchester, UK). Supernatant was decanted and the cell pellet resuspended in a known 
volume of media. An aliquot of cell suspension (100 μl) was stained by adding to trypan 
blue (100 μl, 1:2 dilution), mixed thoroughly and added to a Neubauer haemocytometer 
(Scientific Supplies Co, Middlesex, UK) for counting. 
 
2.1.3: Culture of human 1.1B4 cells 
The hybrid cell line1.1B4 was formed by the electrofusion of a primary culture of human 
pancreatic islets with PANC-1, a human pancreatic ductal carcinoma cell line. The 
generation and characterisation of these cells was previously described (Vasu et al. 2013, 
Green et al. 2015). 1.1B4 cell stocks, containing 1 million cells, were cryopreserved in 
1 ml of freezing medium (80% FBS (v/v), 10% RPMI-1640 (v/v), 10% DMSO (v/v)) 
and stored in 1.5 ml cryovials (Sterilin, Houslow, UK). Cryovials containing stocks were 
stored at -20˚C for 4 h, -80˚C for 24 h, followed by long-term storage in liquid nitrogen. 
1.1B4 cells (passages 15-35) were cultured in RPMI-1640 media with 1% antibiotics 
(v/v), 10% FBS (v/v) at a glucose concentration of 11.1 mM. Cells were grown in 20 ml 
of media in 75 cm3 vented sterile tissue culture flasks at 37˚C in 5% CO2 and 95% air 
inside a LEEC incubator (Laboratory Technical Engineering, Nottingham, UK).  
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When the cells reached confluency (75-90%) they were harvested by washing with 10 
ml of HBSS then incubated with pre-warmed 0.025% (w/v) trypsin/EDTA at 37˚C for 5 
min. Confirmation of detachment was performed by visual inspection using a phase 
contrast microscope (Zeiss, Germany). Cells were resuspended in 10 ml of RPMI-1640 
media, transferred to a 50 ml sterilin tube (Sterilin, Houslow, UK) and centrifuged at 
900 rpm for 5 min using a bench centrifuge (MSE Mistral 200, RHYS International, 
Manchester, UK). Supernatant was decanted and the cell pellet resuspended in a known 
volume of media. An aliquot of cell suspension (100 μl) was stained by adding to trypan 
blue (100 μl, 1:2 dilution), mixed thoroughly and added to a Neubauer haemocytometer 
(Scientific Supplies Co, Middlesex, UK) for counting. 
 
2.1.4: Culture of α-TC1.9 cells 
Alpha TC1 cell line was generated from an adenoma produced in transgenic mice 
expressing SV40 large T antigen controlled under rat preproglucagon promoter (Powers 
et al. 1990). Alpha TC1 clone 9 was cloned from alpha TC1 cell line with no expression 
of insulin or preproinsulin mRNA (Powers et al. 1990). The cell line was a gift from 
Professor Kevin Doherty, University of Aberdeen. α-TC1.9 cell stocks, containing 1 
million cells, were cryopreserved in 1 ml of freezing medium (80% FBS (v/v), 10% 
Dulbecco’s modified Eagle medium (DMEM) (v/v), 10% DMSO (v/v)) and stored in 
1.5 ml cryovials (Sterilin, Houslow, UK). Cryovials containing stocks were stored at -
20˚C for 4 h, -80˚C for 24 h, followed by long-term storage in liquid nitrogen. α-TC1.9 
cells were cultured in DMEM media with 1% antibiotics (v/v), 10% FBS (v/v) at a 
glucose concentration of 25 mM. Cells were grown in 20 ml of media in 75 cm3 vented 
sterile tissue culture flasks at 37˚C in 5% CO2 and 95% air inside a LEEC incubator 
(Laboratory Technical Engineering, Nottingham, UK).  
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When the cells reached confluency (75-90%) they were harvested by washing with 10 
ml of HBSS then incubated with pre-warmed 0.025% (w/v) trypsin/EDTA at 37˚C for 5 
min. Confirmation of detachment was performed by visual inspection using a phase 
contrast microscope (Zeiss, Germany). Cells were resuspended in 10 ml of DMEM 
media, transferred to a 50 ml sterilin tube (Sterilin, Houslow, UK) and centrifuged at 
900 rpm for 5 min using a bench centrifuge (MSE Mistral 200, RHYS International, 
Manchester, UK). Supernatant was decanted and the cell pellet resuspended in a known 
volume of media. An aliquot of cell suspension (100 μl) was stained by adding to trypan 
blue (100 μl, 1:2 dilution), mixed thoroughly and added to a Neubauer haemocytometer 
(Scientific Supplies Co, Middlesex, UK) for counting. For all experiments, cells were 
used between passages 34 and 42.  
 
2.1.5: Acute insulin secretory tests in BRIN-BD11 and 1.1B4 cells 
Confluent BRIN-BD11 or 1.1B4 (70-90%) cells were cultured and harvested as 
described in Sections 2.1.2 and 2.2.3, respectively. Cells were seeded into 24 well plates 
at a density of 150,000 cell per well (Nunclon, Roskilde, DK), supplemented with 1ml 
of RPMI-1640 media then incubated at 37˚C in 5% CO2 and 95% air overnight to allow 
for the development of monolayers. Prior to the acute test, media was decanted from 
each well then 1 ml of 1.1 mM glucose in Krebs Ringer Bicarbonate Buffer pre-
incubation buffer (KRBB, 4.7 mM KCl, 115 mM NaCl, 1.28 mM CaCl2.2H2O, 25 mM 
NaHCO3, 0.1% BSA (w/v), 1.2 mM KH2PO4, 1.2 mM MgSO4.7H2O, 20 mM HEPES 
(pH 7.4) was added for 40 min at 37˚C in 5% CO2 and 95% air. Following pre-
incubation, 1.1 mM glucose was decanted and cells were incubated with ranging 
concentrations (10-12-10-4 M) of GPCR agonists at both 5.6 mM and 16.7 mM glucose 
in KRBB for 20 min at 37˚C in 5% CO2 and 95% air. After 20 min incubation, cell 
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supernatants (900 μl) were collected stored at -20˚C until insulin measurement by 
radioimmunoassay.   
 
2.1.6: 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
BRIN-BD11 cells were cultured as previously described (Sections 2.1.2) and seeded into 
96-well plates at a density of 30,000 cells per well. BRIN-BD11 cells were then 
incubated overnight at 37˚C in 5% CO2 and 95% air. After overnight incubation, media 
was decanted and test solutions consisting of ranging concentrations (10-12-10-4 M) of 
GPCR agonists were added at both 5.6 mM and 16.7 mM glucose supplemented KRBB 
and incubated for 20 min at 37˚C in 5% CO2 and 95% air. Following exposure to GPCR 
treatments, test solutions were decanted and 1 mg/ml of working MTT solution prepared 
in normal culture media was added for 2 h and incubated at 37˚C in 5% CO2 and 95% 
air. Working MTT was decanted and 100µl of DMSO was added to each well, followed 
by 5 min mixing on a horizontal orbital microplate shaker at 500 rpm (Titramax 1000, 
Heidolph Instruments, Schwabach, DE). Absorbances were measured at 570 nm and 630 
nm using the FlexStation 3 (Molecular Devices, CA, USA). 
  
2.2: Insulin Radioimmunoassay (RIA) 
 
2.2.1: Materials  
Thimerosal, iodogen (1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril), BSA, activated 
charcoal, sequencing grade TFA, dextran T-70 and insulin were purchased from Sigma-
Aldrich (Poole, Dorset, UK). Dichloromethane (CH2Cl2) and HPLC grade acetonitrile 
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were sourced from Rathburn (Walkersburn, UK). Radiolabelled sodium iodide (Na125I) 
was supplied by Amersham Pharmacia Biotech (Buchinghamshire, UK). Rat insulin 
standards were purchased from Novo Industria (Copenhagen, Denmark). All other 
chemicals used were obtained from BHD chemicals (Poole, Dorset, UK).      
 
2.2.2: Preparation of iodinated insulin   
Iodogen was dissolved in dichloromethane (100 μg/ml) and 100 μl aliquots were 
transferred to the bottom of microcentrifuge tubes (Sarstedt, Germany) and evaporated 
using a gentle stream of helium for a uniform layer of iodogen. A 20 μl solution of 
insulin (125 μg/ml in 500 mM sodium phosphate buffer, pH 7.4) and 5 μl of Na125 I (100 
mCi/ml) were added to these iodogen coated reaction tubes in a designated controlled 
area with a lead Perspex shielding. The iodination mixture was left on ice for 15 min 
with 3-4 gentle agitations per min. The reaction was stopped by removing the mixture 
from the reaction tube into a fresh microcentrifuge tube, washing the reaction tube with 
500 μl of 50 mM sodium phosphate buffer which was also transferred to the fresh 
microcentrifuge tube. This iodination mixture is kept on ice until RP-HPLC separation 
of bound and unbound fractions. 
RP-HPLC was performed using a Spectra Series P200 TSP HPLC gradient pump system 
(CA, USA) with a Vydac C-8 analytical column (4.6 x 250mm, Phenomenex, 
Macclesfield, UK). The column was equilibrated using 0.12% (v/v) TFA/H2O and 
eluted with 0.1% (v/v) TFA in 70% acetonitrile/H2O from 0-40% over 10 min, from 40-
80% over 40 min and 80-100% over 10 min. A LKB2112 Redirac fraction collector 
(Bromma, Sweeden) was set to collect 1 ml fractions in 72 x 12mm polypropylene tubes 
(Sarstedt, Germany) of which 5 μl aliquots were transferred to plastic LP3 tubes 
(Sarstedt, Germany) and measured using a gamma counter (1470 Wizard multigamma 
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counter, PerkinElmer, USA). The fractions with the highest count per min (CPM) were 
selected for antibody binding and similar binding fractions pooled. Fractions were 
double diluted with 40 mM sodium phosphate buffer (pH 7.4) composed of 1% BSA 
(w/v), 1.2 mg/ml thiomersal and stored at 4˚C. A typical RP-HPLC elution profile of the 
iodination reaction with CMP versus time (min) as displayed in Fig. 2.1. 
 
2.2.3: Determination of insulin by radioimmunoassay 
Insulin was determined using a modified dextran-coated charcoal radioimmunoassay 
(RIA) as previously described (Flatt & Bailey 1981). Stock assay buffer was prepared 
from 40 mM disodium hydrogen orthophosphate with 0.3% NaCl (w/v) and 0.02% 
thimersol (w/v) and titrated with 40 mM sodium dihydrogen orthophosphate to pH 7.4. 
Working assay buffer was prepared composed of 40 mM sodium phosphate buffer (pH 
7.4) supplemented with 0.5% BSA (w/v) which was used to dilute guinea-pig anti-
porcine insulin antibody, rat insulin standards and 125I labelled insulin. The standard 
curve (0.039-20 ng/ml) was prepared by serial dilution of rat insulin standard and 
assayed in triplicate. Guinea-pig anti-porcine insulin antibody was diluted using working 
assay buffer (1:40,000) and 100 μl added to each standard or unknown sample with the 
exception of total and non-specific binding tubes. 125I labelled insulin was diluted in 
assay buffer to 10,000 cpm/ 100 μl which was added to all tubes. 
After 48 h at 4˚C, a 1 ml solution of 1:5 dilution of dextran T-70 coated charcoal in 
working assay buffer was added to all tubes except the total tubes for 20 min at 4˚C. All 
tubes were centrifuged using a Model J-6B Centrifuge (Beckman Instruments, UK) for 
20 min at 2,500 rpm (4˚C), the supernatant decanted and the unbound 125I labelled insulin 
fraction remained as a black pellet which were counted on the gamma counter (1470 
Wizard Multigamma Counter, PerkinElmer, USA). Counts bound to the antibody (total 
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CPM minus CPM bound to charcoal) were inversely proportional to the concentration 
of insulin in standards or unknown samples. The rat insulin standard curve was 
constructed with spline curve fitting algorithm and the unknown samples interpolated 
from the curve. The rat insulin standard stock of 1 ng/ml insulin is equal to 173 pM and 
conversion from ng/ml to pM was performed by multiplication by a factor of 173. A 
typical rat insulin standard curve is shown with CPM versus log insulin concentrations 
in Fig 2.2. 
 
2.3: Intracellular Ca2+ measurement  
 
2.3.1: Materials  
FLIPR calcium assay kits were purchased from Molecular Devices (CA, USA). Black 
walled, clear bottom, 96 well plates were obtained from Greiner Bio-One 
(Gloucestershire, UK). Probenecid and L-alanine were sourced from Sigma-Aldrich 
(Poole, Dorset, UK).  
 
2.3.2: Determination of intracellular Ca2+ in BRIN-BD11 cells  
FLIPR calcium assay kits employ a calcium specific dye that is absorbed into the cell 
cytoplasm during the incubation. Following agonist-receptor activation, intracellular 
calcium bound to the dye is released from the cells increasing the fluorescence intensity. 
BRIN-BD11 cells were seeded at a density of 80,000 cells per well into 96 well black 
walled, clear bottom plate and incubated overnight at 37°C as previously described 
(Section 2.1.2). The assay plate was washed with 1.1 mM glucose KRBB solution 
54 
 
composed of 4.7 mM KCl, 115 mM NaCl, 1.28 mM CaCl2.2H2O, 25 mM NaHCO3, 
0.1% BSA (w/v), 1.2 mM KH2PO4, 1.2 mM MgSO4.7H2O, 25 mM HEPES, 
supplemented with probenecid (500 μM). Probenecid prevents the transport of unbound 
dye out of the cells by organic anion transporters. The assay plate was incubated with 
the dye prepared with KRBB at 5.6 mM or 16.7 mM glucose for 1 h at 37°C. The 
FlexStation 3 (Molecular Devices, CA, USA) was set to run for 5 min at 485 nm 
excitation, 525 nm emission, 515 nm cut-off filter with 2.5 sec intervals. Test solutions 
(x5) were transferred (50 μl) at 60 s from the start of the acquisition at a rate of 78 ml/s. 
Alanine (10 mM) a known modulator of intracellular calcium was used as the positive 
control for all calcium assays. 
 
2.4: Cyclic AMP assay  
 
2.4.1: Materials  
cAMP enzyme immunoassay kits were purchased from Sigma-Aldrich (Poole, Dorset, 
UK). Sterile, flat bottom, 96-well tissue culture plates were obtained from Nunc 
(Roskilde, Denmark).  
 
2.4.2: Measurement of cAMP production in BRIN-BD11 cells 
The assay utilises a polyclonal anti-cAMP antibody to competitively bind to cAMP in the 
sample or alkaline phosphatase with a cAMP molecule attached. This enzymatic reaction 
is based on the colour intensity which is inversely proportional to the concentration of 
cAMP in the standards or samples. BRIN-BD11 cells were seeded into 96-well plates at 
a density of 30,000 cells per well and incubated overnight at 37°C as previously outlined 
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(Section 2.1.2). The contents of the kit were allowed to reach room temperature before 
use and the assay kit was performed as per the manufacturer’s protocol. For standard 
curve preparation, cAMP standards ranging from 0.78-200 pM/ml were diluted in 0.1 M 
HCl which were used within 60 min (Fig. 2.3). Wash buffer was prepared by diluting 
10ml of the concentrated wash buffer in 90 ml of distilled water. RPMI-1640 media was 
aspirated from the plate and cells washed in 300 μl of 1.1 mM KRB buffer for 40 min. 
Test solutions (150 μl) were added to the cells for 20 min incubation at 37°C. After acute 
incubation all test solutions were removed from the plate and 150 μl of 0.1M HCl was 
added to lyse the cells. To ensure adequate lysis had occurred, cells were incubated at 
37°C for 10 min and inspected using a phase contrast microscope (Zeiss, Germany). 
Incubation for a further 10 min was performed if adequate lysis had not occurred and 
once adequate lysis had occurred supernatants were aliquoted into labelled tubes.  
 
Neutralising reagent (50 μl) was added to all wells of the assay plate except the total and 
blank wells while 100 μl of 0.1M HCl was added to the non-specific binding (NSB) and 
standard 0 (0 pM/ml) wells. Unknown samples (100 μl) were added to the corresponding 
wells and 50 μl of 0.1M HCl to the NSB wells. Blue cAMP-alkaline phosphatase 
conjugate (50 μl) and cAMP-EIA antibody (50 μl) was added to all wells except the total 
and blank wells. The assay plate was incubated at room temperature on an orbital plate 
shaker set at 500 rpm for 2 h. Contents of the plate were removed and washed 3 times 
with 200 μl of the wash buffer. cAMP-alkaline phosphatase (5 μl) was transferred to the 
total wells and 200 μl of p-Nitrophenyl phosphate was added to all wells of the assay plate 
which was incubated for 1 h at room temperature. The stop solution (50 μl) was added to 
all wells and read immediately on the Flexstation 3 plate reader (Molecular Devices, CA, 
USA). The plate was read at 405 nm with corrections between 570 nm and 590 nm and 
the mean blank value was subtracted from all readings.  
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2.5: Determination of BRIN-BD11 cell proliferation and apoptosis upon GPCR 
agonist treatment. 
 
2.5.1: Materials 
ApoLive-Glo™Multiplex Assay was purchased from Promega (Wisconsin, US) 
 
2.5.2 Measurement of cell proliferation and apoptosis 
ApoLive-Glo multiplex assay was used to assess BRIN-BD11 cell proliferation and 
apoptosis. Cells were seeded at a density of 20,000 cells per well in a 96 well plate and 
allowed to attach overnight (Section 2.1.2). Agonist test solutions (10-4 mol/l) and 
cytokine cocktail solution (TNF-α [200 U/ml], IFN-γ [20 U/ml], IL-1β [100 U/ml]) were 
prepared in RPMI media to a final volume of 100 µl per well, then added to the cells and 
incubated for 20 h at 37oC. After the test incubation period, 20 µl of Viability Reagent 
was added to each well and briefly mixed by orbital shaking (300–500 rpm for ~30 
seconds), then incubated for 30 min at 37°C. Fluorescence was then measured at the 
following wavelength set: 400Ex/505Em using the Flexstation 3 plate reader (Molecular 
Devices, CA, USA). To determine caspase 3/7 activity, 100µl of Caspase-Glo® 3/7 
Reagent was to all wells, and briefly mixed by orbital shaking (300–500 rpm for ~30 s), 
then incubated for 30 min at room temperature. Luminescence was then determined 
using the FlexStation 3 plate reader (Molecular Devices, CA, USA). 
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2.6: Determination of mRNA expression in BRIN-BD11 cells and Swiss TO mouse 
pancreas  
 
2.6.1: Materials  
TRIzol reagent, propan-2-ol and chloroform was supplied by Sigma (Poole, Dorset, 
UK). Superscript II reverse transcriptase RNase H kit was supplied by Invitrogen 
(Paisley, UK). Eppendorf real-time PCR tube strips & masterclear cap strips were 
sourced from Bio-Rad Laboratories (Herrtfordshire, UK). LightCycler® 480 SYBR 
Green I Master was obtained from Roche (Basel, CH).  
 
2.6.2: mRNA extraction and conversion to cDNA  
mRNA was extracted from all cell lines and tissue using the phenol chloroform method 
as described previously (Chomczynski, Sacchi 1987) Briefly, cells and tissue were 
harvested as previously mentioned (Sections 2.1.2). Tissue was homogenised and lysed 
in 1 ml of TRIzol reagent. Cells were seeded in 6-well plates, treated with test solutions 
for the appropriate time and lysed using TRIzol on ice for 10 min. Cells were agitated 
with gentle stirring. Tissue and cells were transferred to a fresh microcentrifuge tube and 
200 μl of chloroform was added. This suspension was agitated and incubated at room 
temperature for 10 min before undergoing centrifugation at 12,000g for 15 min at 4°C 
(MIKRO 200R, Hettich Zentrifugen, Germany). The clear upper aqueous phase 
containing mRNA was transferred to a new microcentrifuge tube and 0.5 ml of propan-
2-ol was added. The interphase and organic phase were discarded. The mixture was 
agitated and incubated at room temperature for 10 min before centrifugation at 12,000g 
for 10 min at 4°C. The supernatant was discarded, and 70 % ethanol was used to wash 
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the pellet of mRNA then centrifuged at 12,000g for 10 min at 4°C. This was repeated 
for a total of 3 times. The supernatant was then discarded and pellets air dried at room 
temperature for 10 min. Following air drying, the pellet was suspended in 30 μl of RNase 
free water and heated at 70°C for 5 min before determination of the mRNA yield using 
a nanophotometer (Implen, version 2.0). The quality of mRNA was determined by 
260/280 ratios with ratios between 1.9 and 2.1 being deemed of sufficient quality. From 
this mRNA, 1-5 μg was converted to cDNA using the superscript II reverse transcriptase 
– Rnase H kit as per suppliers’ instructions. mRNA samples were stored long term at -
80°C while cDNA was stored at -20°C.  
 
2.6.3: Quantitative real-time PCR (qPCR) 
qPCR was performed using LightCycler® 480 SYBR Green I Master. Reactions were 
performed using 4.5 μl of 2x concentrated SYBR green, 1 μl of forward and reverse 
primers (Table 2.3), 1 μl of cDNA and 3 μl of RNase free water (n=3). All reactions 
included a negative template control with RNase free water added instead of cDNA 
(n=3). The reactions were carried out in 8-well real-time PCR Tube Strips and 
Masterclear™ Cap Strips (Eppendorf, HAM, DE). Amplification conditions were 5 min 
initial denaturation at 95°C, followed by 40 cycles of 30 s denaturation at 95°C, 30sec 
annealing at 58°C and 30 s extension at 72°C and a final elongation step for 5min at 
72°C. Reactions included melting curve analysis with temperature range of 60°C to 
90°C. All reactions were carried out using the MiniOpticon two colour real time PCR 
detection system (BioRad, UK). Analysis of results was performed using the Livak 
method and the mRNA levels of all genes were normalised using the housekeeping gene 
GAPDH. Primer sequences for qPCR are listed in Table 2.3. 
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2.7: Protein expression in BRIN-BD11 cells using western blotting 
 
Cells were seeded at a density of 1,000,000 cells per well in 6-well plates and allowed to 
attach overnight. After treatment, total protein was extracted at 4oC for 10 min using 
RIPA buffer containing 150 mM NaCl, 1.0% Nonidet P-40, 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris HCl, pH 7.6, protease inhibitor cocktail (Sigma, UK) and 
phosphatase inhibitor cocktails 1 + 2 (Abcam, UK). Total protein concentration was 
determined using Bradford reagent (Sigma, UK). Equal amounts of protein were 
aliquoted with Laemmli buffer (1µg/µl), then boiled at 95oC for 10 min. Samples (25µg 
per well) were loaded onto pre-cast gels (NUPAGE 4–12 % Bis–Tris gels, Invitrogen, 
UK) and subjected to SDS-PAGE (70V, 90 min). After transfer to nitrocellulose 
membrane for 16 h at 90 mA, membranes were blocked with 5% skimmed milk and 
probed with primary antibodies (Table 2.2). Membranes were probed with ECL 
horseradish peroxidase donkey anti-rabbit IgG/ECL horseradish peroxidase sheep anti-
mouse IgG (1:10000) (GE Healthcare, UK) and detected using Luminata Forte HRP 
substrate (Millipore, UK). Data were normalised to β-actin and presented relative to 
untreated control. 
 
2.8: Histology  
 
2.8.1: Materials  
BSA, paraformaldehyde (PFA), 4’ 6-diamidino-2-phenylindole (DAPI) nuclear stain and 
ethanol were purchased from Sigma-Aldrich (Poole, Dorset, UK). PBS tablets were 
obtained from Analab (Dublin, Ireland), while xylene was obtained from VWR (Dublin, 
Ireland). All other chemicals used were obtained from BHD chemicals (Poole, Dorset, 
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UK). Suppliers of all primary and secondary antibodies used for immunohistochemical 
staining are shown in Table 2.1.  
 
2.8.2: Immunofluorescence staining of BRIN-BD11 cells  
BRIN-BD11 cells were seeded overnight at 60,000 cells per polylysine-coated slide (25 
x 75 x 1 mm, VWR) and incubated in sterile petri dishes with 25 ml of RPMI-1640 at 
37˚C. Slides were washed twice in PBS for 5 min and cells fixed in 4% PFA/PBS (v/v) 
for 20 min at room temperature. After fixation, slides were washed 3 times in PBS and 
antigen retrieval achieved by incubation in 50 mM sodium citrate (pH 6.0) at 90˚C for 20 
min. Slides were blocked with 1.1% BSA (w/v) for 30 min and primary antibodies added 
(200 μl per slide) at optimised dilutions, overnight at 4˚C or 1 h at 37˚C (Table 2.1). After 
incubation with primary antibodies, slides were washed 3 times in PBS and appropriate 
secondary antibodies added (200 μl per slide) for 45 min at 37˚C, protected from light. 
Slides were washed 3 times in PBS and DAPI (0.1 μg/ml) added to slides for 15 min at 
37˚C. Finally, slides were washed twice in PBS, mounted with a glycerol/ PBS solution 
(1:1) and fixed with clear nail varnish. Slides were analysed under the 350 nm filter 
(DAPI), fluorescein isothiocyante (FITC) filter (488 nm) and tetramethylrhodamine 
isothiocyanate filter (TRITC) filter (594 nm) using a fluorescent microscope (Olympus 
BX51 microscope, South-on-Sea, UK) and images acquired using the DP70 camera. 
 
2.8.3: Tissue processing and immunofluorescence staining of pancreatic tissue  
Non-fasted mice were anesthetised by isoflurane and killed by cervical dislocation. 
Pancreata were extracted into labelled cassettes and placed in 4% PFA (w/v) for at least 
48 h at 4˚C. Tissue samples were embedded in paraffin wax using the automated Leica 
TP1020 automated tissue processor (Leica Bio systems, Germany) as per manufacturer’s 
guidelines. In brief, labelled cassettes were placed in the metal basket attached to the lid 
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of the tissue processor which transferred the cassettes between 4% PFA (w/v), increasing 
concentrations of ethanol, xylene and molten paraffin wax as follows: 70%, 80%, 96% 
ethanol (v/v) for 2 h each, 100% ethanol 2 changes for 2 h, xylene 2 changes for 1 h 30 
min and 2 changes in paraffin wax for 4 h. The following day pancreata were placed in 
moulds, appropriately orientated, covered in molten paraffin wax and labelled cassettes 
attached to the top. Paraffin wax blocks were left to set for 24 h, after which blocks were 
removed from the moulds and stored at room temperature.  
Pancreatic sections were cut at 8 μm using a microtome (RM2035, Leica, Germany), 
floated on a 37˚C water bath and lifted onto polylysine-coated slide (25 x 75 x 1mm, 
VWR). Slides were dried on a hot plate at 37˚C for 2 h and overnight at room 
temperature. The slides were dewaxed by 2 changes of xylene for 10 min, rehydrated 
with 2 changes in 100% ethanol for 5 min, 95% ethanol (v/v) for 5 min, 80% ethanol 
(v/v) for 5 min and distilled water for 5 min. Antigen retrieval, blocking, staining 
procedure, mounting and visualisation of slides was performed as outlined above 
(Section 2.8.2). 
 
2.9: Animal models  
 
All animal experiments were performed in accordance with the UK Animal (Scientific 
Procedures) Act 1986 and the ARRIVE guidelines for experiments involving animals 
(Kilkenny et al. 2010). All mice were housed in an air-conditioned room maintained at 
22 ± 2˚C with a 12 h dark: 12 h light cycle (08:00-20:00).  
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2.9.1: Swiss TO mice  
Male Swiss TO mice (8 wk) were purchased from Envigo (Huntingdon, UK) derived 
from a nucleus colony originally sourced from the National Institute of Health (Maryland, 
USA). Mice were single caged with drinking water and standard rodent maintenance diet 
(60% carbohydrate, 30% protein, 10% fat (12.99 kJ/g), Trouw Nutrition, Cheshire, UK) 
supplied ad libitum. Age-matched, Swiss TO were used as a model of normoglycemia 
and grouped according to body weight and non-fasting plasma glucose.  
 
2.9.2: Diet induced diabetic mice  
Male Swiss TO mice (8-10 wk) were obtained from Envigo (Huntingdon, UK) as 
described previously (Section 2.10.1). Groups of 3-5 mice (10 wk old) were caged with 
drinking water and high fat diet (35% carbohydrate, 20% protein, 45% fat (26.15 kJ/g), 
Special Diet Service, Essex, UK) supplied ad libitum for 4 months to induce obesity-
diabetes. Swiss TO mice on a high fat diet exhibited increased body weight, 
hyperglycaemia and impaired glucose tolerance when compared to mice on the standard 
rodent maintenance diet as outlined previously (Bailey et al. 1986). This form of diet-
induced diabetes in mice closely resembles a high fat western diet and several important 
clinical features identified in human obesity. 
 
2.10: Acute in-vivo glucose tolerance tests  
 
2.10.1: Materials  
Fluoride/ heparin coated microcentrifuge tubes were purchased from Sarstedt (Germany). 
D-glucose and NaCl were obtained from BDH Chemicals (Poole, Dorset, UK). Bayer 
Contour Next glucose meter and strips were sourced from Williams Medical Supplies 
(Rhymney, UK).   
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2.10.2: Glucose tolerance tests  
Two animal models were utilised in these studies including Swiss TO mice and high fat 
fed Swiss TO mice. Mice were fasted for 18 h prior to testing. Groups of mice (n=6) were 
maintained as described in Section 2.9, with food withheld for the duration of the 
experiment. Blood samples were collected via tail vein bleeding of conscious mice prior 
to the commencement of testing (0 min). GPCR agonists were administered orally in 
combination with glucose (18 mmol/kg BW) or in combination with glucose and the DPP 
IV inhibitor Sitagliptin Phosphate (50 mg/kg BW). Blood (50 µl) was collected at 15, 30, 
60, 90 and 120 min post administration and centrifuged at 16,060 × g for 3 min at 4oC. 
Plasma glucose was measured using an automated glucose oxidase procedure with a 
Beckman glucose analyser (Rhymney, UK) and insulin was determined by 
radioimmunoassay. Intestinal hormone secretion was assessed using specific ELISA kits; 
total GLP-1 (Millipore, UK) and total GIP (Millipore, UK). DPP-IV activity was 
evaluated by Gly-Pro-AMC cleavage (Sigma, UK). 
 
 
2.11: Chronic biological effects of ALA and Abn-CBD in high fat fed induced 
diabetic mice  
 
2.11.1: Materials  
ALA and Abn-CBD were purchased from Tocris Bioscience (Bristol, UK). Sitagliptin 
Phosphate was sourced from Apex Bioscience (Durham, North Carolina, USA). Multi 
species GLP-1 total and rat/mouse GIP total ELISA kits were supplied by Merck 
Millipore (Watford, UK). Insulin was purchased from Sigma-Aldrich (Poole, Dorset, 
UK). D-glucose and NaCl were obtained from BDH Chemicals (Poole, Dorset, UK). 
Materials for triglyceride assay were purchased from Instrumentation Laboratory 
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(Warrington, UK) while kits for total cholesterol and HDL were purchased from Randox 
(Co Antrim, UK). Amylase assay kits were purchased from Abcam (Cambridge, UK).  
 
2.11.2: Treatment procedure and parameters assessed  
Long-term daily oral administration of ALA and Abn-CBD (0.1 μmol/kg body weight) 
monotherapy or combinational therapy (Sitagliptin; 50 mg/kg BW) or saline (0.9% w/v 
NaCl) were assessed in high fat fed-induced diabetic Swiss TO mice (n=8) (Section 
2.9.2). Glucose tolerance was assessed by an OGTT which was performed 4 months after 
the commencement of the high fat diet and prior to the study on 18 h fasted Swiss TO 
mice. Food intake, fluid intake, body weight, non-fasted plasma glucose and insulin 
concentrations were monitored every 3 days as indicated in the figures. Blood samples 
were collected and analysed for plasma glucose and insulin, GLP-1, GIP and DPP-IV 
activity. After 21-day oral administration of GPCR agonist-based therapies, glucose 
tolerance was assessed by an OGTT (18 mmol/kg body weight) on 18 h fasted as 
previously outlined (Section 2.10.2).  
 
2.11.3: Insulin sensitivity  
Blood glucose was measured from the cut tail vein tip of non-fasted Swiss TO mice using 
the handheld Acensia Countour glucose meter (Bayer Healthcare, UK) prior to the 
injection of insulin. Following the intraperitoneal injection of insulin (40 U/kg) prepared 
in saline (0.9% v/v), blood glucose was measured at 30, 60 min post injection.  
 
2.11.4: Dual energy X-ray absorption (DEXA)  
Non-fasted mice were anesthetised by isoflurane, killed by cervical dislocation and placed 
on the specimen tray taking care to extend limbs from the body. Calibration and quality 
control were achieved by 25 measures of the aluminium/lucite phantom (0.069 g/cm2, 
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12.0% fat) using a Lunar PIXImus Dual energy X-ray absorption (DEXA) system 
(software version 1.4x). DEXA scanning was performed on all carcasses as per 
manufacturer’s guidelines. The Lunar PIXImus DEXA system calculates percentage 
body fat and the fully integrated densitometer estimates bone mineral density (BDM, 
g/cm3) and bone mineral content (BMC, g). A representative DEXA scan of a lean Swiss 
TO mouse and a high fat fed-induced diabetic mouse are shown in Fig. 2.4. 
 
2.11.4: Measurement of plasma hormones and biomarkers 
Blood was collected via tail vein bleed on conscious mice every 3 days for biochemical 
analysis. Plasma glucose determination was performed using a Bayer Contour Next meter 
(Leverkusen, DE) every 3 days. Plasma insulin was quantified using insulin 
radioimmunoassay as previously described in Section 2.2.3. Rat/mouse GIP total ELISA 
kit (Millipore, Watford, UK) was used to measure total GIP concentrations in mouse 
plasma following chronic treatment. Multi species GLP-1 total ELISA was used to 
measure total GLP-1 content of mouse plasma. Rodent alpha amylase and C-reactive 
protein ELISA kits were performed using terminal plasma samples following 21-day 
treatment. DPP-IV activity was assessed on terminal plasma by Gly-Pro-AMC cleavage. 
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2.11.5: Assessment of plasma lipid profiles  
Plasma triglyceride and HDL cholesterol and total cholesterol concentrations were 
measured using an I-lab 650 clinical chemistry instrument (Instrumentation Laboratory, 
Warrington, UK). Reagents for triglyceride assay were purchased from Instrumentation 
Laboratory (Warrington, UK) while kits for total cholesterol and HDL were purchased 
from Randox (Co Antrim, UK). LDL cholesterol (mM) was calculated using the 
Friedewald equation: 
  
LDL cholesterol = Total cholesterol - HDL cholesterol – 2.2/Triglycerides 
 
2.11.6: Tissue extraction and immunofluorescence staining  
Pancreases were extracted in 4% PFA (w/v) for immunohistochemistry examination or 
snap frozen in liquid nitrogen for measurement of pancreatic insulin content. Pancreatic 
tissues were processed, cut (as previously outlined Section 2.8.3) and stained for insulin, 
glucagon, GPR55, GPR120 and Ki-67 at the dilutions recorded in Table 2.1. Relative 
quantification was performed on >50 islets per treatment group using Cell F software. 
 
2.11.7: Pancreatic insulin content  
Pancreatic tissues were placed in -80˚C for storage prior to the determination of pancreatic 
insulin content. Tissue was thawed and rinsed in ice cold PBS before being weighed 
homogenised in a bijou tube with 5 ml (50 mg tissue) of ice cold RIPA buffer (150 mM 
sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, 
pH 8.0). Samples were centrifuged at 3000 rpm for 20 min using a Beckman 
microcentrifuge (Beckman Instruments, UK) and supernatant transferred to a fresh tube. 
Samples were measured by insulin radioimmunoassay (Section 2.2.3) and normalised to 
total protein content. 
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2.11.8: Measurement of Amylase activity 
Multi-species Amylase Assay Kit (Colorimetric) was used to quantify plasma amylase 
activity. Amylase Assay kit (Colorimetric) (ab102523) detects activity of α-amylase 
through a two-step reaction. α-Amylase will cleave the substrate ethylidene-pNP-G7 to 
produce smaller fragments that are eventually modified by α-glucosidase, causing the 
release of a chromophore that can then be measured at OD = 405 nm. The assay can 
detect α-amylase content as low as 0.2 mU. Plasma (20 µl) was used for analysis. Each 
kit contained one 96 well plate. 
Components of the kit were pre-warmed to room temperature before commencing the 
assay as per manufacturer’s protocol. A 0-20 nmol amylase standard and positive 
controls were prepared following manufacturers protocol. An aliquot (100 µl) of 
reaction mix was prepared for each reaction by mixing 50 µl of assay buffer with 50 µl 
of substrate buffer. Samples, standards and controls were added to each well, followed 
by 100 µl of reaction mix. The plate was then mixed on an orbital shaker for 1 min at 
400 rpm. The absorbance was then immediately determined at OD=405 in a kinetic 
mode, every 2 min for 60 min at 25oC using a FlexStation 3. Two time points (T1 and 
T2) within the linear range of the standard were chosen to calculate the amylase activity, 
as per manufacturer’s protocol.  
 
2.12: DPP-IV assay 
 
2.12.1: Materials 
All water used was purified using Milli-Q Water Purification System (Millipore 
Corporation, Milford, MA, USA). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), N, N-Dimethyl-formamide (DMF), Gly-Pro-7-amido-4-methylcoumarin (Gly-
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pro AMC), 7-amino-4-methylcoumarin (AMC) and acetic acid were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). Black, flat bottom, 96-well plates were obtained 
from Greiner Bio-One (Gloucestershire, UK). 
 
2.12.2: Measurement of plasma DPP-IV activity 
This fluorometric method is based on the liberation of AMC from the substrate Gly-Pro-
AMC by the enzyme DPP-IV in plasma or tissue. A stock solution of 50 mM AMC was 
dissolved in DMF and from this stock 100 μl was added to 5 ml of distilled water. This 
provides a 1 mM AMC solution which is used to prepare the standard curve ranging from 
0.24-15.6 μM dissolved in 1 mM HEPES buffer (pH 7.4) (Fig. 2.5). Standards were 
performed in triplicate by adding 35 μl to each well. Unknown samples were also 
performed in triplicate by the addition of 10 μl sample with 25 μl of 1 mM HEPES 
containing Gly-pro AMC substrate (1.8 mM). The 384 well plate was incubated at 37˚C 
for 60 min and reaction stopped by adding 70 μl of 3M acetic acid (pH 2.6). AMC was 
measured on the FlexStation 3 (Molecular Devices, CA, USA) using excitation 
wavelength of 370 nm with 9 nm slit-width and emission of 440 nm with 2.5 nm slit-
width. Unknown samples were interpolated from the curve and one unit of DPP-IV 
activity was defined as the enzyme activity which produced 1 μM of AMC per 10 μl of 
plasma in 1 min (μM/ml/min). 
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2.13: Enzyme-linked immunosorbent assay (ELISA) 
 
2.13.1: Materials 
Multi species GLP-1 total ELISA and rat/mouse GIP total ELISA kits were purchased 
from Merck Millipore (Watford, UK). Mouse C-reactive Protein was purchased from 
Abcam (Cambridge, UK)  
 
2.13.2: Measurement of GLP-1 
Multi species GLP-1 total ELISA kits were used to quantify the GLP-1 content of both 
plasma and cell culture supernatant samples. This is a sandwich-based ELISA which 
measures both the 7-36 and 9-36 forms of GLP-1. Plasma (20 µl) was used for analysis. 
Each kit contained one 96 well plate. 
Components of the ELISA were pre-warmed to room temperature before commencing 
the assay as per manufacturer’s protocol. A 4.1-100 pM GLP-1 standard was prepared 
from 1000 pM GLP-1 standard. Quality control 1 and quality control 2 were 
reconstituted in H2O. Blank, standard and quality control wells were tested in duplicate 
while unknown samples were assayed in triplicate. Following plate preparation as per 
manufacturer’s protocol, 50 μl of standards, quality controls and unknown samples were 
added and incubated at room temperature for 1.5 h on a horizontal orbital microplate 
shaker at 450 rpm. Solutions were decanted and wells washed 3 times with wash buffer 
(300 μl). Detection antibody (100 μl) was added and plate incubated for 1 h on a 
horizontal orbital microplate shaker at room temperature at 450 rpm. Detection antibody 
was decanted and wells washed 3 times with 300 μl of wash buffer before the addition 
of 100 μl of enzyme solution and incubation for 30 min on a horizontal orbital microplate 
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shaker at 450 rpm. Enzyme solution was decanted, wells washed 3 times with wash 
buffer (300 μl) and 100 μl of substrate solution added. The plate was incubated on a 
horizontal orbital microplate shaker at 450 rpm until a blue colour was formed. Stop 
solution (100 μl) was added and absorbance read at 450 nm and 590 nm using a 
FlexStation 3. A typical GLP-1 standard curve is shown with absorbance versus log 
GLP-1 concentrations in Fig. 2.6. 
 
2.13.3: Measurement of GIP 
Rat/mouse GIP total ELISA kits were used to quantify plasma GIP concentrations. This 
is a sandwich-based ELISA which measures both the 1-42 and 3-42 forms of GIP. 
Plasma (20µl) was used for analysis. Each kit contained one 96 well plate. 
Components of the ELISA were pre-warmed to room temperature before commencing 
the assay as per manufacturer’s protocol. An 8.2 to 2000 pM GIP standard was prepared 
from a 2000 pM GIP standard. Quality control 1 and quality control 2 were reconstituted 
in H2O. Blank, standard and quality control wells were tested in duplicate while 
unknown samples were assayed in triplicate. Following plate preparation as per 
manufacturer’s protocol, 10 μl of standards, quality controls and unknown samples were 
added to the appropriate wells and incubated at room temperature for 1.5 h on a 
horizontal orbital microplate shaker at 450 rpm. Solution were decanted and wells 
washed 3 times with wash buffer (300 μl). Detection antibody (100 μl) was added for 1 
h on a horizontal orbital microplate shaker at room temperature at 450 rpm. Detection 
antibody was decanted and wells washed 3 times with 300 μl of wash buffer before the 
addition of 100 μl of enzyme solution and incubation for 30min on a horizontal orbital 
microplate shaker at 450 rpm. Enzyme solution was decanted, wells were washed 3 
times with wash buffer (300 μl) and 100 μl of substrate solution was added. The plate 
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was incubated on a horizontal orbital microplate shaker at 450 rpm until a blue colour 
was formed. Stop solution (100 μl) was added then absorbance was read at 450 nm and 
590 nm using a FlexStation 3. A typical GIP standard curve is shown with absorbance 
versus log GIP concentrations in Fig. 2.7. 
 
2.13.4 Measurement of C-Reactive Protein 
Mouse C-Reactive Protein (CRP) ELISA kits were used to quantify plasma CRP 
concentrations. Plasma (20 µl) was used for analysis. Each kit contained one 96 well 
plate. 
Components of the ELISA were pre-warmed to room temperature before commencing 
the assay as per manufacturer’s protocol. A 156.25 to 40000 pg/ml CRP was prepared 
from a 4000 pg/ml standard (Fig. 2.8). Each well was incubated for 5 min in 300 μl of 
wash buffer. Wash buffer was decanted and wells received 50 μl of sample or standard. 
Blank, standard and quality control wells were tested in duplicate while unknown 
samples were assayed in triplicate. Following plate preparation, 50 μl of antibody 
solution was added to each well and incubated at room temperature for 1 h on a 
horizontal orbital microplate shaker at 400 rpm. Solutions were decanted and wells 
washed 3 times with wash buffer (300 μl). TMB substrate solution (100 μl) was added 
to the plate and incubated for 10 min on a horizontal orbital microplate shaker at room 
temperature at 400 rpm in the dark. Stop solution (100 μl) a was added to each well and 
mixed on a horizontal orbital microplate shaker at 400 rpm for 1 min. Optical density 
was read at 450 nm using a FlexStation 3.  
 
 
72 
 
2.14: Statistics 
  
Data are expressed as the mean ± the standard error of the mean (SEM). Results were 
compared using the Student’s t-test or one-way ANOVA followed by Newman-Keuls 
pos-hoc test as appropriate on Prism graph pad version 5.0. Incremental area under the 
curve (AUC) with baseline subtraction, were calculated using Prism graph pad. 
Differences in data were considered to be statistically significant for p<0.05. 
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Table 2.1: Primary and secondary antibodies used for immunohistochemical 
staining. 
 
Primary 
Antibodies 
Host Species Dilution Source 
Insulin Guinea pig 1:500 Abcam (Cambridge, UK) 
Glucagon Guinea pig 1:200 Raised in-house 
GPR120 Rabbit 1:100 Santa Cruz Biotechnology 
(CA, USA) 
GPR55 Rabbit 1:100 Cayman Chemical 
(Michigan, US) 
Ki-67 Rabbit 1:200 Abcam (Cambridge, UK) 
 
Secondary 
Antibodies 
Host Species Dilution Source 
Anti-guinea pig  
Alexafluor 488 nm 
Goat 1:400 Molecular probes, Life 
Technologies (Paisley, UK) 
Anti-Rabbit  
Alexafluor 488 nm 
Goat 1:400 Molecular probes, Life 
Technologies (Paisley, UK) 
Anti-guinea pig  
Alexafluor 594 nm 
Donkey 1:400 Molecular probes, Life 
Technologies (Paisley, UK) 
Anti-Rabbit  
Alexafluor 594 nm 
Donkey 1:400 Molecular probes, Life 
Technologies (Paisley, UK) 
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Table 2.2: Primary and secondary antibodies used for western blotting. 
 
Primary 
Antibodies 
Host Species Dilution Source 
Total ERK1/2 Rabbit 1:1000 Cell Signalling (MA, USA) 
Phospho ERK1/2 Rabbit 1:1000 Cell Signalling (MA, USA) 
Total JNK Rabbit 1:200 Santa Cruz Biotechnology 
(CA, USA) 
Phospho JNK Rabbit 1:200 Santa Cruz Biotechnology 
(CA, USA) 
Total p38 Rabbit 1:200 Santa Cruz Biotechnology 
(CA, USA) 
Phospho p38 Rabbit 1:200 Santa Cruz Biotechnology 
(CA, USA) 
GPR120 Rabbit 1:150 Santa Cruz Biotechnology 
(CA, USA) 
GPR55 Rabbit 1:150 Cayman Chemical 
(Michigan, US) 
Β-actin Mouse 1:2500 Cell Signalling (MA, USA) 
 
Secondary 
Antibodies 
Host Species Dilution Source 
Anti-Rabbit IgG Donkey 1:10000 GE Healthcare (IL, USA) 
Anti-Mouse IgG Sheep 1:10000 GE Healthcare (IL, USA) 
 
 
 
 
 
75 
 
Table 2.3: Primers used for qPCR. 
Rat: 
Gene 
nomenclature 
Name/Alias Primer Sequence 
(5’ – 3’) 
GAPDH Glyceraldehyde 
3-phosphate 
dehydrogenase 
Sense- GCATCTTCTTGTGCAGTGCC 
Anti-sense - GAGAAGGCAGCCCTGGTAAC 
Ffar4 GPR120 Sense - AAGTCAATCGCACCCACTTC 
Anti-sense - GAAGAGGTTGAGCACCAAGC 
Gpr55 GPR55 Sense - GGGATACAAGTGCTTCCACA 
Anti-sense - AAAGGAGACCACGAAGACGA 
INS Insulin Sense - GCCCAGGCTTTTGTCAAACA 
Anti-sense - CTCCCCACACACCAGGTAGAG 
 
Mouse: 
Gene 
nomenclature 
Name/Alias Primer Sequence 
(5’ – 3’) 
GAPDH Glyceraldehyde 
3-phosphate 
dehydrogenase 
Sense- GGACCTCATGGCCTACATGG 
Anti-sense - TAGGGCCTCTCTTGCTCAGT 
Ffar4 GPR120 Sense - CTGGGGCTCATCTTTGTCGT 
Anti-sense - ACGACGAGCACTAGAGGGAT 
Gpr55 GPR55 Sense - ATTTGGAGCAGAGGCACGAA 
Anti-sense - AGGTTGAGAACCAGGCCAAG 
INS Insulin Sense - CTGGTGGGCATCCAGTAACC 
Anti-sense - CAAAAGCCTGGGTGGGTTTG 
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Figure 2.1: Typical HPLC profile representing iodinated insulin.  
 
 
  
 
Insulin labelled with Na125I was prepared using the iodogen method described in Section 
2.2.2. Separation of bound and unbound fractions was achieved by RP-HPLC using a 
Vydac C-8 column. Elution of the iodination reaction mixture occurred using 70% 
acetonitrile/H2O (v/v) increased to 40% after 10 min, to 80% over 40 min and 80-100% 
over 10 min. Unbound Na125I was initially eluted between 3-6 min while insulin labelled 
with Na125I was eluted between 24-30 min as indicated by the black arrows on the graph. 
Fractions with the highest CPM underwent antibody binding testing and fractions with 
similar binding were pooled and stored at 4˚C.        
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Figure 2.2: Typical standard curve obtained for insulin RIA from rat insulin 
standards. 
 
 
 
A rat insulin standard curve ranging from 0.039-20 ng/ml by serial dilutions of the stock 
standard (R2 = 0.96). Unknown values were interpolated from the standard curve and 
insulin concentrations anti-logged into ng/ml. Values are ± SEM (n=3). 
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Figure 2.3: A typical standard curve obtained from a cAMP assay. 
 
 
 
A cAMP curve with standard concentrations of 0.78-200 pM/ml by serial dilution of a 
2,000 pM/ml stock (R2 = 0.984). Unknown values are interpolated for the determination 
of cAMP concentration and anti-logged into pM/ml. Values are ± SEM (n=3). 
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Figure 2.4: Representative Dual energy X-ray absorption (DEXA) images of (A) a 
lean Swiss TO mouse and (B) high fat fed-induced diabetic Swiss TO mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mice were analysed after prior calibration and quality control with the aluminium/lucite 
phantom (0.069 g/cm2, 12.0% fat) obtained by DEXA using a PIXImus system 
(software version 1.4x). 
A 
B 
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Figure 2.5: A typical standard curve obtained from a DPP-IV activity assay. 
 
 
 
 
A DPP-IV standard curve with standard concentrations of AMC ranging from 0.24-15.6 
μM (R2 = 0.999). Unknown values are interpolated for the determination of AMC 
concentration and DPP-IV activity calculated as μM/ml/min. Values are ± SEM (n=3). 
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Figure 2.6: Typical standard curve obtained for multi species GLP-1 total ELISA. 
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A GLP-1 standard curve with standard concentrations of 4.1-1000 pM by serial dilution 
of a 1000 pM stock. Absorbance of unknown values was used to interpolate their 
concentration from the standard curve to quantify GLP-1 concentration. Quality control 
samples (QC1, QC2) which both fell within the recommended range were provided by 
the supplier and used to validate the assay. Values are ± SEM (n=2). 
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Figure 2.7: Typical standard curve obtained for rat/mouse GIP total ELISA. 
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A GIP standard curve with standard concentrations of 8.2-2000 pM by serial dilution of 
a 2000 pM stock. Absorbance of unknown values was used to interpolate their 
concentration from the standard curve to quantify GIP concentration. Quality control 
samples (QC1, QC2) which both fell within the recommended range were provided by 
the supplier and used to validate the assay. Values are ± SEM (n=2). 
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Figure 2.8: Typical standard curve obtained for mouse C-reactive protein ELISA. 
 
 
100 1000 10000 100000
0.0
0.5
1.0
1.5
2.0
C-Reactive Protein [log (pg/ml)]
A
b
s
o
rb
a
n
c
e
 (
4
5
0
-5
9
0
 n
m
)
 
A CRP standard curve with standard concentrations of 1.56-40000 pg/ml by serial 
dilution of a 40000 pg/ml stock. Absorbance of unknown values was used to interpolate 
their concentration from the standard curve to quantify CRP concentration. Values are 
± SEM (n=2). 
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Chapter 3 
 
Evaluation of the effects of GPR120 
activation on insulin secretion and 
islet cell function in-vitro 
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3.1: Summary 
  
Long-chain fatty acid (LCFA) sensing G-protein coupled receptors (GPCRs) have been 
identified as potential anti-diabetic targets, through the enhancement of islet and intestinal 
cell function. The acute metabolic effects of GPR120 activation towards insulin secretion 
and islet cell regeneration was evaluated by utilising a range of endogenous and synthetic 
GPR120 agonists. 
Insulinotropic activity and specificity of GPR120 agonists were assessed in rodent 
(BRIN-BD11) and human (1.1B4) pancreatic cells, with agonist cytotoxicity assessed by 
MTT analysis. Secondary messenger signalling pathways intracellular Ca2+, cAMP and 
MAPKs were investigated upon GPR120 activation. Effects of GPR120 agonist treatment 
on islet cell proliferation and apoptosis were assessed in BRIN-BD11 and α-TC1.9 cells.  
Expression of GPR120 mRNA and protein were evaluated by qPCR and western blotting 
in BRIN-BD11 cells upon agonist treatment in both normoglycaemic and hyperglycaemic 
conditions. 
A range of GPR120 agonists (ALA, DHA, EPA, GW9508, Compound A, GSK137647) 
demonstrated insulinotropic capabilities in pancreatic BRIN-BD11 (p<0.05-p<0.001) and 
1.1B4 (p<0.05-p<0.001) cells, with endogenous ALA demonstrating the most potent 
effect (p<0.05-p<0.001) from BRIN-BD11 cells at 5.6 mmol/l (2-fold; EC50 = 9.25 x 10
-
9 mol/l) and 16.7 mmol/l (1.9-fold; EC50 = 6.886 x 10
-8 mol/l) glucose. Potent GPR120 
antagonist (AH-7614) impaired the insulinotropic response of GSK137647 (p<0.05-
p<0.001) and Compound-A (p<0.05-p<0.001) in BRIN-BD11 cells. GPR40 antagonist 
(GW1100) had no effect on the potency of GSK137647 and Compound A. GPR120 
agonist had no effect on cAMP production, whilst antagonising the IP3 receptor reduced 
the insulinotropic response of ALA and GSK137647 by 69-84% (p<0.01-p<0.001) in 
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BRIN-BD11 cells. GPR120 agonists induced ERK1/2 and p38 phosphorylation, whilst 
reducing JNK phosphorylation in-vitro. Overall, GPR120 agonists improved beta cell 
viability (p<0.05-p<0.01) and reduced beta apoptosis (p<0.05-p<0.01), with opposing 
effects demonstrated towards pancreatic alpha cells. Incubation of BRIN-BD11 cells with 
GPR120 agonists increased GPR120 (p<0.01) gene expression at 16.7 mM glucose, with 
a corresponding increase in GPR120 (p<0.05-p<0.01) protein expression confirmed by 
western blotting. GPR120 upregulation was attenuated under normoglycaemic conditions 
(p<0.05).  
These findings indicate that targeting GPR120 has therapeutic potential for the treatment 
of type 2 diabetes by potentiating insulin secretion and islet cell regeneration.  
 
 3.2: Introduction 
 
G-protein coupled receptor 120 (GPR120), also known as FFAR4, is a G-protein coupled 
receptor that is agonised by long chain saturated fatty acids (C14-18) and unsaturated 
fatty acid molecules (C16-22) (Lagerstrom & Schioth 2008, Hara et al. 2011). The 
genomic sequence for the human GPR120 gene is expressed on chromosome 10 at 
position q23.3 (Ichimura et al. 2009). The translated GPR120 protein is expressed in 
numerous tissues throughout the body including the lungs, spleen, intestines, pro-
inflammatory macrophages and peripheral tissues (Moore et al. 2009). In addition, recent 
studies have identified the extensive expression of GPR120 in the pancreatic islet, with 
further experimentation demonstrating expression within pancreatic beta cell lines 
(BRIN-BD11, RINm5f, INS-1E, MIN6) (Dhayal et al. 2008, Moran et al. 2014). 
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Previous reports have identified that free fatty acid (FFA) molecules are the endogenous 
agonists for GPR40 (FFAR1), GPR41 (FFAR3), GPR43 (FFAR2), GPR84 and GPR120 
(FFAR4) (Ichimura et al. 2009, Hara et al. 2012, Houthuijzen et al. 2017). Short chain 
fatty acid molecules exhibit specificity towards GPR41 and GPR42, medium chain fatty 
acids stimulate GPR84 activation, whereas long chain fatty acid molecules potentiate 
GPR120 and GPR40 activation (Ichimura et al. 2009, Hara et al. 2012, Houthuijzen et al. 
2017). Furthermore, GPR40 and GPR120 display 10% sequence homology and both can 
be agonised by ligands sharing structural similarities. As the functional role of GPR40 is 
well understood, it has been attributed to the beneficial effects associated with long chain 
fatty acid molecules, particularly omega-3 fatty acids (Itoh, et al. 2003, Moran et al. 2014, 
Moran et al. 2016). The function of the recently discovered GPR120 receptor remains 
elusive and warrants further investigation.  
Many studies have identified GPR120 to act as a lipid sensor in the body, through the 
biological regulation of adipogenesis, inflammation and glucose homeostasis. Moreover, 
a recent report demonstrated that a mutated variant of GPR120 (p.R270H) impairs the 
signalling response of the receptor upon agonist binding. Subsequently, defects were 
observed towards GPR120-mediated intracellular calcium mobilisation and GLP-1 
secretion from intestinal L-cells (Ichimura et al. 2012, Bonnefond et al. 2015). An 
additional study demonstrated that siRNA mediated GPR120 gene disruption impaired 
the protective effects of omega-3 fatty acid agonists in serum starved STC-1 cells 
(Iaboubov et al. 2006). 
GPR120 has been shown to have a regulatory function within the gastrointestinal (GI) 
tract and controls the release of intestinal hormones from intestinal L-cells and K-cells, 
such as glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and 
cholecystokinin (CCK). In addition, high expression of GPR120 was observed in 
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intestinal cell lines, including STC-1 and GLUT-ag cells (Hirasawa et al. 2005, Iaboubov 
et al. 2006, Sankoda et al. 2017). Another study demonstrated GPR120 activation with 
endogenous agonist alpha-linolenic acid (ALA) to mediate GLP-1 secretion in rats 
(Hirasawa et al. 2005). However, conflicting studies have also indicated that GPR120 has 
no secretory effect towards GLP-1 in the intestines (Paulsen et al. 2014).  
Although, the functional role of GPR120 in the GI tract has been heavily documented, 
the metabolic effect of GPR120 activation in the pancreatic beta cell has remained elusive 
until recently (Moran et al. 2014). GPR120 activation was demonstrated to have a 
regulatory effect on glucose stimulated insulin secretion (GSIS) from clonal pancreatic 
beta cells and mouse islets with a range of endogenous and synthetic agonists, including 
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), alpha-linolenic acid (ALA) 
and GW-9508 (Moran et al. 2014). Furthermore, these agonists demonstrated glucose 
lowering and insulinotropic actions in-vivo (Moran et al. 2014). 
Upon agonist binding and receptor activation, GPR120 stimulates an array of downstream 
signalling events mediated through the Gαq intracellular subunit. Gαq phosphorylation 
stimulates a range of secondary signalling events through phospholipase C (PLC), 
including intracellular calcium mobilisation and mitogen-activated protein kinase 
(MAPK) phosphorylation (Hirasawa et al. 2005, Burns et al. 2014, Gerbino & Colella 
2018). At present, the mechanism of GPR120-mediated insulin secretion from the 
pancreatic beta cell remains inconclusive. However, initial studies have shown a range of 
GPR120 agonists to augment intracellular calcium, which indicates involvement of 
inositol trisphosphate (IP3) on intracellular calcium stores through PLCβ signalling 
(Moran et al. 2014). ALA and DHA have been shown to promote the transient and rapid 
phosphorylation of the receptor in HEK293 cells (Burns et al. 2014). Although, the PLC 
and protein kinase C (PKC) pathways are predominately associated with GPR120 
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signalling, DHA has also been shown to stimulate G-protein coupled receptor kinase 
(GPK6) through GPR120 activation (Burns et al. 2014). Thr(347), Ser(350) and Ser(357) 
have been identified as the primary phosphorylation sites of GPR120 in the C-terminal 
tail (Burns et al. 2014).  
Recently, novel long chain fatty acid molecules with high specificity for GPR120 have 
become available. Oh et al., have developed an orally available, selective, high affinity, 
small GPR120 agonist (Compound A) that exhibits a range of anti-diabetic effects, with 
initial studies showing oral administration to improve glucose tolerance, increase insulin 
sensitivity and exert anti-inflammatory effects in-vivo (Oh et al. 2014). In addition, 
Sparks et al., identified a potent GPR120 agonist GSK137647 that exhibited secretory 
effects towards insulin and GLP-1 in-vitro (Sparks et al. 2014). In addition, in-vivo 
findings showed that GSK137647 induced GLP-1 release by mouse circumvallate 
papillae (Martin et al. 2012, Sparks et al. 2014)  
The extensive expression of GPR120 in numerous tissues with metabolic function 
(pancreatic islet, intestines, adipose) indicates that it may have therapeutic potential in the 
maintenance of glucose homeostasis (Hirasawa et al. 2005, Tanaka et al. 2008, Moran et 
al. 2014). This present study aims to evaluate the acute metabolic effects and intracellular 
signalling events of GPR120 activation in the pancreatic beta cell using a range of 
endogenous and synthetic ligands.  
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3.3: Materials and methods 
 
3.3.1: Materials 
ALA, GW9508, DHA, EPA, alanine and AH7614 were purchased from Sigma-Aldrich 
(Poole, Dorset). GSK137647 was purchase from Tocris (Bristol, UK) and Compound A 
from Cayman Chemical (Michigan, US). All other materials were purchased from 
suppliers as detailed in Section 2.  
 
3.3.2: Acute insulin secretion studies from pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were sub-cultured and seeded into 24-well plates at a density of 
150,000 cells per well, then supplemented with 1 ml of RPMI media and allowed to attach 
overnight, as outlined in Section 2.1.2.  ALA, GW9508, DHA, EPA, GSK137647, 
Compound A (10-12-10-4 mol/l) and AH7614 (10-5 mol/l) were added to KRBB buffer, 
supplemented with 5.6 mmol/l or 16.7 mmol/l glucose. Cells were pre-treated with 1.1 
mmol/l glucose KRBB for 40 min at 37oC. After pre-incubation, test solutions were added 
and incubated for 20 min at 37oC. Aliquots (900 µl) of cell supernatant were removed and 
stored at -20oC until determination of insulin concentrations by radioimmunoassay, as 
outlined in Section 2.2.3. MTT cytotoxicity analysis was conducted with identical test 
parameters as insulin secretory studies previous detailed in Section 2.1.6.  
 
3.3.3: Determination of GPR120 mRNA expression in pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
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attach overnight, as outlined in Section 2.1.2. Cell were pre-incubated with 1.1 mmol/l 
glucose for 1 h min at 37oC. Agonist test solutions (10-4 mol/l) were prepared in KRBB 
buffer at 5.6 mmol/l or 16.7 mmol/l glucose. Test solutions were incubated for 4 h at 
37oC. After incubation, cells were lysed and RNA harvested with TRIzol reagent (Sigma, 
UK). RNA was purified then converted to cDNA as previously described in Section 2.6.2. 
SYBR green PCR kit (Roche, UK) was used for qPCR as previously detailed in Section 
2.6.3. 
 
3.3.4: Immunofluorescence staining of BRIN-BD11 cells  
As detailed in Section 2.8.2. 
 
3.3.5: Determination of cAMP production in pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cells were pre-incubated with 1.1 mmol/l 
glucose for 40 min at 37oC. Agonist test solutions (10-4 mol/l) and IBMX (10 mmol/l) 
were prepared in KRBB buffer at 16.7 mmol/l glucose and assessed for cAMP production. 
After incubation, cells were lysed and cAMP detected with the cAMP ELISA kit as 
previously described in Section 2.4.2. 
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3.3.6: MAPK signalling and GPR120 expression analysis by western blotting in 
pancreatic BRIN-BD11 cells  
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cells were pre-incubated with 1.1 mmol/l 
glucose for 40 min at 37oC. Agonist test solutions (10-4 mol/l) and PMA (200 nmol/l) 
were prepared in KRBB buffer at 5.6 mmol/l or 16.7 mmol/l glucose. After incubation, 
cells were lysed at various timepoints with RIPA buffer, supplemented with protease and 
phosphatase inhibitors. Cell lysates (25 µg) were prepared and separated by SDS-PAGE 
and transferred to a nitrocellulose membrane, as previously described in Section 2.7. 
Membranes were probed with total and phosphorylated anti-ERK1/2, anti-JNK and anti-
p38 antibodies for MAPK signalling and anti-GPR120 for receptor expression. β-actin 
was used as a control to normalise data. Images were captured using a G:BOX Chemi 
XX9 imager (Syngene, UK) and densitometry analysis performed using ImageJ. 
 
3.3.7: ERK1/2 signalling analysis by flow cytometry in pancreatic BRIN-BD11 cells  
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cells were pre-incubated with 1.1 mmol/l 
glucose for 40 min at 37oC. Agonist test solutions (10-4 mol/l) and PMA (200 nmol/l) 
were prepared in KRBB buffer at 16.7 mmol/l glucose. After incubation, cells were 
detached with trypsin, pelleted by centrifugation then re-suspended in 600µl of flow 
cytometry staining buffer, supplemented with anti-phospho-ERK1/2 antibodies. Samples 
were conjugated with an AlexaFluor488 secondary antibody. Samples were gated prior 
to FITC-GFP expression analysis by flow cytometry.   
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3.3.8: Cellular viability and apoptosis studies on pancreatic BRIN-BD11 and α-
TC1.9 cells 
BRIN-BD11 and α-TC1.9 cells were sub-cultured and seeded into a clear 96-well plate 
at a density of 40,000 cells per well and allowed to attach overnight, as previously 
outlined in Sections 2.1.2 and 2.1.4. Agonist test solutions (10-4 mol/l) and cytokine 
cocktail solution (TNF-α [200 U/ml], IFN-γ [20 U/ml], IL-1β [100 U/ml]) were prepared 
in RPMI/DMEM media, then added to the cells and incubated for 20 h at 37oC. Cell 
viability and apoptosis was determined with Apo-Live-Glo multiplex analysis as per 
manufacturer’s protocol; cell viability by protease activity, cell apoptosis by caspase 3/7 
activity (Promega, USA). 
 
3.4: Results 
 
3.4.1: Effect of GPR120 agonists on insulin secretion from clonal pancreatic BRIN-
BD11 cells. 
The insulinotropic effect of a range of naturally occurring (ALA, EPA, DHA) and 
synthetic (GW9508, Compound A, GSK137647) GPR120 agonists was assessed in the 
clonal pancreatic BRIN-BD11 cell line. Essential omega-3 fatty acid ALA (10-9-10-4 
mol/l) stimulated insulin secretion at 5.6 mmol/l glucose (p<0.001) (Fig. 3.1A). At 
stimulatory glucose concentrations of 16.7 mmol/l, ALA (10-8-10-4 mol/l) stimulated 
insulin secretion (p<0.05-p<0.001), with a 2.2-fold increase observed at the highest 
concentration (10-4 mol/l) (Fig. 3.2A).  
Non-essential omega-3 fatty acid DHA (10-10-10-4 mol/l) augmented insulin release 
(p<0.01-p<0.001) from BRIN-BD11 cells at 5.6 mmol/l glucose (Fig. 3.3A). The 
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insulinotropic response of DHA (10-9-10-4 mol/l) was also observed at stimulatory 
glucose concentrations, with a 2.5-fold increase exhibited at the highest concentration 
(10-4 mol/l) (Fig. 3.4A). Naturally occurring EPA (10-9-10-4 mol/l) stimulated a 1.3-1.7-
fold (p<0.05-p<0.001) increase on insulin secretion at 5.6 mmol/l glucose (Fig. 3.5A). At 
a stimulatory glucose concentration of 16.7 mmol/l, EPA (10-8-10-4 mol/l) demonstrated 
a 1.4-1.9-fold (p<0.01-p<0.001) increase on insulin secretion, with an 85% increase 
demonstrated at the highest concentration tested (10-4 mol/l) (Fig. 3.6A). 
Chemically synthetic GW9508 (10-8-10-4 mol/l) stimulated insulin secretion (p<0.01-
p<0.001) at a basal glucose concentration with a 2.2-fold increase observed at the highest 
concentration (Fig. 3.7A). At hyperglycaemic glucose concentrations (16.7 mmol/l 
glucose) GW9508 augmented insulin release by 1.7-3.4-fold (p<0.05-p<0.001) (Fig. 
3.8A).  
Novel synthetic agonist GSK137647 (10-8-10-4 mol/l) stimulated insulin secretion 
(p<0.05-p<0.001) at 5.6 mmol/l glucose (Fig. 3.9A). GSK137647 augmented a 1.6-2.8-
fold (p<0.01-p<0.001) increase on insulin secretion at 16.7 mmol/l glucose (Fig. 3.10A). 
The recently discovered GPR120 ligand Compound A (10-10-10-4 mol/l) augmented an 
insulinotropic response (p<0.05-p<0.001) from BRIN-BD11 cells at 5.6 mmol/l glucose 
(Fig. 3.11A). The insulin secretory effect (p<0.05-p<0.001) of Compound A (10-7-10-4 
mol/l) was also observed at stimulatory 16.7 mmol/l glucose (Fig. 3.12A). 
At basal glucose concentrations of 5.6 mmol/l, agonist potency towards insulin secretion 
was as follows in descending order: EPA (2.11 x 10-9 mol/l), GW9508 (4.97 x 10-9 mol/l), 
ALA (9.25 x 10-9 mol/l), DHA (1.36 x 10-7 mol/l), GSK137647 (1.36 x 10-7 mol/l), 
Compound A (2.97 x 10-7 mol/l). At hyperglycaemic glucose concentrations of 16.7 
mmol/l, agonist potency towards insulin secretion was as follows in descending order: 
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GW9508 (5.55 x 10-8 mol/l), Compound A (6.57 x 10-8 mol/l), ALA (6.88 x 10-8 mol/l), 
DHA (7.37 x 10-7 mol/l), EPA (1.21 x 10-6 mol/l), GSK137647 (3.69 x 10-6 mol/l).  
The positive control (alanine) augmented insulin secretion (p<0.001) for all insulin 
secretory analysis (Fig. 3.1-12A). Cytotoxicity analysis by MTT demonstrated no adverse 
effects towards BRIN-BD11 cell viability at 5.6 mmol/l and 16.7 mmol/l glucose upon 
incubation with all agonists at a range of concentrations (Fig. 3.1-12B). 
 
3.4.2: Effect of GPR120 agonists on insulin secretion from clonal human pancreatic 
1.1B4 cells 
The insulin secretory effect of naturally occurring (ALA) and synthetic (GW9508, 
Compound A) agonists was further assessed in the human clonal pancreatic 1.1B4 cell 
line at 5.6 mmol/l and 16.7 mmol/l glucose concentrations. Endogenous omega-3 fatty 
acid ALA (10-8-10-4 mol/l) stimulated insulin secretion by 1.3-2.0-fold (p<0.05-p<0.001) 
at 5.6 mmol/l glucose (Fig. 3.13A). The insulinotropic action of ALA (10-8-10-4 mol/l) 
was also observed at 16.7 mmol/l glucose, with a 77% (p<0.001) increase demonstrated 
at the highest concentration tested (10-4 mmol/l) (Fig. 3.13B).  
Synthetic agonist GW9508 augmented insulin secretion by 1.3-1.6-fold (p<0.05-p<0.01) 
at 5.6 mmol/l (Fig. 3.14A). At a stimulatory glucose concentration of 16.7 mmol/l 
glucose, GW9508 (10-7-10-4 mol/l) increased insulin secretion (p<0.05-p<0.01), with a 
46% (p<0.01) increase observed at the highest agonist concentration tested (10-4 mol/l) 
(Fig. 3.13B). Novel synthetic Compound A (10-8-10-4 mol/l) stimulated insulin secretion 
(p<0.05-p<0.001) at a basal glucose concentration (Fig. 3.14A). At 16.7 mmol/l, 
Compound A (10-8-10-4 mol/l) augmented insulin secretion (p<0.05-p<0.001), with a 
192% (p<0.001) increase towards insulin secretion (Fig. 3.14B).  
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ALA was the most potent agonist at 5.6 mmol/l with an EC50 value of 5.059 x 10
-8 mol/l, 
followed by GW9508 (1.15 x 10-7 mol/l) then Compound A (1.22 x 10-6 mol/l). In order 
of potency at 16.7 mmol/l glucose; GW9508 (9.98 x 10-7 mol/l), ALA (1.15 x 10-6 mol/l) 
and Compound A (7.97 x 10-6 mol/l) (Table. 3.1). 
 
3.4.3: Effect of GPR120 antagonist (AH7614) and GPR40 antagonist (GW1100) on 
Compound A and GSK137647 induced insulin secretion from clonal pancreatic 
BRIN-BD11 cells 
Compound A and GSK137647 were co-incubated with GPR120 antagonist (AH7614 and 
GPR40 antagonist (GW1100). The insulin secretory effect of Compound A and 
GSK137647 was not influenced upon co-incubation with the GPR40 antagonist GW1100 
(10-5 mol/l), as a similar insulinotropic response was observed in the presence of the 
antagonist, compared to agonist only (Figure 3.16 A, B; Figure 3.17 A, B).  
Co-incubation of the GPR120 antagonist AH-7614 (10-5 mol/l) significantly reduced the 
insulin secretory response of Compound A and GSK137647. At 5.6 mmol/l glucose, in 
the presence of the GPR120 antagonist, Compound A (10-6-10-4 mol/l) augmented insulin 
secretion by 1.25- to 1.3-fold (p<0.05), resulting in a 65% reduction at 10-4 mol/l. 
GSK137647 demonstrated no significant insulin secretory effect in the presence of the 
antagonist (Fig. 3.16B). At 16.7 mmol/l glucose in the presence of the GPR120 
antagonist, Compound A (10-5-10-4 mol/l) augmented insulin secretion by 1.7- to 1.8-fold 
(p<0.05), resulting in a 65% reduction compared to agonist only (10-4 mol/l) (Fig. 3.17A). 
GSK137647 at 10-7-10-4 mol/l increased insulin secretion by 1.7- to 2.1-fold. (P<0.01) 
(Fig. 3.17B), exhibiting a 40% reduction compared to agonist only at 10-4 mol/l. 
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3.4.4: Expression and distribution of GPR120 and insulin in clonal pancreatic 
BRIN-BD11 cells 
Immunocytochemistry analysis was employed to determine the distribution of (A) DAPI, 
(B) insulin, (C) GPR120 in BRIN-BD11 cells (Fig. 3.18) High expression of GPR120 
and insulin was present in the BRIN-BD11 cell line, with areas of co-localisation 
displayed between GPR120 and insulin observed upon double immuno-fluorescence 
staining (Fig. 3.18D).  
 
3.4.5: Effects of GW9508, ALA, Compound A and GSK137647 on GPR120 
expression in clonal pancreatic BRIN-BD11 cells 
Western blotting and qPCR were employed to determine GPR120 protein and mRNA 
expression in BRIN-BD11 cells upon agonist treatment at 5.6 mmol/l and 16.7 mmol/l 
glucose. (Fig. 3.19; Fig. 3.20). GW9508 and ALA reduced GPR120 mRNA expression 
by 23-39% (p<0.05) at 5.6 mmol/l glucose (Fig. 3.19A), compared to 5.6 mmol/l glucose 
control. Complimentary western blotting showed GW9508 to reduce GPR120 protein 
expression (p<0.05), whilst ALA had no effect on receptor protein expression (Fig. 
3.19C). At 16.7 mmol/l glucose, GW9508 and ALA increased GPR120 mRNA 
expression by 1.7-2.3-fold (p<0.01), with complimentary western blotting demonstrating 
GW9508 (3.4-fold) and ALA (4.8-fold) to increase GPR120 protein expression (p<0.01) 
(Fig. 3.19B; Fig. 3.19D). 
At normoglycaemic (5.6 mmol/l glucose) Compound A and GSK137647 down-regulated 
GPR120 receptor mRNA expression (p<0.05) in BRIN-BD11 cells, compared to 5.6 
mmol/l glucose (Fig. 3.20A). When exposed to 16.7 mmol/l glucose, Compound A and 
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GSK137647 incubation increased GPR120 mRNA expression (p<0.01), compared to 
16.7 mmol/l glucose control (Fig. 3.20B).   
Complimentary western blotting demonstrated GSK137647 to upregulate (p<0.05) 
GPR120 protein expression by 1.9-fold (p<0.05) in hyperglycaemic conditions, whilst 
Compound A had no significant effect (Fig. 3.20D). GPR120 protein expression was not 
altered upon agonist incubation in normoglycaemic conditions (Fig. 3.20C). 
 
3.4.6: Effect of GPR120 agonists on cAMP production and intracellular Ca2+ 
modulated insulin secretion from clonal pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were incubated with ALA, GW9508 and GSK137647 (10-4 mol/l) and 
IBMX (10 mmol/l) for 20 min in KRBB supplemented with 16.7 mmol/l glucose. All 
agonists demonstrated no effects on cAMP production, whilst the positive control 
(IBMX) stimulated a 19-fold (p<0.001) increase (Figure 3.21A).  
To investigate intracellular Ca2+-modulated insulin secretion, pancreatic BRIN-BD11 
cells were co-incubated with GPR120 agonists (ALA, GSK137647) and Xestospongin C 
(IP3 receptor antagonist), resulting in impaired insulin secretory effects (p<0.01-
p<0.001). Xestospongin C reduced the insulinotropic effects of ALA and GSK137647 by 
69-86% (p<0.01-p<0.001) at 10-4 mol/l. At 10-5 mol/l, Xestospongin C abolished the 
insulinotropic effects of ALA and GSK137647 (p<0.001) (Figure 3.21B). 
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3.4.7: Effect of GSK137647, GW9508, ALA and PMA on ERK1/2 (p44/42) signalling 
in clonal pancreatic BRIN-BD11 cells 
SDS-PAGE western blotting demonstrated GSK137647, GW9508 and ALA to stimulate 
ERK1/2 phosphorylation after 15 min incubation in BRIN-BD11 cells (Fig. 3.22). 
GSK137647 also induced ERK1/2 phosphorylation after 5 min incubation. PMA was 
used as a positive control and subsequently induced ERK1/2 phosphorylation in a time 
dependent manner at 10, 15, 30 and 60 min incubation. Total-ERK1/2 concentrations 
remained unaffected compared to the non-treated control upon agonist treatment at all 
timepoints.  
In addition, flow cytometry demonstrated similar findings, with GSK137647, GW9508, 
ALA and PMA stimulating ERK1/2 phosphorylation in BRIN-BD11 cells after 15 min 
incubation (Fig. 3.23). PMA emitted the most potent effect, with 19% ERK1/2 
phosphorylation of total cells observed (Fig. 3.23B). In descending order of potency, 
GPR120 agonists ALA (17%; Fig. 3.23E), GW9508 (8%; Fig. 3.23C) and GSK137647 
(7%; Fig. 3.23D) stimulated ERK1/2 phosphorylation after 15 min incubation. 
 
3.4.8: Effect of GSK137647 on JNK, p38 and ERK1/2 MAPK signalling in clonal 
pancreatic BRIN-BD11 cells 
The effect of GSK137647 on mitogen-activated protein kinase (MAPK) signalling was 
assessed by western blotting in BRIN-BD11 cells (Fig. 3.24). Positive control PMA (200 
nm) induced JNK and p38 phosphorylation at 20 min and ERK1/2 phosphorylation at 30 
min. GSK137647 treatment from 5-30 min reduced JNK phosphorylation compared to 
the non-treated control, whilst total-JNK remained unchanged. GSK137647 induced p38 
phosphorylation after 5 min incubation, with the response reduced to baseline after 10 
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min. Total-p38 concentrations were unaffected upon agonist treatment at all timepoints. 
GSK137647 augmented ERK1/2 phosphorylation at 5- and 15-min incubation, with total-
ERK1/2 concentrations remaining unchanged at all timepoints (Fig. 3.24).   
 
3.4.9: Effect of GW9508, ALA and GSK137647 on clonal pancreatic BRIN-BD11 
cell viability and apoptosis 
BRIN-BD11 cells were incubated with GPR120 agonists for 20 h. Cell viability was 
determined by protease activity and apoptosis by caspase3/7 activity (Fig. 3.25). At 10-6 
mol/l, GW9508 increased cell viability by 15% (p<0.05), whilst ALA and GSK137647 
had no effect. At a higher agonist concentration (10-4 mol/l), GW9508 (p<0.01) and ALA 
(p<0.01) increased cell viability by 23% with GSK137647 having no effect. Cytokine 
cocktail incubation reduced cell viability by 13% after 20 h (Fig. 3.25A).  
At 10-6 mol/l, ALA and GSK137647 reduced caspase3/7 activity by 50% (p<0.01) and 
27% (p<0.05) respectively, whilst GW9508 had no significant effect. At 10-4 mol/l, 
GW9508 (p<0.05) and GSK137647 (p<0.05) increased caspase3/7 activity by 26-40% 
with ALA having no effect. Cytokine cocktail incubation increased caspase3/7 by 47% 
(p<0.01) after 20 h (Fig. 3.25B). 
 
3.4.10: Effect of GW9508, ALA and GSK137647 on clonal pancreatic α-TC1.9 cell 
viability and apoptosis 
α-TC1.9 cells were incubated with GPR120 agonists for 20 h. Cell viability was 
determined by protease activity and apoptosis by caspase3/7 activity (Fig. 3.26). At 10-6 
mol/l, GW9508, ALA and GSK137647 had no effect towards cell viability. At a higher 
agonist concentration (10-4 mol/l), GW9508, ALA and GSK137647 reduced cell viability 
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by 23-46% (p<0.01-p<0.001). Cytokine cocktail incubation reduced cell viability by 32% 
after 20 h (Fig. 3.26A).  
At 10-6 mol/l, ALA (18%) and GSK137647 (20%) reduced caspase3/7 activity (p<0.01-
p<0.001), whilst ALA had no significant effect. At a higher agonist concentration (10-4 
mol/l), ALA and GSK137647 increased caspase3/7 activity by 16-28% (p<0.001) with 
GW9508 having no significant effect. Cytokine cocktail incubation increased caspase3/7 
by 15% (p<0.01) after 20 h (Fig. 3.26B). 
 
3.5: Discussion 
 
In recent years, research focusing on long chain fatty acids receptors has intensified due 
to their regulatory role in the maintenance of glucose and lipid homeostasis, including 
GPR40, GPR120, GPR55 and GPR119 (Hara et al. 2011,  McKillop et al 2013, McKillop 
et al. 2016). Many of the endogenous ligands for long chain fatty acid sensing receptors, 
such as omega 3 fatty acids DHA and ALA have previously demonstrated insulinotropic 
and anti-inflammatory properties that are of interest for the treatment of obesity and type 
2 diabetes (Oh et al. 2010, Moran et al. 2014). Interestingly, a GPR40 agonist Fasiglifam 
(TAK-875) recently underwent stage III clinical trials. During the trial, Fasiglifam 
demonstrated insulinotropic capabilities to the same potency of the current sulphonylurea 
Glimepiride, whilst omitting the risk of hypoglycaemia (Otieno et al. 2017). 
GPR120, also known as free fatty acid receptor 4 (FFAR4) is a class A (rhodopsin) GPCR 
that has been shown to exert a range of glucose lowering properties (Moran et al. 2014). 
With particular interest, GPR120 was recently shown to be highly expressed in pancreatic 
islet cells with insulin secretory capabilities upon activation (Moran et al. 2014). The 
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ability of GPR120 to stimulate GLP-1 from intestinal L-cells, accompanied with its 
regulatory role in islet cell function makes it an attractive therapeutic target (Martin et al. 
2012). Furthermore, as GPR120 and GPR40 can be activated by similar ligands, such as 
synthetic GW9508, specific agonists are essential to evaluate the anti-diabetic potential 
of GPR120.  
In this present study, the functional role of GPR120 was assessed in the pancreatic BRIN-
BD11 cell line, using a range of endogenous (ALA, DHA, EPA) and synthetic (GW9508, 
Compound A, GSK137647) agonists. The biological effects of these agonists towards 
insulin secretion, islet cell regeneration and downstream receptor signalling were 
evaluated. The insulinotropic activities of the GPR120 agonists were assessed in the 
pancreatic BRIN-BD11 cell line at both normoglycaemic and hyperglycaemic glucose 
concentrations. At normoglycemia, ALA and EPA demonstrated the most potent insulin 
secretory effect for the endogenous agonists (EC50 ~10
-9 mol/l), whereas, GW9508 was 
the most potent synthetic agonist (EC50 4.97 x 10
-9 mol/l). At stimulatory glucose 
concentrations, ALA (EC50 = 6.88 x 10
-8 mol/l) and GW9508 (5.55 x 10-8 mol/l) remained 
the most potent endogenous and synthetically derived agonists.   
Complimentary analysis using the human 1.1B4 cell line was employed to validate the 
insulinotropic capability of GPR120 activation in human beta cells. Endogenous (ALA) 
and synthetic (GW9508, Compound A) induced insulin secretion from the human cell 
line at a similar potency to rodent cells, whilst previous studies have also demonstrated 
glucoregulatory effects of omega 3 fatty acids in humans (Bhaswant et al. 2015). With 
respect to cytotoxicity, previous studies demonstrated ALA, DHA, EPA and GW9508 to 
have no effects on lactate dehydrogenase (LDH) release from pancreatic cells (Moran et 
al. 2014). Whilst LDH is a marker that requires breakage of the cell membrane for 
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detection, the present study also revealed that GPR120 agonists demonstrate no cytotoxic 
effects when assessed by cellular metabolic activity (Bopp & Lettieri et al. 2008).  
As GPR120 and GPR40 can be activated by similar ligands, the specificity of many 
endogenous and synthetic GPR120 agonists remains uncertain. Therefore, it is difficult 
to attribute the biological effects of these putative agonists solely to GPR120 activation. 
Recently, selective GPR120 agonists (Compound A and GSK137647) have become 
commercially available (Oh et al. 2014, Sparks et al. 2014). To demonstrate the 
selectivity of the novel agonists towards GPR120, potent antagonists for GPR120 and 
GPR40 were used in insulin secretory studies. In the presence of GPR40 antagonist 
(GW1100), the insulin secretory response of both Compound A and GSK137647 was 
relatively unaffected. In contrast, the GPR120 antagonist (AH-7614) impaired the 
insulinotropic properties of both Compound A and GSK137647, suggesting that these 
novel agonists stimulate glucose dependent insulin secretion through the mechanics of 
GPR120 and not GPR40 in the pancreatic beta cell.  
Immunocytochemistry demonstrated high expression and co-localisation of GPR120 and 
insulin in pancreatic BRIN-BD11 cells, which further elucidates the role of GPR120 in 
insulin secretion from the pancreatic beta cell. Upon agonist treatment, expression 
analysis demonstrated an upregulation of GPR120 in BRIN-BD11 cells exposed to 
hyperglycaemia, suggesting that GPR120 may have a regulatory role in the pancreatic 
islet when exposed to diabetic stress factors. In contrast, agonist treatment under 
normoglycaemic conditions significantly attenuated GPR120 expression. Thus, revealing 
the glucose responsive properties of GPR120 expression and the suitability of GPR120 
as an anti-diabetic target. In harmony with these findings, previous studies have also 
demonstrated GPR120 expression to be upregulated in the gut of diet induced obese mice 
(Paulsen et al. 2014). 
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The mechanism of GPR120-mediated insulin secretion from BRIN-BD11 cells was 
investigated by assessing cyclic adenosine monophosphate (cAMP) and intracellular Ca2+ 
modulation. GPR120 activation results in the phosphorylation of the intracellular Gαq 
subunit, whereas GPR40 has been shown to activate both Gαq and Gαs with some 
agonists (Moran et al. 2016). ALA, GSK137647 and GW9508 had no effect on cAMP 
production in BRIN-BD11 cells, potentially suggesting the involvement of intracellular 
Ca2+ modulation through Gαq activation, with previous studies also showing a range of 
putative agonists to augment intracellular Ca2+ in BRIN-BD11 cells (Moran et al. 2014). 
To correlate this GPR120-induced increase in intracellular Ca2+ with insulin secretion, an 
inositol 1,4,5-trisphosphate (IP3) receptor antagonist (Xestospongin C) was utilised to 
block calcium release from the endoplasmic reticulum upon receptor activation. 
Antagonising the IP3 receptor impaired the insulinotropic capabilities of endogenous 
ALA and selective GSK137647, which compliments previous findings and suggests that 
GPR120-induced insulin secretion is primarily potentiated through Gαq/PLC/IP3 
signalling.   
As phospholipase C (PLC) phosphorylation occurs upon GPR120 activation, the 
diacylglycerol (DAG) branch of the PLC pathway was also investigated. Downstream of 
DAG, protein kinase C (PKC) can be activated, resulting in the phosphorylation of 
mitogen-activated protein kinases (MAPK) ERK1/2, JNK and p38. (Putney 2012). 
MAPK pathways are critical for the regulation of cell survival and growth, whilst also 
regulating a range of cellular responses, such as proliferation, apoptosis, differentiation 
and development (Mebratu, 2009, Stewart et al. 2015). ERK1/2 activation is associated 
with cell proliferation and survival, whilst JNK and p38 activation are linked with cell 
apoptosis and cell death (Mebratu 2009, Stewart et al. 2015). 
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Subsequently, the effect of GPR120 agonists towards ERK1/2, JNK and p38 were 
investigated. GSK137647, GW9508 and ALA induced ERK1/2 phosphorylation after 15 
min when assessed by western blotting and flow cytometry. Interestingly, ALA was the 
most potent agonist assessed, which mirrors the insulin secretory potency findings and 
indicates the involvement of ERK1/2 activation in GPR120-indued insulin release. 
Moreover, GPR120 activation reduced the stress related JNK pathway after 5 min with 
the effect prolonged throughout the experimental timeframe, indicating a cytoprotective 
effect of GPR120 activation as JNK activation has been previously linked with beta cell 
apoptosis (Hou et al. 2008, Zhou et al. 2014). Previous studies also demonstrated that 
ERK1/2 phosphorylation is key regulator of insulin synthesis and beta cell proliferation, 
thus indicating the role of downstream GPR120 signalling in beta cell survival and 
regeneration (Lawerence et al. 2008, Stewart et al. 2015).  
To assess the effects of GW9508, ALA and GSK137647 on beta cell survival and 
apoptosis, protease and caspase 3/7 activities were determined upon agonist treatment. 
ALA and GW9508 at super-physiological concentrations increased cell viability, 
revealing a proliferative effect of GPR120 activation in the pancreatic beta cell. 
Complimentary analysis investigating apoptosis showed that ALA and GSK137647 at 
physiological concentrations markedly reduced apoptosis. Unlike the synthetic agonists 
tested (GW9508, GSK137647), the endogenous agonist (ALA) exhibited positive effects 
towards both cell viability and cell apoptosis, therefore revealing the therapeutic potential 
of ALA in the regeneration of beta cell mass.  
Although GPR120 expression has been heavily documented in beta cells, expression has 
also been shown in glucagon producing alpha cells, whilst endogenous DHA has been 
shown to potentiate GPR120-dependent glucagon secretion in mice (Whalley et al. 2011, 
Suckow et al. 2014). Subsequently, the present study also investigated the proliferative 
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effects of GPR120 activation in α-TC1.9 cells. GW9508, ALA and GSK137647 had no 
effect on alpha cell proliferation at physiological concentrations, whilst an overall 
reduction was observed at super-physiological concentrations. Complimentary analysis 
showed that super-physiological concentrations of ALA and GSK137647 induced alpha 
cell apoptosis, whilst physiological concentrations of GW9508 and GSK37647 reduced 
alpha cell apoptosis. Interestingly, in direct contrast to the analysis in BRIN-BD11 cells, 
endogenous (ALA) increased alpha cell apoptosis and reduced alpha cell viability.  
The study has shown a range of endogenous and synthetic GPR120 agonists to enhance 
glucose stimulated insulin secretion in rodent and human pancreatic beta cell lines. The 
biological activation of GPR120 with endogenous and selective agonists potentiates 
intracellular calcium and MAPK signalling, with increases in beta cell survival also 
observed. Finally, receptor expression analysis demonstrated the glucose responsive 
properties of GPR120 under hyperglycaemic stress, a characteristic which may be utilised 
in the future development of an anti-diabetic agent targeting GPR120. 
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Table 3.1: Half maximal effective concentration (EC50) of GPR120 agonists in 
rodent BRIN-BD11 and human 1.1B4 cells at 5.6 mM and 16.7 mM glucose.  
 
Rodent BRIN-BD11 cells 
Agonist 5.6 mM glucose 16.7 mM glucose 
 
ALA 9.25 x 10-9 mol/l 6.88 x 10-8 mol/l 
DHA 1.36 x 10-7 mol/l 7.37 x 10-7 mol/l 
GW9508 4.97 x 10-9 mol/l 5.55 x 10-8 mol/l 
GSK137467 1.36 x 10-7 mol/l 3.69 x 10-6 mol/l 
EPA 2.11 x 10-9 mol/l 1.21 x 10-6 mol/l 
Compound A 2.97 x 10-7 mol/l 6.57 x 10-8 mol/l 
 
Human 1.1B4 cells 
Agonist 5.6 mM glucose 16.7 mM glucose 
 
ALA 5.05 x 10-8 mol/l 1.15 x 10-6 mol/l 
GW9508 1.15 x 10-7 mol/l 9.98 x 10-7 mol/l 
Compound A 1.22 x 10-6 mol/l 
 
7.97 x 10-6 mol/l 
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Figure 3.1: Acute effect of ALA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of ALA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
***p<0.001 compared to glucose control. 
10
-12
10
-11
10
-10
10
-9
10
-8
10
-7
10
-6
10
-5
10
-40
50
100
150
200 5.6 mmol/l glucose
Alanine 10 mmol/l
ALA in 5.6 mmol/l glucose
H2O2 1mmol/l
***
Concentration of ALA (mol/l)
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
10
-12
10
-11
10
-10
10
-9
10
-8
10
-7
10
-6
10
-5
10
-40
100
200
300
400
500
600
700
5.6 mmol/l glucose
Alanine 10 mmol/l
ALA in 5.6 mmol/l glucose
***
***
*** ***
*** ***
***
EC50 = 9.25 x 10
-9 mol/l
Concentration of ALA (mmol/l)
In
s
u
li
n
 s
e
c
re
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
A 
 
B 
 
109 
 
Figure 3.2: Acute effect of ALA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of ALA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.3: Acute effect of DHA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of DHA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.4: Acute effect of DHA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of DHA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.5: Acute effect of EPA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of EPA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.6: Acute effect of EPA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of EPA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.7: Acute effect of GW9508 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GW9508 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.8: Acute effect of GW9508 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GW9508 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM 
glucose. Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell 
viability. *p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.9: Acute effect of GSK137647 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GSK137647 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.10: Acute effect of GSK137647 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GSK137647 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM 
glucose. Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell 
viability. **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.11: Acute effect of Compound A on insulin secretion and cell viability 
from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of Compound A (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.12: Acute effect of Compound A on insulin secretion and cell viability 
from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of Compound A (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM 
glucose. Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell 
viability. *p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 3.13: Acute effect of ALA on insulin secretion from clonal human 
pancreatic 1.1B4 cells at 5.6 mM and 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of ALA (10-12-10-4 M) and alanine (10 mM) on insulin secretion at (A) 5.6 
mM and (B) 16.7 mM glucose from human pancreatic 1.1B4 cells. Results are the mean 
± SEM (n=8) for insulin secretion. *p<0.05, **p<0.01, ***p<0.001 compared to glucose 
control. 
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Figure 3.14: Acute effect of GW9508 on insulin secretion from clonal human 
pancreatic 1.1B4 cells at 5.6 mM and 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GW9508 (10-12-10-4 M) and alanine (10 mM) on insulin secretion at (A) 
5.6 mM and (B) 16.7 mM glucose from human pancreatic 1.1B4 cells. Results are the 
mean ± SEM (n=8) for insulin secretion. *p<0.05, **p<0.01, compared to glucose 
control. 
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Figure 3.15: Acute effect of Compound A on insulin secretion from clonal human 
pancreatic 1.1B4 cells at 5.6 mM and 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of Compound A (10-12-10-4 M) and alanine (10 mM) on insulin secretion at 
(A) 5.6 mM and (B) 16.7 mM glucose from human pancreatic 1.1B4 cells. Results are 
the mean ± SEM (n=8) for insulin secretion. *p<0.05, **p<0.01, ***p<0.001, compared 
to glucose control. 
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Figure 3.16: Effect of GPR120 antagonist (AH7614) and GPR40 antagonist 
(GW1100) on Compound A and GSK137647 induced insulin secretion from clonal 
pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of AH7614 (10-5 M) and GW1100 (10-5 M) on the insulinotropic effect of (A) 
Compound A (10-12-10-4 M) and (B) GSK137647 at 5.6 mM glucose in clonal pancreatic 
BRIN-BD11 cells. Results are the mean ± SEM (n=8) for insulin secretion. *p<0.05, 
**p<0.01, ***p<0.001, compared to glucose control. +p<0.05, ++p<0.01, compared to 
agonist only. 
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Figure 3.17: Effect of GPR120 antagonist (AH7614) and GPR40 antagonist 
(GW1100) on Compound A and GSK137647 induced insulin secretion from clonal 
pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of AH7614 (10-5 M) and GW1100 (10-5 M) on the insulinotropic effect of (A) 
Compound A (10-12-10-4 M) and (B) GSK137647 at 16.7 mM glucose in clonal pancreatic 
BRIN-BD11 cells. Results are the mean ± SEM (n=8) for insulin secretion. *p<0.05, 
**p<0.01, ***p<0.001, compared to glucose control. +p<0.05, ++p<0.01, +++p<0.001, 
compared to agonist only. 
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Figure 3.18: Immunocytochemistry staining of GPR120, insulin and DAPI nuclear 
stain in clonal pancreatic BRIN-BD11 cells.  
 
 
 
 
Expression and distribution of (A) DAPI, (B) insulin (C) GPR120 and (D) double 
antibody immunofluorescence of insulin and GPR120 at 40x magnification in clonal 
pancreatic BRIN-BD11 cells. Examples of co-localisation between GPR120 and insulin 
are indicated by white arrows. 
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Figure 3.19: Effect of GW9508 and ALA on GPR120 mRNA and protein 
expression in clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Effect of GW9508 (10-4 mol/l) and ALA (10-4 mol/l) on GPR120 (A, B) mRNA 
expression and (C, D) protein expression in clonal pancreatic BRIN-BD11 cells after 4 h 
incubation at (A, B) 5.6 mM and (C, D) 16.7 mM glucose. Results are the mean ± SEM 
(n=3) for qPCR and (n=2) for western blotting. *p<0.05, **p<0.01, compared to glucose. 
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Figure 3.20: Effect of Compound A and GSK137647 on GPR120 mRNA and 
protein expression in clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Effect of Compound A (10-4 mol/l) and GSK137647 (10-4 mol/l) on GPR120 (A, B) 
mRNA expression and (C, D) protein expression in clonal pancreatic BRIN-BD11 cells 
after 4 h incubation at (A, B) 5.6 mM and (C, D) 16.7 mM glucose. Results are the mean 
± SEM (n=3) for qPCR and (n=2) for western blotting. *p<0.05, **p<0.01, compared to 
glucose. 
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Figure 3.21: Effect of GPR120 agonists on cAMP and intracellular Ca2+ modulated 
insulin secretion from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Effect of GPR120 agonists on (A) cAMP production and (C) calcium-induced insulin 
secretion in clonal pancreatic BRIN-BD11 cells at 16.7 mmol/l glucose. Agonists were 
co-incubated with inositol trisphosphate receptor antagonist (Xestospongin C, 350 
nmol/l) for 20 min for calcium analysis. *p<0.05, **p<0.01, ***p<0.001, compared to 
glucose control. ++p<0.01, +++p<0.001, compared to agonist only. 
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Figure 3.22: Western blotting demonstrating the effect of GSK137647, GW9508, 
ALA and PMA on ERK1/2 (p44/42) signalling in clonal pancreatic BRIN-BD11 
cells. 
 
 
 
Effect of GSK137647 (10-4 mol/l), GW9508 (10-4 mol/l), ALA (10-4 mol/l) and PMA 
(200 nm) on ERK1/2 signalling in clonal pancreatic BRIN-BD11 cells at various 
timepoints (0, 5, 10, 15, 30, 60 min). Following incubation, cell lysates were separated 
via SDS-PAGE, then probed with antibodies for anti-p-ERK1/2 and anti-t-ERK1/2.   
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Figure 3.23: Flow cytometry demonstrating the effect of GSK137647, GW9508, 
ALA and PMA on ERK1/2 (p44/42) signalling in clonal pancreatic BRIN-BD11 
cells. 
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Effects of (B) PMA, (C) GW9508, (D) ALA and (E) GSK137647 on ERK1/2 
phosphorylation in clonal pancreatic BRIN-BD11 cells. After 15 min exposure, cells were 
probed with anti-phospho-ERK1/2 and anti-Alexa Fluor 488 antibodies, then gated for 
flow cytometry analysis. 
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Figure 3.24: Effect of GPR120 agonist GSK137647 on mitogen-activated protein 
kinase (MAPK) signalling in clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
Effect of GPR120 agonist GSK137647 (10-4 mol/l) and PMA (200 nm) on JNK, p38 and 
ERK1/2 (MAPK) signalling in clonal pancreatic BRIN-BD11 cells at various timepoints 
(0, 5, 10, 15, 30 min). Following incubation, cell lysates were separated via SDS-PAGE, 
then probed with antibodies for total and phosphorylated ERK1/2, p38 and JNK.  
133 
 
Figure 3.25: Effect of GW9508, ALA and GSK137647 on clonal pancreatic BRIN-
BD11 cell viability and apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of GW9508, ALA and GSK137647 on clonal pancreatic BRIN-BD11 cell 
viability and apoptosis after 20 h incubation.  Results determined with multiplex analysis; 
cell viability by protease activity, cell apoptosis by caspase 3/7 activity. Cytokine cocktail 
(TNF-α [200 U/ml], IFN-γ [20 U/ml], IL-1β [100 U/ml]) was used as a positive control. 
Results are the mean ± SEM (n=3). *p<0.05, **p<0.01, compared to non-treated control.  
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Figure 3.26: Effect of GW9508, ALA and GSK137647 on clonal pancreatic α-
TC1.9 cell proliferation and apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of GW9508, ALA and GSK137647 on clonal pancreatic α-TC1.9 cell viability and 
apoptosis after 20 h incubation.  Results determined with multiplex analysis; cell viability 
by protease activity, cell apoptosis by caspase 3/7 activity. Cytokine cocktail (TNF-α [200 
U/ml], IFN-γ [20 U/ml], IL-1β [100 U/ml]) was used as a positive control. Results are the 
mean ± SEM (n=3). **p<0.01, ***p<0.001, compared to non-treated control.  
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Chapter 4 
 
Investigating the effects of GPR55 on 
insulin secretion, downstream receptor 
signalling and islet cell regeneration in-
vitro 
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4.1: Summary 
 
G-protein coupled receptor 55 (GPR55) has recently been identified as a novel 
endocannabinoid receptor that is highly expressed in numerous tissues, including the 
pancreatic islet, intestines, peripheral tissues and the brain. Recent studies have 
implicated the role of GPR55 in beta cell function and glucose homeostasis. The present 
study investigates the effect and mechanistic function of GPR55 towards insulin release, 
downstream receptor signalling and beta cell regeneration using clonal pancreatic islet 
cells. 
Insulinotropic capabilities and cytotoxicity of cannabinoid GPR55 agonists were assessed 
in rodent pancreatic BRIN-BD11 cells, with secretory effects confirmed in human 1.1B4 
cells. Downstream GPR55 signalling pathways including intracellular Ca2+, cAMP and 
MAPKs were investigated upon receptor activation. Effect of GPR55 agonist treatment 
towards islet cell proliferation and apoptosis was assessed in insulin secreting BRIN-
BD11 and glucagon secreting α-TC1.9 cells.  Expression of GPR55 and insulin mRNA 
and protein concentrations were determined by qPCR and western blotting in BRIN-
BD11 cells at both normoglycemia and hyperglycaemia. 
Endocannabinoid and atypical cannabinoid GPR55 agonists stimulated insulin secretion 
(p<0.05-p<0.001) from pancreatic BRIN-BD11 and 1.1B4 cells, with synthetic Abn-CBD 
demonstrating the most potent insulinotropic effect (p<0.05-p<0.001) from BRIN-BD11 
cells at 5.6 mmol/l (2.7-fold; EC50 = 1.506 x 10
-8 mol/l) and 16.7 mmol/l (3.1-fold; EC50 
= 5.18 x 10-9 mol/l) glucose. GPR55 agonists prompted an increase in intracellular Ca2+ 
(p<0.05-p<0.001), with no effects on cAMP production. Abn-CBD, AM251 and OEA 
had no effect on ERK1/2 phosphorylation, whilst Abn-CBD reduced phospho-JNK and 
phospho-p38 activation in BRIN-BD11 cells. Abn-CBD and AM251 improved beta cell 
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viability (14-16%, p<0.05), whilst Abn-CBD and O-1602 reduced beta apoptosis (24-
39%, p<0.05-p<0.01). Abn-CBD, AM251 and O-1602 reduced alpha cell viability by 39-
52% (p<0.001) and increased alpha cell apoptosis by 13-82% (p<0.0-p<0.001) at super-
physiological concentrations. Incubation of BRIN-BD11 cells with Abn-CBD and 
AM251 reduced GPR55 mRNA (p<0.01) expression at 5.6 mmol/l and 16.7 mmol/l 
glucose.  
These findings demonstrate that the novel endocannabinoid receptor GPR55 regulates 
insulin secretion and beta regeneration, thus promoting the receptor as a therapeutic target 
for type 2 diabetes.  
 
4.2: Introduction 
 
The previously considered orphan G-protein coupled receptor 55 (GPR55) has been 
identified as a novel endocannabinoid receptor (Lagerstrom & Schioth 2008, Ryberg et 
al. 2009, Tuduri et al. 2017). Although classified as a member of the endocannabinoid 
system, GPR55 exhibits only 13% and 14% sequence homology with the CB1 and CB2 
receptors, respectively (Tuduri et al. 2017). Numerous studies have demonstrated the 
biological activation of GPR55 to be mediated by a range of cannabinoid ligands, 
including plant (phytocannabinoids), small synthetic cannabinoids and endogenous 
cannabinoid ligands (McKillop et al. 2013, Tuduri et al. 2017,). As the functional role of 
the CB1 and CB2 receptors is well known, it has been hypothesised that GPR55 is 
accountable for the non-CB1/CB2 effects exerted by the cannabinoid ligands (Shore & 
Reggio 2015, Tuduri et al. 2017). 
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The gene encoding human-GPR55 is located on chromosome 2 at q37, with the translated 
GPR55 protein comprised of 319 amino acid residues (Sawzdargo et al. 1999).  Rat and 
mouse GPR55 display 78% and 75% sequence homology with human-GPR55, 
respectively (Tudurí et al. 2017). Expression of GPR55 has been reported in many tissues 
of the human body, with abundant expression observed in adipose tissue, brain, peripheral 
tissue, central nervous system, endocrine-pancreas and the gastrointestinal (GI) tract 
(Sawzdargo et al. 1999, Ryberg et al. 2009, McKillop et al. 2013). 
GPR55 has a regulatory role in GI tract physiology of both humans and rodents, with high 
receptor expression demonstrated in the duodenum, jejunum, ileum and colon (Schicho 
& Storr 2012). The biological function of GPR55 in the GI tract is not fully understood, 
however, some studies have reported the receptor to potentiate anti-inflammatory and 
motility functions (Schicho et al. 2011, Stancic et al. 2015). Furthermore, the endogenous 
GPR55 agonist OEA is widely produced in the GI tract and exhibits potent inhibitory 
effects towards food intake (Schicho & Storr 2012). However, conflicting evidence has 
also demonstrated the atypical GPR55 agonist O-1602 to induce food intake and adiposity 
in rats (Diaz-Arteaga et al. 2012). 
The endocannabinoid system is known to exhibit a regulatory role in multiple biological 
processes, including psychological, cardiovascular and intestinal functions (Pacher & 
Kunos 2013). However, recent studies have indicated that it may also have a pivotal role 
in the maintenance of glucose and lipid homeostasis, particularly through GPR55 
activation (McKillop et al. 2013, McKillop et al. 2016, Tudurí et al. 2017). 
With respect to the endocrine-pancreas, GPR55 is heavily expressed in human and rodent 
pancreatic islets, with abundant expression demonstrated within insulin secreting beta 
cells (McKillop et al. 2013, Liu et al. 2016). In rodent islets, GPR55 expression was 
shown to be exclusive to pancreatic beta cells, with no expression observed on glucagon 
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and somatostatin secreting alpha and delta cells, respectively (McKillop et al. 2013). 
However, immunohistochemical analysis using human islets displayed co-expression of 
GPR55 and glucagon in pancreatic alpha cells (Liu et al. 2016). 
Accompanied with high expression of GPR55 in pancreatic beta cells, agonising the 
receptor induces insulin secretion (McKillop et al. 2013, Liu et al. 2016). In particular, a 
range of endogenous (OEA, PEA) and atypical (Abn-CBD, O-1602, AM251) ligands 
were shown to induce glucose stimulated insulin secretion (GSIS) from pancreatic BRIN-
BD11 cells (McKillop et al. 2013).  The insulinotropic effect of the cannabinoid ligands 
was impaired when co-incubated with a GPR55 antagonist. Furthermore, administration 
of GPR55 agonists was shown to improve glucose tolerance and enhance insulin secretion 
in mice (McKillop et al. 2013, McKillop et al. 2016). Chronic administration of 
cannabidiol analogue Abn-CBD improved glucose control, increased plasma insulin 
concentrations and lowered cholesterol in streptozotocin-induced diabetic mice, with 
reductions in food intake and bodyweight also observed (McKillop et al. 2016). 
Although, numerous studies have demonstrated the glucose lowering and insulinotropic 
properties of GPR55, its mechanism of insulin secretion is poorly understood. Upon 
activation, GPR55 primarily couples to Gα12/13 and Gαq intracellular G-protein 
subunits, resulting in phospholipase C (PLC) and RhoA signalling (Lauckner et al. 2008, 
Leyva-Illades & DeMorrow 2013). This can stimulate an array of downstream cellular 
responses, such as myosin contractility, cell cycle maintenance, cellular morphological 
polarization, cellular secretion, cellular development and transcriptional control (Leyva-
Illades & DeMorrow 2013, Yu & Brown 2015). With respect to the pancreatic beta cell, 
initial studies have demonstrated a range of cannabinoid ligands to augment intracellular 
Ca2+ concentrations, indicating the involvement of inositol trisphosphate (IP3) on 
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intracellular calcium stores through PLCβ signalling (McKillop et al. 2013, Liu et al. 
2016). 
Another study demonstrated Abn-CBD to exhibit proliferative and cytoprotective effects 
towards pancreatic mouse islets (Ruz‐Maldonado et al. 2018). The effects observed were 
proven to be GPR55 specific with the use of GPR55 knockout mice (Ruz‐Maldonado et 
al. 2018). However, the mechanistic function of GPR55-mediated islet cytoprotection and 
regeneration remains elusive. Interestingly, Abn-CBD has been closely linked with 
mitogen-activated protein kinase (MAPK) signalling, a highly conserved family of 
serine/threonine protein kinases that are involved in a range of cellular responses, 
including differentiation, proliferation, apoptosis, survival, stress response and motility. 
MAPK pathways (ERK1/2, JNK, p38) can be activated upon G-protein coupled receptor 
signalling and may contribute to the beneficial effects of GPR55 in the pancreatic islet 
(Matouk et al. 2017). 
Currently, there are limited reports on the regulatory role of GPR55 in the pancreatic islet. 
The present study aims to characterise the mechanistic function of GPR55 with respect 
to insulin release, islet cell regeneration and receptor expression. Downstream signalling 
molecules were investigated (intracellular Ca2+, cAMP and MAPKs) to explore the 
functional role of GPR55, whilst receptor expression analysis further evaluated the 
therapeutic potential of GPR55 activation.  
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4.3: Materials and methods 
 
4.3.1: Materials 
Abn-CBD, AM251, O-1602, OEA, PEA and alanine were purchased from Tocris 
Bioscience (Bristol, UK). All other materials were purchased from suppliers as detailed 
in Section 2.  
 
4.3.2: Acute insulin secretion studies from pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were sub-cultured and seeded into 24-well plates at a density of 
150,000 cells per well, then supplemented with 1 ml of RPMI media and allowed to attach 
overnight, as outlined in Section 2.1.2.  Abn-CBD, AM251, O-1602, OEA, PEA (10-4-
10-12 mol/l) were added to KRBB buffer, supplemented with 5.6 mmol/l or 16.7 mmol/l 
glucose. Cells were pre-treated with 1.1 mmol/l glucose KRBB for 40 min at 37oC. After 
pre-incubation, test solutions were added and incubated for 20 min at 37oC. Aliquots 
(900µl) of cell supernatant were removed and stored at -20oC until determination of 
insulin concentrations by radioimmunoassay, as outlined in Section 2.2.3. MTT 
cytotoxicity analysis was conducted with identical test parameters as insulin secretory 
studies previous detailed in Section 2.1.6. 
 
4.3.3: Determination of GPR55 mRNA expression in pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cell were pre-incubated with 1.1 mmol/l 
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glucose for 1 h at 37oC. Agonist test solutions (10-4 mol/l) were prepared in KRBB buffer 
at 5.6 mmol/l or 16.7 mmol/l glucose. Test solutions were incubated for 4 h at 37oC. After 
incubation, cells were lysed and RNA harvested with TRIzol reagent (Sigma, UK). RNA 
was purified then converted to cDNA as previously described in Section 2.6.2.  SYBR 
green PCR kit (Roche, UK) was used for qPCR as previously detailed in Section 2.6.3. 
 
4.3.4: Immunofluorescence staining of BRIN-BD11 cells  
As detailed in Section 2.8.2. 
 
4.3.5: Determination of cAMP production in pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cells were pre-incubated with 1.1 mmol/l 
glucose for 40 min at 37oC. Agonist test solutions (10-4 mol/l) and IBMX (10 mmol/l) 
were prepared in KRBB buffer at 16.7 mmol/l glucose and assessed for cAMP production. 
After incubation, cells were lysed and cAMP detected with the cAMP ELISA kit as 
previously described in Section 2.4.2. 
 
4.3.6: Intracellular Ca2+ measurement 
BRIN-BD11 cells were sub-cultured and seeded into 24-well plates at a density of 80,000 
cells per well, then supplemented with 1 ml of RPMI media and cultured overnight, as 
outlined in Section 2.1.2. Alanine (10 mmol/l) and GPR55 agonists (Abn-CBD, AM251, 
O-1602, OEA, PEA) at 10-4 mol/l were added to KRBB buffer, supplemented with 5.6 
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mmol/l or 16.7 mmol/l glucose. The assay plate was pre-incubated with the dye prepared 
with KRBB and 50µl of the test solutions were transferred to the plate with fluorescence 
intensity measured for 5 min using the FlexStation 3 plate reader (Molecular devices, CA, 
USA), as detailed in Section 2.3.2. 
 
4.3.7: MAPK signalling and GPR55 expression analysis by western blotting in 
pancreatic BRIN-BD11 cells  
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cells were pre-incubated with 1.1 mmol/l 
glucose for 40 min at 37oC. Agonist test solutions (10-4 mol/l) and PMA (200 nmol/l) 
were prepared in KRBB buffer at 5.6 mmol/l or 16.7 mmol/l glucose. After incubation, 
cells were lysed at various timepoints with RIPA buffer, supplemented with protease and 
phosphatase inhibitors. Cell lysates (25µg) were prepared and separated by SDS-PAGE 
and transferred to a nitrocellulose membrane, as previously described in Section 2.7. 
Membranes were probed with total and phosphorylated anti-ERK1/2, anti-JNK and anti-
p38 antibodies for MAPK signalling and anti-GPR55 for receptor expression. β-actin was 
used as a control to normalise data. Images were captured using a G:BOX Chemi XX9 
imager (Syngene, UK) and densitometry analysis performed using ImageJ.    
 
4.3.8: ERK1/2 signalling analysis by flow cytometry in pancreatic BRIN-BD11 cells  
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cells were pre-incubated with 1.1 mmol/l 
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glucose for 40 min at 37oC. Agonist test solutions (10-4 mol/l) and PMA (200 nmol/l) 
were prepared in KRBB buffer at 16.7 mmol/l glucose. After incubation, cells were 
detached with trypsin, pelleted by centrifugation then re-suspended in 600µl of flow 
cytometry staining buffer, supplemented with anti-phospho-ERK1/2 antibodies. Samples 
were conjugated with an AlexaFluor488 secondary antibody. Samples were gated prior 
to FITC-GFP expression analysis by flow cytometry.   
 
4.3.9: Cellular viability and apoptosis studies on pancreatic BRIN-BD11 cells and α-
TC1.9 cells 
BRIN-BD11 cells were sub-cultured and seeded into a clear 96-well plate at a density of 
40,000 cells per well and allowed to attach overnight, as previously outlined in Sections 
2.1.2 and 2.1.4. Agonist test solutions (10-4 mol/l) and cytokine cocktail solution (TNF-α 
[200 U/ml], IFN-γ [20 U/ml], IL-1β [100 U/ml]) were prepared in RPMI media, then 
added to the cells and incubated for 20 h at 37oC. Cell viability and apoptosis was 
determined with Apo-Live-Glo multiplex analysis as per manufacturer’s protocol; cell 
viability by protease activity, cell apoptosis by caspase 3/7 activity (Promega, USA). 
 
4.4: Results 
 
4.4.1: Effect of GPR55 agonists on insulin secretion from clonal pancreatic BRIN-
BD11 cells 
The insulin secretory effect of a range of endogenous (OEA, PEA) and synthetic (Abn-
CBD, AM251, O-1602) GPR55 agonists was investigated using the clonal pancreatic 
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BRIN-BD11 cell line at 5.6 mmol/l and 16.7 mmol/l glucose. Atypical CBD analogue 
Abn-CBD (10-9-10-4 mol/l) stimulated insulin release at 5.6 mmol/l (p<0.05-p<0.001) 
(Fig. 4.1A). At 16.7 mmol/l glucose, the insulinotropic effect of Abn-CBD (10-9-10-4 
mol/l) was increased (p<0.05-p<0.001), with a 3.1-fold increase observed at the highest 
concentration tested (10-4 mol/l) (Fig. 4.2A). Rimonabant analogue AM251 (10-8-10-4 
mol/l) induced insulin secretion (p<0.05) at 5.6 mmol/l glucose (Fig. 4.3A). At 
stimulatory glucose concentrations (16.7 mmol/l glucose), AM251 (10-5-10-4 mol/l) 
exhibited insulinotropic capabilities (p<0.01-p<0.001), with a 68% increase demonstrated 
at the highest concentration tested (10-4 mol/l) (Fig. 4.4A). 
The synthetically composed CBD analogue O-1602 (10-8-10-4 mol/l) stimulated insulin 
release at 5.6 mmol/l glucose, with an increase of 83% (p<0.01) observed at the highest 
concentration tested (Fig. 4.5A). At 16.7 mmol/l glucose, O-1602 (10-8-10-4 mol/l) 
demonstrated enhanced insulinotropic capabilities, with a 127% increase observed at the 
highest agonist concentration investigated (10-4 mol/l) (Fig. 4.6A). 
Naturally occurring GPR55 agonist PEA (10-5-10-4 mol/l) stimulated insulin secretion 
(p<0.05-p<0.001) at 5.6 mmol/l glucose (Fig. 4.7A). When incubated at 16.7 mmol/l 
glucose, PEA (10-8-10-4 mol/l) demonstrated enhanced insulinotropic capabilities, whilst 
omitting a 93% (p<0.001) increase at the highest agonist concentration tested (10-4 mol/l) 
(Fig. 4.8A). Endogenous endocannabinoid OEA (10-8-10-4 mol/l) induced insulin release 
(p<0.05-p<0.001) at 5.6 mmol/l glucose (Fig. 4.9A). At stimulatory glucose 
concentrations of 16.7 mmol/l glucose, OEA (10-7-10-4 mol/l) augmented insulin 
secretion (p<0.01-p<0.001), with a 1.8-fold increase demonstrated at the highest agonist 
concentration tested (10-4 mol/l) (Fig. 4.10A). 
At basal glucose concentrations (5.6 mmol/l), GPR55-induced insulin release and agonist 
potencies were as follows (in descending order): Abn-CBD (1.506 x 10 -8 mol/l), AM251 
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(7.6 x 10-8 mol/l), O-1602 (1.24 x 10-7 mol/l), OEA (4.6 x 10-7 mol/l), PEA (3.439 x 10-6 
mol/l). At hyperglycaemic concentrations of 16.7 mmol/l, agonist potency was as follows 
(in descending order): Abn-CBD (5.18 x 10-9 mol/l), PEA (2.394 x 10-8 mol/l), OEA 
(1.131 x 10-6 mol/l), O-1602 (5.87 x 10-6 mol/l), AM251 (1.04 x 10-5 mol/l) (Table 4.1).  
The positive control (alanine) augmented insulin secretion (p<0.001) for all insulin 
secretory analysis (Fig. 4.1-4.10A). Cytotoxicity analysis by MTT demonstrated no 
adverse effects towards pancreatic BRIN-BD11 cells at 5.6 mmol/l and 16.7 mmol/l 
glucose upon incubation with all agonists at the range of concentrations tested (Fig. 4.1-
4.12B). 
 
4.4.2: Effect of GPR55 agonists on insulin secretion from clonal human pancreatic 
1.1B4 cells 
The insulinotropic properties of the potent GPR55 agonists (Abn-CBD and AM251) were 
further investigated in the human clonal pancreatic 1.1B4 cell line at 5.6 mmol/l and 16.7 
mmol/l glucose. Atypical cannabinoid Abn-CBD (10-9-10-4 mol/l) stimulated insulin 
secretion by 1.4-2.0-fold at 5.6 mmol/l glucose (p<0.01-p<0.001) (Fig. 4.11A). At 16.7 
mmol/l glucose, Abn-CBD (10-6-10-4 mol/l) augmented insulin release (p<0.05-p<0.001), 
with an 82% (p<0.001) increase observed at the highest concentration tested (10-4 mol/l) 
(Fig. 4.1B). 
Rimonabant analogue AM251 (10-10-10-4 mol/l) induced insulin secretion by 1.2-2-fold 
(p<0.05-p<0.001) at 5.6 mmol/l glucose (Fig. 4.3A). At stimulatory glucose 
concentrations of 16.7 mmol/l glucose, AM251 (10-8-10-4 mol/l) maintained 
insulinotropic capabilities (p<0.01-p<0.001), with a 117% increase demonstrated at the 
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highest concentration tested (10-4 mol/l) (Fig. 4.12B). The positive control (alanine) 
augmented insulin secretion (p<0.001) for all insulin secretory analysis (Fig. 4.11-4.12). 
AM251was the most potent agonist tested at 5.6 mmol/l with an EC50 value of 5.442 x 
10-7 mol/l, followed by Abn-CBD (1.610 x 10-6 mol/l). At 16.7 mmol/l glucose, AM251 
remained the most potent with an EC50 value of 1.610 x 10
-6 mol/l, followed by Abn-CBD 
(3.225 x 10-6 mol/l) (Table. 4.1). 
 
4.4.3: Expression and distribution of GPR55 and insulin in clonal pancreatic BRIN-
BD11 cells 
Immunocytochemistry analysis was employed to determine the distribution of (A) DAPI, 
(B) insulin, (C) GPR55 in BRIN-BD11 cells (Fig. 4.13). High expression of GPR55 and 
insulin was demonstrated in BRIN-BD11 cells, with areas of co-localisation observed 
between GPR55 and insulin using double immuno-fluorescence analysis (Fig. 4.13D).  
 
4.4.4: Effects of Abn-CBD and AM251 on GPR55 and insulin expression in clonal 
pancreatic BRIN-BD11 cells 
qPCR and western blotting were employed to determine GPR55 mRNA and protein 
expression in BRIN-BD11 cells upon agonist treatment at 5.6 mmol/l and 16.7 mmol/l 
glucose (Fig. 4.14). Abn-CBD and AM251 reduced GPR55 mRNA expression by 25-
40% (p<0.05) at 5.6 mmol/l glucose. At 16.7 mmol/l glucose, AM251 reduced GPR55 
mRNA expression by 60% (p<0.05), whilst Abn-CBD had no effect. Complimentary 
western blotting demonstrated a down regulation (39-42%) of GPR55 protein expression 
in the pancreatic BRIN-BD11 cells upon activation with Abn-CBD and AM251 at 16.7 
mM glucose (Fig. 4.14C).  
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At 5.6 mmol/l glucose, Abn-CBD and AM251 up regulated insulin mRNA expression by 
2.7-3.0-fold (p<0.05-p<0.01) (Fig. 4.15A). At 16.7 mmol/l glucose, Abn-CBD and 
AM251 up regulated insulin mRNA by 1.8-2-fold (p<0.05) (Fig. 4.15B).  
 
4.4.5: Effect of GPR55 agonists on intracellular Ca2+ and cAMP modulation in 
clonal pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were incubated with GPR55 agonists (Abn-CBD, AM251, O-1602, 
PEA, AM251) at 10-4 mol/l and IBMX or alanine at 10 mmol/l in KRBB supplemented 
with 16.7 mmol/l glucose. In pancreatic BRIN-BD11 cells AM251 (p<0.001), PEA 
(p<0.001), O-1602 (p<0.05) and Abn-CBD (p<0.05) prompted an increase in intracellular 
calcium concentrations at 16.7 mmol/l glucose, whilst OEA had no effect (Fig. 4.16)  
After 20 min incubation, all GPR55 agonists demonstrated no significant effects on 
cAMP production, whilst the positive control (IBMX) stimulated a 19-fold (p<0.001) 
increase (Fig. 4.17).  
4.4.6: Effect of Abn-CBD, AM251, OEA and PMA on ERK1/2 (p44/42) signalling in 
clonal pancreatic BRIN-BD11 cells 
SDS-PAGE western blotting demonstrated Abn-CBD, AM251 and OEA to have no effect 
on ERK1/2 phosphorylation at time points ranging from 5-60 min in BRIN-BD11 cells. 
Whereas, the positive control (PMA) induced ERK1/2 phosphorylation after 30 and 60 
min incubation (Fig. 4.18).Further analysis using flow cytometry demonstrated that Abn-
CBD (Fig. 4.19C), AM251 (Fig. 4.19D) and OEA (Fig. 4.19E) had no effect on ERK1/2 
phosphorylation as each agonist demonstrated a response (7.8-8.7%) similar to the non-
treated control (7.8%) (Fig. 4.19A). The positive control (PMA) induced ERK1/2 
phosphorylation by 19.9% in BRIN-BD11 cells (Fig. 4.19B). 
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4.4.7: Effect of Abn-CBD on JNK, p38 and ERK1/2 MAPK signalling in clonal 
pancreatic BRIN-BD11 cells 
The effect of Abn-CBD on mitogen-activated protein kinase (MAPK) signalling was 
assessed by western blotting in BRIN-BD11 cells (Fig. 4.20). Abn-CBD abolished JNK 
phosphorylation after 5 min incubation, with JNK phosphorylation returning to basal after 
further 5 min incubation and continued for the remainder of experimental timeframe (10-
30 min). Abn-CBD reduced p38 phosphorylation after 10-30 min incubation. No effect 
on ERK1/2 phosphorylation was observed throughout the experimental timeframe (5-
30min). Total JNK, p38 and ERK1/2 remained constant at all time points. Positive control 
(PMA) induced JNK, p38 and ERK1/2 phosphorylation within 15-30 min incubation.  
 
4.4.8: Effect of Abn-CBD, AM251 and O-1602 on clonal pancreatic BRIN-BD11 cell 
viability and apoptosis 
BRIN-BD11 cells were incubated with GPR55 agonists for 20 h. Cell viability was 
determined by protease activity and apoptosis by caspase3/7 activity (Fig. 4.21). Abn-
CBD (10-4 mol/l and 10-6 mol/l) and AM251 (10-6 mol/l) increased cell viability by 14-
16% (p<0.05), whilst O-1602 had no effect at both concentrations (10-4 mol/l and 10-6 
mol/l). Cytokine cocktail incubation reduced cell viability by 13% after 20 h incubation 
(Fig. 4.21A).  
At 10-6 mol/l, Abn-CBD, AM251 and O-1602 had no effect on caspase3/7 activity. At a 
higher agonist concentration (10-4 mol/l), Abn-CBD and O-1602 reduced by 24% 
(p<0.05) and 39% (p<0.01), respectively, whilst AM251 increased caspase3/7 activity by 
97% (p<0.001). Cytokine cocktail incubation increased caspase3/7 by 47% (p<0.01) after 
20 h incubation (Fig. 4.21B). 
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3.4.9: Effect of Abn-CBD, AM251 and O-1602 on clonal pancreatic α-TC1.9 cell 
viability and apoptosis 
Α-TC1.9 cells were incubated with GPR55 agonists for 20 h. Cell viability was 
determined by protease activity and apoptosis by caspase3/7 activity (Fig. 4.22). At 10-6 
mol/l, Abn-CBD, AM251 and O-1602 had no effect on cell viability. At a higher agonist 
concentration (10-4 mol/l), Abn-CBD, AM251 and O-1602 reduced cell viability by 39-
52% (p<0.001). Cytokine cocktail incubation reduced cell viability by 32% after 20 h 
(Fig. 4.22A).  
At 10-6 mol/l, Abn-CBD (18%) and O-1602 (15%) reduced caspase3/7 activity (p<0.01-
p<0.001), whilst AM251 had no significant effect. At a higher agonist concentration (10-
4 mol/l), Abn-CBD, AM251 and O-1602 increased caspase3/7 activity by 13-82% 
(p<0.01-p<0.001). Cytokine cocktail incubation increased caspase3/7 by 15% (p<0.01) 
after 20 h (Fig. 4.22B). 
 
4.5: Discussion: 
 
Novel therapeutic strategies that enhance islet cell function and beta cell regeneration are 
required for the treatment of type 2 diabetes. Recently, research has intensified on the 
endocannabinoid system upon the discovery of the novel endocannabinoid receptors 
GPR55, GPR18 and GPR119 (Lagerstrom & Schioth 2008, Ryberg et al. 2009). Previous 
studies have demonstrated a range of beneficial effects exerted by endocannabinoid 
receptors upon activation with long chain fatty acid agonists, including the regulation of 
glycaemic control, energy metabolism and anti-inflammatory responses (McKillop et al. 
2013, McKillop et al. 2016, Tudurí et al. 2017). 
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The CB1 and CB2 receptors of the endocannabinoid system are known to modulate a 
range of physiological functions including appetite, memory, mood and pain-sensitisation 
(Aizpurua-Olaizola et al. 2017). The CB1 receptor is predominately expressed in the 
brain and the central nervous system, whereas the CB2 receptor is mainly expressed in 
the immune system and in hematopoietic cells (Pacher and Kunos 2013). Cannabinoid 
ligands bind stereo-selectively and reversibly to the CB1 and CB2 receptors. Selective 
subtype cannabinoids have been synthetically composed and present potential for the 
treatment of obesity and other metabolic diseases, with a CB1 inverse agonist 
Rimonabant (SR141716) previously used as an anti-obesity drug (Henness et al. 2006). 
Although categorised as an endocannabinoid receptor, GPR55 is not associated with the 
control of psychological responses and shares limited sequence homology with the CB1 
and CB2 receptors (Morales & Reggio 2017). Recent studies have indicated that GPR55 
is responsible for the anti-diabetic effects exerted by cannabinoid ligands through the 
regulation of insulin release and glucose homeostasis (McKillop et al. 2013, McKillop et 
al. 2016, Tuduri et al. 2017).  
The present study utilised a range of endogenous (OEA, PEA) and synthetic (Abn-CBD, 
AM251, O-1602) GPR55 agonists to investigate the anti-diabetic efficacy of the receptor 
through the regulation of insulin release and beta cell regeneration. At normoglycemia, 
endogenous (OEA) and synthetic (Abn-CBD) were the most potent agonists tested, whilst 
previous complimentary studies also demonstrated the insulinotropic properties of Abn-
CBD in human islets (Ruz‐Maldonado et al. 2018). Interestingly, at hyperglycaemic 
concentrations, PEA was the most potent endogenous agonist, whilst Abn-CBD remained 
the most potent synthetic agonist tested. The secretory response of Abn-CBD was 
enhanced in hyperglycaemia, thus revealing its glucose responsive properties and 
therapeutic potential for the treatment of hyperglycaemia. Studies using human 1.1B4 
152 
 
cells revealed that GPR55 agonists emit similar potencies in both rodent and human 
pancreatic beta cells; an important finding for the development and characterisation of 
future GPR55 targeting therapeutics. Moreover, for the first time, the study revealed that 
treatment of GPR55 agonists upregulated insulin mRNA expression in beta cells, 
suggesting that GPR55 may potentiate second phase insulin secretion.  
At present, the mechanism of GPR55-induced insulin secretion from pancreatic beta cells 
is not fully understood; however, initial studies have shown GPR55 agonism to augment 
intracellular Ca2+ concentrations (McKillop et al. 2013, Liu et al. 2016). The present 
study explored the effects of GPR55 agonists on intracellular Ca2+ modulation, cAMP 
production and MAPK phosphorylation in beta cells, which are downstream Gαq, Gαs 
and Gαi secondary signalling molecules linked with all cannabinoid receptor signalling. 
Complimentary to previous findings, GPR55 agonists increased intracellular Ca2+ after 5 
min, indicating the stimulatory effect of GPR55 activation on first phase insulin release.  
All agonists tested demonstrated no effect on cAMP production, suggesting that the Gαs 
and Gαi intracellular protein subunits, modulating adenylyl cyclase activity, are not 
stimulated following GPR55 activation. This also indicates that GPR119 (Gαs mediated), 
is not responsible for the effects observed. As studies have acknowledged the 
cardioprotective effects of Abn-CBD mediated by ERK1/2 signalling (Su & Vo 2007, 
Matouk et al. 2018), ERK1/2 phosphorylation was assessed in beta cells upon GPR55 
agonism. Interestingly, all agonists demonstrated no effects on ERK1/2 phosphorylation, 
suggesting that GPR55 signalling may be tissue specific. However, Abn-CBD abolished 
JNK phosphorylation and reduced p38 phosphorylation, indicating that Abn-CBD 
promotes beta cell survival by attenuating the activation of the stress-related MAPK 
pathways. In harmony with this, Abn-CBD has been recently shown to induce beta cell 
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proliferation in a GPR55-dependent manner, however, the mechanism of action was not 
assessed in this study (Ruz‐Maldonado et al. 2018).  
Subsequently, the effect GPR55 activation on islet cell viability (protease activity) and 
apoptosis (caspase 3/7 activity) was investigated in the present study. Abn-CBD and 
AM251 increased cell viability, elucidating the proliferative role of GPR55 activation in 
pancreatic beta cells. Abn-CBD and O-1602 reduced beta cell apoptosis (caspase3/7 
activity) which compliments findings showing Abn-CBD to down-regulate stress linked 
JNK and p38 phosphorylation. Thus, for the first time, indicating the role of MAPK 
phosphorylation in GPR55-induced beta cell proliferation. Although GPR55 is lesser 
expressed in glucagon-secreting alpha cells, the proliferative effects of GPR55 activation 
were also assessed in this cell type. Increased alpha cell proliferation is associated with 
the pathophysiology of type 2 diabetes and may counteract positive proliferative effects 
demonstrated by GPR55 activation in beta cells. In direct contrast to beta cells, GPR55 
agonism induced a marked reduction in alpha cell proliferation, accompanied with an 
increase of alpha cell apoptosis. Overall, findings suggest that GPR55 activation may 
encourage beta cell growth/survival, whilst reducing alpha cell population in the 
pancreatic islet. 
In conclusion to the study, GPR55 agonism induces first and second phase insulin release 
in rodent and human pancreatic beta cells, with no cytotoxicity. The mechanism of 
GPR55-induced insulin release is predominately mediated by intracellular Ca2+, with no 
involvement of cAMP and ERK1/2 signalling. Abn-CBD treatment reduced JNK and p38 
phosphorylation and promotes regenerative effects in the pancreatic islet exclusive to 
insulin-producing beta cells. These findings reveal a range of anti-diabetic properties 
exerted by cannabinoid ligands and promotes GPR55 as a novel therapeutic target. 
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Table 4.1: Half maximal effective concentration (EC50) of GPR55 agonists in 
rodent BRIN-BD11 and human 1.1B4 cells at 5.6 mM and 16.7 mM glucose.  
 
Rodent BRIN-BD11 cells 
Agonist 5.6 mM glucose 16.7 mM glucose 
 
AM-251 7.6 x 10-8 mol/l 1.04 x 10-5 mol/l 
Abn-CBD 1.50 x 10-8 mol/l 5.18 x 10-9 mol/l 
O-1602 1.24 x 10-7 mol/l 5.87 x 10-6 mol/l 
OEA 4.60 x 10-7 mol/l 1.13 x 10-6 mol/l 
PEA 3.43 x 10-6 mol/l 2.39 x 10-8 mol/l 
 
Human 1.1B4 cells 
Agonist 5.6 mM glucose 16.7 mM glucose 
 
AM-251 5.44 x 10-7 mol/l 1.61 x 10-6 mol/l 
Abn-CBD 1.16 x 10-6 mol/l 3.22 x 10-6 mol/l 
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Figure 4.1: Acute effect of Abn-CBD on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of Abn-CBD (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 4.2: Acute effect of Abn-CBD on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of Abn-CBD (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion 
and (B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM 
glucose. Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell 
viability. *p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 4.3: Acute effect of AM251 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of AM251 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, ***p<0.001 compared to glucose control. 
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Figure 4.4: Acute effect of AM251 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of AM251 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 4.5: Acute effect of O-1602 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of O-1602 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 4.6: Acute effect of O-1602 on insulin secretion and cell viability from 
clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of O-1602 (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, **p<0.01,  ***p<0.001 compared to glucose control. 
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Figure 4.7: Acute effect of PEA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of PEA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, ***p<0.001 compared to glucose control. 
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Figure 4.8: Acute effect of PEA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of PEA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 4.9: Acute effect of OEA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 5.6 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of OEA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 5.6 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
*p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 4.10: Acute effect of OEA on insulin secretion and cell viability from clonal 
pancreatic BRIN-BD11 cells at 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of OEA (10-12-10-4 M) and alanine (10 mM) on (A) insulin secretion and 
(B) cell viability (MTT) from clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8) for insulin secretion and (n=3) for cell viability. 
**p<0.01, ***p<0.001 compared to glucose control. 
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Figure 4.11: Acute effect of Abn-CBD on insulin secretion from clonal human 
pancreatic 1.1B4 cells at 5.6 mM and 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of Abn-CBD (10-12-10-4 M) and alanine (10 mM) on insulin secretion at (A) 
5.6 mM and (B) 16.7 mM glucose from human pancreatic 1.1B4 cells. Results are the 
mean ± SEM (n=8) for insulin secretion. **p<0.01, ***p<0.001 compared to glucose 
control. 
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Figure 4.12: Acute effect of AM251 on insulin secretion from clonal human 
pancreatic 1.1B4 cells at 5.6 mM and 16.7 mM glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of AM251 (10-12-10-4 M) and alanine (10 mM) on insulin secretion at (A) 
5.6 mM and (B) 16.7 mM glucose from human pancreatic 1.1B4 cells. Results are the 
mean ± SEM (n=8) for insulin secretion. *p<0.05, **p<0.01, ***p<0.001, compared to 
glucose control. 
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Figure 4.13: Immunocytochemistry staining of GPR55, insulin and DAPI nuclear 
stain in clonal pancreatic BRIN-BD11 cells.  
 
 
 
 
 
Expression and distribution of (A) DAPI, (B) insulin (C) GPR55 and (D) double antibody 
immunofluorescence of insulin and GPR55 at 40x magnification in clonal pancreatic 
BRIN-BD11 cells. Examples of co-localisation between GPR55 and insulin are indicated 
by white arrows. 
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B A 
C 
Figure 4.14: Effect of Abn-CBD and AM251 on GPR55 mRNA and protein 
expression in clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Effect of Abn-CBD (10-4 mol/l) and AM251 (10-4 mol/l) on GPR55 (A, B) mRNA and 
(C) protein expression in clonal pancreatic BRIN-BD11 cells after 4 h incubation at (A) 
5.6 mM and (B, C) 16.7 mM glucose. Results are the mean ± SEM (n=3) for qPCR and 
(n=2) for western blotting. *p<0.05, compared to glucose control. 
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B A 
Figure 4.15: Effect of Abn-CBD and AM251 on insulin mRNA expression in clonal 
pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Effect of Abn-CBD (10-4 mol/l) and AM251 (10-4 mol/l) on insulin mRNA expression in 
clonal pancreatic BRIN-BD11 cells after 4 h incubation at (A) 5.6 mM and (B) 16.7 mM 
glucose. Results are the mean ± SEM (n=3) for qPCR and (n=2) for western blotting. 
*p<0.05, **p<0.01, compared to glucose control. 
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Figure 4.16: Effect of GPR55 agonists on intracellular Ca2+ modulation in clonal 
pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of alanine and GPR55 agonists (OEA, Abn-CBD, O-1602, PEA, AM251) at 10-4 
mol/l on intracellular Ca2+ modulation in clonal pancreatic BRIN-BD11 cells at 16.7 
mmol/l glucose with (A) intracellular Ca2+ measurements (RFU) for 5 min and (B) 
corresponding AUC data. Results are the mean ± SEM *p<0.05, ***p<0.001, compared 
to glucose control.  
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Figure 4.17: Effect of GPR55 agonists on cAMP production in clonal pancreatic 
BRIN-BD11 cells at 16.7 mM glucose. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Effect of GPR55 agonists (OEA, Abn-CBD, O-1602, PEA, AM251) and IBMX on cAMP 
production in clonal pancreatic BRIN-BD11 cells at 16.7 mmol/l glucose. BRIN-BD11 
cells were incubated with treatments for 20 min. Result are the mean SEM (n=3). 
***p<0.001, compared to glucose control.  
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Figure 4.18: Western blotting demonstrating the effect of Abn-CBD, AM251, OEA 
and PMA on ERK1/2 (p44/42) signalling in clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
Effect of Abn-CBD (10-4 mol/l), AM251 (10-4 mol/l), OEA (10-4 mol/l) and PMA (200 
nM) on ERK1/2 signalling in clonal pancreatic BRIN-BD11 cells at various timepoints 
(0, 5, 10, 15, 30, 60 min). Following incubation, cell lysates were separated via SDS-
PAGE, then probed with antibodies for anti-p-ERK1/2 and anti-t-ERK1/2.   
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Figure 4.19: Flow cytometry demonstrating the effect of Abn-CBD, AM251, OEA 
and PMA on ERK1/2 (p44/42) signalling in clonal pancreatic BRIN-BD11 cells. 
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(E) OEA (10-4 mol/l) 
 
 
 
 
 
 
 
(F)  
 
 
 
 
 
Effects of (B) PMA, (C) Abn-CBD, (D) AM251 and (E) OEA on ERK1/2 
phosphorylation in clonal pancreatic BRIN-BD11 cells. After 15 min exposure, cells were 
probed with anti-phospho-ERK1/2 and anti-Alexa Fluor 488 antibodies, then gated for 
flow cytometry analysis. 
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Figure 4.20: Effect of GPR55 agonist Abn-CBD mitogen-activated protein kinase 
(MAPK) signalling in clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
Effect of GPR55 agonist Abn-CBD (10-4 mol/l) and PMA (200 nM) on JNK, p38 and 
ERK1/2 (MAPK) signalling in clonal pancreatic BRIN-BD11 cells at various timepoints 
(0, 5, 10, 15, 30 min). Following incubation, cell lysates were separated via SDS-PAGE, 
then probed with antibodies for total and phosphorylated ERK1/2, p38 and JNK.  
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Figure 4.21: Effect of Abn-CBD, AM251 and O-1602 on clonal pancreatic BRIN-
BD11 cell viability and apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of Abn-CBD, AM251 and O-1602 on clonal pancreatic BRIN-BD11 cell viability 
and apoptosis after 20 h incubation.  Results determined with multiplex analysis; cell 
viability by protease activity, cell apoptosis by caspase 3/7 activity. Cytokine cocktail 
(TNF-α [200 U/ml], IFN-γ [20 U/ml], IL-1β [100 U/ml]) was used as a positive control. 
Results are the mean ± SEM (n=3). *p<0.05, **p<0.01, ***p<0.001, compared to non-
treated control.  
0
50
100
150
200
250
**
**
***
*
Non-treated (Media only)
Cytokine cocktail
Agonist at 10
-6
mmol/l
Agonist at 10
-4
mmol/l
Abn-CBD AM251
C
a
s
p
a
s
e
3
/7
 a
c
ti
v
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
O-1602
0
50
100
150
*
*
* *
Cytokine cocktail
Non-treated (Media only)
Agonist at 10
-6
mmol/l
Agonist at 10
-4
mmol/l
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
Abn-CBD AM251 O-1602
A 
 
B 
 
177 
 
Figure 4.22: Effect of Abn-CBD, AM251 and O-1602 on clonal pancreatic α-TC1.9 
cell proliferation and apoptosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects of Abn-CBD, AM251 and O-1602 on clonal pancreatic α-TC1.9 cell viability and 
apoptosis after 20 h incubation.  Results determined with multiplex analysis; cell viability 
by protease activity, cell apoptosis by caspase 3/7 activity. Cytokine cocktail (TNF-α [200 
U/ml], IFN-γ [20 U/ml], IL-1β [100 U/ml]) was used as a positive control. Results are the 
mean ± SEM (n=3). **p<0.01, ***p<0.001, compared to non-treated control.  
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Chapter 5 
 
Determining the specificity and 
pharmacological role of putative GPR55 
and GPR120 agonists in islets using 
innovative CRISPR/Cas9 gene editing. 
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5.1: Summary 
 
Long chain fatty acid (LCFA) sensing GPR55 and GPR120 are novel anti-diabetic targets 
which enhance beta cell function and insulin secretion. The specificity of many LCFA 
ligands acting through GPR55 and GPR120 remains elusive. The aim of this study is to 
assess metabolic functionality of GPR55/GPR120 agonists in beta cells using innovative 
CRISPR Cas9 gene editing to elucidate their importance in beta cell function. 
Clonal GPR55 and GPR120 knockout insulin secreting beta cells derived from the rat 
BRIN-BD11 cell line were generated by CRISPR/Cas9 gene editing and used to 
investigate insulin secretion/expression and downstream receptor signalling (intracellular 
Ca2+ and cAMP).  
Atypical (Abn-CBD, O-1602, AM251) and endogenous (PEA, OEA) endocannabinoid 
ligands (10-7-10-4 M) stimulated insulin secretion (p<0.05-p<0.001) in wild type BRIN-
BD11 cells, with 2-2.7-fold (p<0.001) increase demonstrated at the highest concentration 
tested (10-4 M). The insulinotropic effect of CBD and Rimonabant analogues Abn-CBD 
and AM251 was impaired by 42% (p<0.05) and 30% respectively in GPR55 knockout 
BRIN-BD11 cells at 10-4M, with the secretory effect of O-1602 abolished altogether 
(p<0.001). The secretory effect of endogenous PEA was reduced by 53% (p<0.05), whilst 
OEA-induced insulin secretion was retained in GPR55 knockout cells. GPR55 ablation 
abolished release of intracellular Ca2+ upon treatment with O-1602, Abn-CBD and PEA 
at 10-4M.  No effect on cAMP production was observed upon agonist treatment in wild 
type and GPR55 knockout cells. While treatment of BRIN-BD11 cells with Abn-CBD 
and AM251 increased insulin mRNA expression at 5.6 mM glucose by 2.7-3-fold 
(p<0.01) and by 1.7-2-fold (p<0.001), respectively at 16.7 mM glucose, it was greatly 
diminished (p<0.001) in GPR55 null cells.  Endogenous (ALA, DHA, EPA) and synthetic 
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(GW9508, GSK137647, Compound A) GPR120 agonists at 10-7-10-4M augmented 
insulin secretion (p<0.05-p<0.001) in wild type BRIN-BD11 cells, with DHA omitting 
the most potent effect (3.3 fold; p<0.001) at the highest concentration tested (10-4 M). At 
physiological concentrations of 10-6M, the insulinotropic effect of ALA, DHA, 
GSK137647 and Compound A were abolished in GPR120 knockout BRIN-BD11 cells. 
The secretory effect of dual agonist GW9508 was reduced by 53% (p<0.05), whilst EPA-
induced insulin secretion was retained in GPR120 knockout cells. GPR120 deletion 
abolished release of intracellular Ca2+ upon treatment with ALA, EPA, GSK137647 and 
Compound A at 10-4M. 
These findings demonstrate the specificity of several putative GPR55 and GPR120 
agonists in the pancreatic beta cell, with Abn-CBD and ALA omitting the most potent 
and selective properties, respectively. 
 
5.2: Introduction 
 
Several long chain fatty acid (LCFA) receptors have recently been identified as novel 
therapeutic targets in the treatment of metabolic diseases, including GPR40, GPR41, 
GPR43, GPR120, GPR18, GPR55 and GPR119 (Lagerstrom & Schioth 2008, Moran et 
al. 2016, Tuduri et al. 2017). In particular, current research is now directed towards the 
biological actions of the novel endocannabinoid receptor GPR55 and long chain fatty acid 
sensing GPR120 (McKillop et al. 2013, Moran et al. 2014). Although the specificity of 
many LCFA ligands remains poorly understood (Stewart et al. 2006), the use of specific 
agonists is essential to accurately characterise the functionality of novel receptors. 
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The novel endocannabinoid receptor GPR55 is highly expressed in the intestines, 
endocrine-pancreas, peripheral tissue, brain and central nervous system of the human 
body (Sawzdargo et al. 1999, Ryberg et al. 2009, McKillop et al. 2013). Upon activation, 
GPR55 has been shown to demonstrate a wide range of biological effects in the pancreatic 
islet, including enhanced insulin release and beta cell regeneration (Chapter 4). The 
insulinotropic effects of some putative GPR55 agonists were diminished upon GPR55 
antagonism with cannabidiol (CBD), however, potential synergistic activity and 
antagonist selectivity may have influenced the findings observed (Chapter 4, McKillop et 
al. 2013).   
Studies evaluating the effects of global receptor deletion using GPR55 knockout mice 
reported a mild impairment in glucose homeostasis, with no effect on glucose stimulated 
insulin secretion (GSIS) (Tuduri et al. 2017). Recently, another study using isolated islets 
from wild type and GPR55 knockout mice reported that the synthetic agonist O-1602 
augmented intracellular Ca2+ and insulin secretion, with effects diminished in GPR55 
deficient islets, thus demonstrating that the atypical cannabinoids can have a direct effect 
in the pancreatic islet through GPR55-dependent signalling (Liu et al. 2016). In contrast, 
the cannabinoid agonist Abn-CBD stimulated insulin release from both wild type and 
GPR55 knockout mouse islets, indicating a GPR55-independent mechanism of action 
(Ruz-Maldonado et al. 2018). However, the same report demonstrated that the positive 
effects of Abn-CBD treatment on beta cell proliferation were diminished in GPR55 
knockout islets, which indicates that Abn-CBD has a GPR55-mediated function in the 
pancreatic islet (Ruz-Maldonado et al. 2018). 
At present, the specificity of endogenous endocannabinoids and synthetic cannabinoid 
ligands towards GPR55 remains unknown as many may also target other novel 
endocannabinoid receptors, GPR18 and GPR119 (Moran et al. 2014, Henstridge et al. 
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2011). Even though GPR18 and GPR119 are linked with the endocannabinoid system, 
they are still considered orphan receptors as their respective endogenous agonists remain 
unknown (Henstridge et al. 2011). 
LCFA sensing GPCRs have been shown to regulate glucose homeostasis upon activation 
with a range of endogenous and synthetic agonists (Moran et al. 2014). In particular, the 
structurally related GPR40 and GPR120 receptors have been shown to exhibit therapeutic 
effectiveness for the treatment of type 2 diabetes, with the GPR40 agonist Fasiglifam 
(TAK-875) recently undertaking stage 3 clinical trials (Marcinak et al. 2017).  
GPR120 is highly expressed in the pancreatic islet and augments insulin release and beta 
cell proliferation in pancreatic beta cells through a series of downstream Gαq signalling, 
including intracellular Ca2+ and ERK1/2 (Chapter 3). Recently, chemically synthesised 
agonists (GSK137647, Compound A) have become commercially available for the 
selective activation of GPR120 and have also demonstrated insulinotropic and 
proliferative effects in clonal beta cells (Sparks et al. 2014, Oh et al. 2014). The secretory 
effects observed by a range of GPR120 agonists were greatly diminished in the presence 
of the high affinity GPR120 antagonist (AH7614) (Chapter 3). Although, this range of 
experimentation is highly dependent on ligand binding affinity and the total biological 
function of the antagonist.   
Endogenous GPR120 omega-3 fatty acid agonists (ALA, DHA, EPA) have been shown 
to demonstrate a range of biological activity in the maintenance of glucose and lipid 
homeostasis, however, the specificity of these molecules remains elusive as many have 
been shown to activate both GPR120 and GPR40 receptors (Bradberry & Hilleman 2013, 
Moran et al. 2014, Hauge et al. 2014). Receptor binding studies have demonstrated 
GPR120 activation with endogenous ALA and DHA in human HEK293 cells. In addition, 
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these molecules were shown to phosphorylate both isoforms of human GPR120 (Burns 
& Moniri 2010).   
Although numerous studies using knockout mice and receptor antagonists have been 
performed, the specificity of many putative GPR55 and GPR120 agonists in the 
pancreatic beta cell remains poorly understood (Liu et al. 2016, Houthuijzen 2016). 
CRISPR/Cas9 gene editing has emerged as a revolutionary gene editing tool that can be 
employed to disrupt gene transcription and mediate protein deletion, including receptor 
knockout (Ran et al. 2013).  
Previously, Naylor et al. utilised CRISPR/Cas9 to develop clonal GLP-1 and GIP 
knockout pancreatic beta cells using the INS-1 832/13 cell line (Naylor et al. 2016). 
Surpassing the capabilities of antagonist binding, these knockout cell lines were used to 
accurately characterise the functionality and specificity of dual GLP-1/GIP peptides 
(Naylor et al. 2016). Using a similar approach, CRISPR/Cas9 induced deletion of GPR55 
and GPR120 greatly contributes to the effective characterisation of the respective 
receptors within in the pancreatic beta cell.  
Numerous methods of gene disruption are available to alter receptor expression, including 
siRNA, TALEN, RNAi and shRNA (Rao et al. 2009, Boettcher & McManus 2015). The 
major advantage of CRISPR/Cas9 is its ability to generate complete gene knockout rather 
than gene knockdown, which enables absolute characterisation of a given gene. In 
addition, CRISPR/Cas9 is the highly favoured method for generating a clonal knockout 
cell line due to its specificity, efficiency and target design simplicity (Ran et al. 2013, 
Boettcher & McManus 2015). To characterise the role of a receptor in a specific cell type 
(i.e. beta cell), the development of a clonal knockout cell line is preferred as use of tissues 
from knockout mice is greatly complicated by induction of complimentary compensatory 
pathways (Barbaric et al. 2007, Ran et al. 2013). 
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The present study, for the first time, has investigated the specificity and downstream 
signalling of numerous putative GPR55 and GPR120 agonists using wild type and 
receptor knockout beta cells generated by CRISPR/Cas9 gene editing.  
 
5.3: Materials and methods 
 
5.3.1: Materials 
Rabbit anti-GPR55 polyclonal antibody was purchased from Cayman chemical 
(Michigan, USA) and Rabbit anti-GPR120 from Santa Cruz (Santa Cruz, UK). 
pSpCas9(BB)-2A-Puro (PX459) V2.0 and pSpCas9(BB)-2A-GFP (PX458) were gifts 
from Feng Zhang (Addgene plasmids; #62988, #48138). 
 
5.3.2: Constructs 
The S.pyogenes Cas9 vector plasmid used for the dual luciferase assay was pSpCas9(BB)-
2A-Puro (PX459) V2.0. The S. pyogenes Cas9 vector plasmid used for FACS sorting was 
pSpCas9(BB)-2A-GFP (PX458), both plasmids were a gift from Feng Zhang (Broad 
Institute, MIT; Addgene plasmid #62988). sgRNA specific to GPR55 and GPR120 was 
designed incorporating the start codon at position 5-8 and 3-6 in the respective guide 
sequences, hereafter named sgGPR55 and sgGPR120. Guide sequences were cloned into 
the respective plasmids following a published protocol (Ran et al. 2013). briefly, 
pSpCas9(BB)-2A-Puro and pSpCas9(BB)-2A-GFP were digested with BbsI (NEB, US) 
and the following oligos, 5′-CACCGGAACATGAGTCAGCTAGACA-3′, 5′-
AAACCTTGTACTCAGTCGATCTGTC-3′ for sgGPR55 and 5′-CACCG 
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CGCACACTCAGGGGACATGC-3′, 5′-AAACGCATGTCCCCTGAGTGTGCGC-3′ 
for sgGPR120 (Life Technologies, UK), were annealed and ligated into the digested 
plasmids. To assess Cas9 cleavage efficiency directed by sgGPR55/sgGPR120, a firefly 
luciferase expression plasmid with a 50bp insert of GPR55/GPR120 sequence encoding 
the target site were inserted into psiTEST-LUC-Target (York Bioscience Ltd, York, UK), 
hereafter named as GPR55WT-Luc and GPR120WT-Luc. An expression construct for 
Renilla luciferase (pRL-CMV, Promega, Southampton, UK) was used for the dual-
luciferase assay to normalize transfection efficiency. 
 
5.3.3: Dual-luciferase assay 
A dual-luciferase assay was used to determine cleavage efficiency of the Cas9-sgGPR55 
and Cas9-sgGPR120 expression constructs, using methods previously described (Allen 
et al. 2013, Courtney et al. 2014, Atkinson et al. 2011).  HEK AD293 cells (Life 
Technologies, UK) were transfected using Lipofectamine 3000 (Life Technologies, UK); 
the GPR55WT-Luc and GPR120WT-Luc expression constructs were co-transfected with 
either sgNSC, sgGPR55 or sgGPR120 constructs and a Renilla luciferase expression 
plasmid. Cells were incubated for 72 h before being lysed and the activities of both Firefly 
and Renilla luciferase quantified.  
 
5.3.4: Construct transfection and FACS sorting 
Wild type insulin secreting BRIN-BD11 cells were transfected with the plasmid co-
expressing Cas9, sgGPR55/sgGPR120 and GFP using Lipofectamine 3000 following 
manufactures recommended protocol. The generation, characteristics and culture of these 
cells have been previously described (McClenaghan et al. 1996). 72 h post-transfection, 
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cells were detached with trypsin/EDTA and resuspended in sterile PBS. Flow cytometry 
was employed to detect and FACS sort the cells expressing GFP. Cells emitting the top 
1% of FITC-A GFP expression were isolated into single cell populations in a 96-well 
plate and allowed to expand under normal culture conditions for 3 weeks to form colonies.    
 
5.3.5: Sequencing and determination of GPR55/GPR120 knockout  
Upon clonal expansion, gDNA was extracted using DNA extraction kit (Qiagen, UK). 
Individual samples were then subjected to PCR amplification using the following primers 
to amplify the targeted region: 5′-AGCCCCTCGTTCTGTGTTTA-3′, 5′-
AGGAGGAAGGTGGGAATGTG-3′ for GPR55 and 5′-CAGTGTTGCCAGGCACTT-
3′, 5′- GCGGAACAAGATGCAGAGG-3′ for sgGPR120. PCR products were gel 
purified and ligated into the CloneJet cloning vector (Life Technologies, UK), then 
transformed into competent DH5α cells (Life Technologies, UK). DNA from 40-50 
BRIN-BD11 cell clones were prepared using a plasmid miniprep kit (Life Technologies, 
UK) following manufacturer’s protocol. Isolated DNA was then sequenced (Department 
of Biochemistry, University of Cambridge) using the forward PCR amplification primer. 
 
5.3.6: Insulin secretion from BRIN-BD11 cells 
Wild type, GPR55 and GPR120 knockout BRIN-BD11 cells were used. In brief, cells 
were seeded (150, 000 cells per well) into 24-well plates and allowed to attach overnight. 
Following a 40 min pre-incubation (1.1 mmol/l glucose), cells were incubated (20 min; 
37oC) in KRB buffer with established stimulators of beta cell function and 
GPR55/GPR120 agonists (10−7-10−4 mol/l). Supernatants were removed, then frozen at -
20oC until determination of insulin by radioimmunoassay (Flatt & Bailey 1981). 
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5.3.7: Determination of cAMP production in pancreatic BRIN-BD11 cells 
BRIN-BD11 cells were sub-cultured and seeded into 6-well plates at a density of 
1,000,000 cells per well, then supplemented with 2 ml of RPMI media and allowed to 
attach overnight, as outlined in Section 2.1.2. Cells were pre-incubated with 1.1 mmol/l 
glucose for 40 min at 37oC. Agonist test solutions (10-4 mol/l) and GLP-1 (10 mmol/l) 
were prepared in KRBB buffer at 16.7 mmol/l glucose and assessed for cAMP production. 
After incubation, cells were lysed and cAMP detected with the cAMP ELISA kit as 
previously described in Section 2.4.2. 
 
5.3.8: Intracellular Ca2+ measurement 
BRIN-BD11 cells were sub-cultured and seeded into 24-well plates at a density of 80,000 
cells per well, then supplemented with 1 ml of RPMI media and cultured overnight, as 
outlined in Section 2.1.2. Alanine (10 mmol/l) and GPR55 agonists (Abn-CBD, AM251, 
O-1602, OEA, PEA) at 10-4 mol/l were added to KRBB buffer, supplemented with 16.7 
mmol/l glucose. The assay plate was pre-incubated with the test dye prepared in KRBB 
and 50µl of the test solutions were transferred to the plate with fluorescence intensity 
measured for 5 min using the FlexStation 3 plate reader (Section 2.3.2) (Molecular 
Devices, San Diego, CA, USA). 
 
5.3.9: Gene expression analysis by qPCR 
mRNA was extracted from wild type and GPR55 knockout BRIN-BD11 cells following 
exposure to agonist treatment for 4 h using the RNeasy Mini kit adhering to 
manufacturer’s protocol (Qiagen, UK). Isolated mRNA (3 µg) was converted to cDNA 
using SuperScript II Reserve Transcriptase (Life Technologies, UK). SYBR green 
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amplification parameters for GPR55, GLP-1R and GIPR were set at 95oC for 
denaturation, 58oC for primer annealing and 72oC for elongation for a total of 40 cycles, 
followed with melting curve analysis, with temperature range set at 60oC to 90oC. Values 
were analysed using the Livak 2(-Delta C(T)) method (Livak & Schmittgen 2001) and 
normalised to Gapdh expression.  
 
5.3.10: Protein expression using western blotting 
Wild type, GPR55 and GPR120 knockout BRIN-BD11 cells were seeded at a density of 
1 x 106 cells per well in 6-well plates and allowed to attach overnight. Total protein was 
extracted at 4oC for 10 min using RIPA buffer containing 150 mM NaCl, 1.0% Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris HCl, pH 7.6 and protease 
inhibitor cocktail (Sigma, UK). Total protein concentration was determined using 
Bradford reagent (Sigma, UK). Equal amounts of protein were aliquoted with Laemmli 
buffer (1µg/µl), then heated at 95oC for 10 min. Samples (25µg per well) were loaded 
onto pre-cast gels (NUPAGE 4–12 % Bis–Tris gels, Invitrogen, UK) and subjected to 
SDS-PAGE (70V, 90 min). After transfer to nitrocellulose membrane for 16 h at 90mA, 
membranes were blocked with 5% skimmed milk and probed with rabbit anti-GPR55 
(1:150) (Cayman Chemical, US), rabbit anti-GPR120 (1:150) (Santa Cruz, UK) or mouse 
anti-β-actin (1:2500) (Cell Signalling, US). Membranes were probed with ECL 
horseradish peroxidase donkey anti-rabbit IgG/ECL horseradish peroxidase sheep anti-
mouse IgG (1:10000) (GE Healthcare, UK) and detected using Luminata Forte HRP 
substrate (Millipore, UK), with images captured using the G:BOX Chemi XX9 imager 
(Syngene, UK). Data were normalised to β-actin and presented relative to untreated 
control. 
 
189 
 
5.4: Results 
 
5.4.1: Development of a GPR55 null BRIN-BD11 cell line using CRISPR/Cas9 gene 
editing 
The CRISPR/Cas9 construct (px458) used co-expresses GFP, which was utilised to select 
the cells which had been successfully transfected (Fig. 5.1A). A sgRNA was designed to 
target 1bp upstream of the GPR55 start codon to induce gene disruption by non-
homologous end joining (NHEJ); the sgRNA was targeted early in the transcript, 
encompassing the ATG start codon at position 5-8 in the guide sequence and is referred 
to as sgGPR55 (Fig. 5.1A, B). sgGPR55 was shown to have good cleavage efficiency, 
resulting in a 60% reduction in firefly luciferase activity (p<0.001), when assessed with 
a dual luciferase assay (Fig. 5.1C).  
Post-transfection (72h) with the Cas9-sgGPR55-GFP expression construct, cells emitting 
the top 1% of GFP expression were single cell sorted by FACS, followed by clonal 
expansion (Fig. 5.2).   
To   determine which cells had bi-allelic indels, individual PCR products from clonal cell 
populations were sequenced; for clone 2 sequence analysis revealed a 29 and 33 
nucleotide deletion on allele 1 and allele 2 respectively (Fig. 5.3A). In addition, a 2-
nucleotide insertion mutation was present on allele 2 (Fig. 5.3A).  This indicates a bi-
allelic deletion of the GPR55 start codon was present in this cell line that would be 
predicted to abolish expression of GPR55 protein (Fig. 5.3B).  
GPR55 mRNA expression was ablated in GPR55 knockout BRIN-BD11 cells, compared 
to wild type cells (Fig. 5.4A). Incretin receptor mRNA expression (GLP-1 R and GIP R) 
were unaffected in the GPR55 knockout cell line, compared to wild type cells (Fig. 4A). 
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Western blotting demonstrated the absence of GPR55 protein in the GPR55 null cell line, 
whilst GPR55 protein was demonstrated in wild type cells (Fig. 5.4B). Both wild type 
(p<0.05) and GPR55 knockout (p<0.05) BRIN-BD11 cells demonstrated glucose 
stimulated insulin secretion (GSIS) at 16.7 mM glucose (Fig. 5.4C). Wild type and 
GPR55 knockout BRIN-BD11 cells also demonstrated identical insulin secretory 
responses (p<0.001) to a wide range of insulinotropic modulators (Fig. 5.4C).  
 
5.4.2: Effects of GPR55 agonists on insulin secretion from wild type and GPR55 
knockout BRIN-BD11 cells 
The insulinotropic capabilities and specificity of a range of putative GPR55 agonists were 
assessed using wild type and GPR55 knockout BRIN-BD11 cells. At 16.7 mM glucose, 
a synthetic CBD analogue (Abn-CBD) augmented insulin secretion at 10-7-10-4M by 0.8-
2.7-fold (p<0.05-p<0.001) in wild type BRIN-BD11 cells (Fig. 5.5A). The secretory 
response of Abn-CBD was significantly impaired at 10-5-10-4M (p<0.05) in GPR55 
knockout BRIN-BD11 cells, with a 42% (p<0.05) reduction demonstrated at the highest 
agonist concentration (10-4 M) (Fig. 5.5A).  
Rimonabant analogue (AM251) stimulated insulin secretion at 10-7-10-4M by 0.3-2.1-fold 
(p<0.05-p<0.001) in wild type BRIN-BD11 cells (Fig. 5.5B). AM251-induced insulin 
secretion was reduced by 30% at 10-4M in GPR55 knockout BRIN-BD11 cells (Fig. 
5.5B). Synthetic CBD analogue (O-1602) induced insulin secretion at 10-7-10-4M by 0.6-
2.7-fold (p<0.05-p<0.001) in wild type BRIN-BD11 cells (Fig. 5.6A). The insulinotropic 
effect of O-1602 was abolished at 10-7-10-4M in GPR55 knockout BRIN-BD11 cells. At 
the highest agonist concentration (10-4 M), an 85% (p<0.001) reduction in insulin 
secretion was observed between wild type and GPR55 knockout cells (Fig. 5.6A). 
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Endogenous endocannabinoid PEA (10-7-10-4 M) augmented insulin secretion by 0.6-2.0-
fold (p<0.01-p<0.001) from wild type BRIN-BD11 cells (Fig. 5.6B). The insulinotropic 
response of PEA at the highest concentration (10-4 M) was impaired by 53% (p<0.05) in 
GPR55 knockout cells (Fig. 5.6B). Endogenous OEA (10-7-10-4 M) induced insulin 
secretion by 0.7-2.2-fold from wild type BRIN-BD11 cells (Fig. 5.7). When assessed in 
GPR55 knockout cells, the insulinotropic response of OEA was retained at all 
concentrations tested (Fig. 5.7).  
 
5.4.3: Effects of GPR55 agonists on intracellular Ca2+ and cAMP in wild type and 
GPR55 knockout BRIN-BD11 cells 
Exposure of wild type BRIN-BD11 cells to AM251, PEA, O-1602 and Abn-CBD at 10-
4M induced a prompt increase in intracellular Ca2+ concentrations (p<0.05-p<0.001) (Fig. 
5.8A). Using AUC data, AM251 demonstrated the most potent effect, with a 17-fold 
increase observed, compared to 5.6 mM glucose alone (Fig. 5.8B). Increases in 
intracellular Ca2+ mediated by PEA, O-1602 and Abn-CBD were abolished when 
assessed in GPR55 knockout BRIN-BD11 cells, whilst the effect of AM251 was reduced 
by 43% (Fig. 5.9A, B). None of the agonists affected cAMP production in either wild 
type nor GPR55 knockout BRIN-BD11 cells (Fig. 5.10). 
 
5.4.4: Effects of GPR55 agonists on insulin mRNA expression in wild type and 
GPR55 knockout BRIN-BD11 cells 
Culture of cells for 4 h with atypical cannabinoid GPR55 agonists Abn-CBD and AM251 
induced a 2.8-3.0-fold (p<0.05-p<0.01) increase of insulin mRNA expression in wild type 
BRIN-BD11 cells at 5.6 mM glucose, whilst a 1.8-2.1-fold (p<0.05) was demonstrated at 
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16.7 mM glucose (Fig. 5.11A, B). In contrast, incubation Abn-CBD and AM251 greatly 
diminished (p<0.001) insulin mRNA expression in GPR55 KO cells at both 5.6 mM and 
16.7 mM glucose (Fig. 5.11C, D). 
 
5.4.5: Development of GPR120 null BRIN-BD11 clonal cell lines using 
CRISPR/Cas9 gene editing 
The CRISPR/Cas9 construct (px458) used co-expresses GFP, which was utilised to select 
the cells which had been successfully transfected (Fig. 5.12A). A sgRNA was designed 
to target 1bp downstream of the GPR120 start codon to induce gene disruption by non-
homologous end joining (NHEJ); the sgRNA was targeted within the transcript, 
encompassing the ATG start codon at position 3-6 in the guide sequence and is referred 
to as sgGPR120. (Fig. 5.12A, B). sgGPR120 was shown to have good cleavage efficiency, 
resulting in a 65% reduction in firefly luciferase activity (p<0.001), when assessed with 
a dual luciferase assay (Fig. 5.12C).  
Using the same approach for GPR55 KO cell line development, 72 h post-transfection 
with the Cas9-sgGPR120-GFP expression construct, cells emitting the top 1% of GFP 
expression were single cell sorted by FACS, followed by clonal expansion (Fig. 5.13).  
To   determine which cells had bi-allelic indels, individual PCR products from clonal cell 
populations were sequenced; for clone 5 sequence analysis revealed an identical single 
nucleotide indel on both alleles (Fig. 5.14A). The insertion mutation was positioned 
within the GPR120 start codon, indicating disruption of transcription initiation that would 
be predicted to abolish expression of GPR120 protein. (Fig. 5.14B). However, GPR120 
protein expression was retained within the Clone 5 (Fig. 5.14C). 
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Multiple clones were screened for indels upstream of the GPR120 start codon (ATG) by 
sanger sequencing, followed by western blotting to determine GPR120 protein 
expression. Clones 13, 14 and 15 revealed null GPR120 expression when assessed by 
western blotting and were subsequently brought forward for functional analysis (Fig. 
5.15B).  
 
5.4.6: Effects of GPR120 agonists on insulin secretion from wild type and GPR120 
knockout BRIN-BD11 cells 
The insulinotropic capabilities and specificity of a range of putative GPR120 agonists 
were assessed using wild type and 3 individual GPR120 knockout BRIN-BD11 cell lines. 
At 16.7 mM glucose, parent omega 3 fatty acid (ALA) augmented insulin secretion at 10-
7-10-4M by 2.1-2.9-fold (p<0.05-p<0.001) in wild type BRIN-BD11 cells (Fig. 5.16A). 
The secretory response of ALA was ablated at all concentrations tested (p<0.001) in 
GPR120 knockout BRIN-BD11 cells (Fig. 5.16A).  
Endogenous DHA stimulated insulin secretion at 10-7-10-4M by 2.2-3.3-fold (p<0.001) in 
wild type BRIN-BD11 cells (Fig. 5.5B). DHA-induced insulin secretion was reduced by 
83% (p<0.001) when assessed using the GPR120 knockout BRIN-BD11 cells (Fig. 
5.16B). Endogenous EPA induced insulin secretion at 10-7-10-4M by 1.5-1.9-fold 
(p<0.01-p<0.001) in wild type BRIN-BD11 cells (Fig. 5.17A). The insulinotropic effect 
of EPA was retained in GPR120 knockout BRIN-BD11 cells (Fig. 5.17A). 
Synthetic dual agonist GW9508 (10-7-10-4 M) augmented insulin secretion by 2.3-3.4-
fold (p<0.001) from wild type BRIN-BD11 cells (Fig. 5.17B). The insulinotropic 
response of GW9508 (10-4 M) was impaired by 54% (p<0.05) in GPR120 knockout cells 
(Fig. 5.17B). Synthetic GSK137647 (10-7-10-4 M) increased insulin release by 2.5-2.8-
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fold in wild type BRIN-BD11 cells (Fig. 5.18A). The secretory effect of GSK137647 was 
abolished from 10-7-10-5M (p<0.001), however, a secretory response of 1.4-fold (p<0.05) 
was observed at the highest concentration tested (10-4 M) (Fig. 5.18A). Synthetic 
Compound A induced insulin secretion (10-7-10-4 M) by 1.8-2.2-fold in wild type cells 
(Fig. 5.18B). The secretory response of Compound A was ablated at 10-7-10-5M (p<0.001) 
in GPR120 knockout cells, however, Compound A induced insulin release by 1.3-fold at 
the highest concentration tested (10-4 M) (Fig. 5.18B). 
 
5.4.7: Effects of GPR120 agonists on intracellular Ca2+ in wild type and GPR120 
knockout BRIN-BD11 cells 
Exposure of wild type BRIN-BD11 cells to endogenous and synthetic agonists (10-4 M) 
at 16.7 mM glucose induced a prominent increase in intracellular Ca2+ concentrations 
(p<0.05-p<0.01) (Fig. 5.19A, 5.21A). Using AUC data, DHA omitted a 70% (p<0.01) 
increase and was the most potent endogenous agonist, whilst GW9508 demonstrated a 
69% (p<0.01) was the most potent synthetic agonist (Fig. 5.19B, 5.21B). Increases of 
intracellular Ca2+ mediated by ALA, EPA, Compound A and GSK137647 were abolished 
when assessed in GPR120 knockout BRIN-BD11 cells, whilst the effect of GW9508 and 
DHA were reduced by 9% and 32%, respectively (Fig. 5.20, 5.22).  
 
5.5: Discussion 
 
Novel therapies that enhance beta cell function and regeneration are required for the 
treatment of type 2 diabetes, with interest intensifying on the involvement of two novel 
long chain fatty acid sensing GPCRs, namely GPR55 and GPR120 (Moran et al. 2016, 
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McKillop et al. 2013, Moran et al. 2014). GPR55 and GPR120 have recently been shown 
to omit a range of beneficial effects in the maintenance of glucose homeostasis, including 
enhanced glucoregulatory hormone secretion and islet cell proliferation (Moran et al. 
2014, McKillop et al. 2016, Liu et al. 2016).  
Although a range of endogenous and synthetic agonists exist for the activation of each 
receptor; their specificity remains largely unknown (Hauge et al. 2014, Liu et al. 2014, 
Ruz-Maldonado et al. 2018). With respect to the endocannabinoid system, the biological 
activation of other novel receptors GPR18 and GPR119 may be partially responsible for 
the beneficial effects observed upon GPR55 activation (Irving et al. 2017). Likewise, the 
GPR120 and GPR40 receptor share similar sequence homology and can be activated by 
similar ligands (Hauge et al. 2014). Therefore, determination of agonist specificity is 
essential to characterise the respective receptors.   
GPR55 is a rhodopsin (class A) GPCR that has been previously shown to demonstrate 
anti-diabetic effects through the regulation of insulin secretion and glycaemic control 
(McKillop et al. 2013, McKillop et al. 2016) with no cytotoxicity effects.  In the present 
study, the acute metabolic effects and specificity of several naturally occurring and 
atypical endocannabinoid ligands were assessed using a clonal GPR55 knockout BRIN-
BD11 cell line developed using CRISPR/Cas9 gene editing. Previous studies (Liu et al. 
2016, Ruz-Maldonado et al. 2018) have used islets from GPR55 knockout mice but this 
study evaluates, for the first time, the functionality of GPR55 solely and specifically 
within the pancreatic beta cell.  
To establish the GPR55 knockout BRIN-BD11 cells, the Cas9 enzyme was directed to 
cleave immediately adjacent to the GPR55 start codon, stimulating the NHEJ DNA repair 
machinery which often, as in the selected clone, introduces indel mutations at the cleavage 
site. The resultant GPR55 knockout clone contained a bi-allelic deletion of the GPR55 
196 
 
start codon, with GPR55 mRNA expression and protein translation abolished. In addition, 
the knockout cell line displayed identical secretory responses to wild type cells in 
response to a wide range of insulinotropic modulators, demonstrating the retention of the 
beta cell phenotype. 
Subsequently, the insulin secretory effects and specificity of putative GPR55 agonists 
were assessed using the wild type and GPR55 knockout BRIN-BD11 cells. Naturally 
occurring (OEA, PEA) and atypical (Abn-CBD, AM251, O-1602) agonists demonstrated 
potent insulinotropic effects in wild type cells. The insulin secretory effect of CBD 
analogue (Abn-CBD) was impaired in the knockout cell line by 42%, indicating the 
involvement of GPR55 in Abn-CBD mediated insulin secretion. In addition, the secretory 
response of another CBD analogue (O-1602) was totally abolished in the knockout cell 
line, suggesting O-1602 as a selective agonist for GPR55 activation in the pancreatic beta 
cell.    
Rimonabant analogue (AM251) demonstrated insulinotropic capabilities in wild type and 
GPR55 knockout BRIN-BD11 cells. However, the secretory response of AM251 was 
reduced by 30% in the knockout cell line, indicating that AM251 induced insulin 
secretion is only partly driven by GPR55 in pancreatic beta cells.  
Endogenous cannabinoid ligands (OEA, PEA) augmented insulin secretion in wild type 
and GPR55 knockout BRIN-BD11 cells, illustrating the non-selective properties of the 
endogenous endocannabinoids. The secretory response of OEA was fully retained within 
the knockout cell line, indicating that OEA is not a GPR55 agonist within the pancreatic 
beta cell. In contrast, the secretory response of PEA was impaired by 53% in the GPR55 
deficient cell line, demonstrating that PEA induced insulin secretion is partially mediated 
through GPR55 with potential synergistic agonism of another endocannabinoid receptor, 
such as GPR119 and GPR18 (Irving et al. 2017). 
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Intracellular Ca2+ and cAMP signalling studies were employed on wild type and GPR55 
knockout BRIN-BD11 cells to determine the downstream effects of the endocannabinoid 
ligands. Complimentary to insulin secretory studies, increases of intracellular Ca2+ 
observed in the wild type cells by O-1602, PEA and Abn-CBD were abolished in GPR55 
knockout cells, while response to AM251 was only impaired. No changes in cAMP 
production were observed in wild type or knockout cells, suggesting that GPR55 
signalling is primarily modulated through Gαq activation and release of Ca2+ from 
intracellular stores (Putney & Tomita 2012). However, Gα12/13 activation may also 
contribute to the actions of GPR55. 
Complimentary gene expression analysis by qPCR demonstrated increased insulin 
mRNA expression upon Abn-CBD and AM251 treatment in normoglycaemic and 
hyperglycaemic conditions; indicating the role of the cannabinoid ligands in second phase 
insulin release. Interestingly, Abn-CBD and AM251 treatment greatly diminished insulin 
mRNA expression in GPR55 knockout cells, thus, revealing the importance of GPR55 in 
the production of intracellular insulin stores. 
To investigate the functional role of GPR120, a similar approach was employed to 
develop clonal GPR120 knockout cells using CRISPR/Cas9 gene editing. The Cas9 
enzyme was directed to cleave directly within the GPR120 start codon, which 
subsequently initiates the NHEJ repair mechanism that often introduces indels at the 
cleavage site. As observed in Clone 5, a single nucleotide insertion was observed within 
the GPR120 start codon, shifting the reading frame and disrupting the transcription 
initiation site. Interestingly, GPR120 protein expression was retained within Clone 5 
when assessed by western blotting. This may be due to the intact kozak consensus 
sequence directly upstream of the cleavage site, which has a major role in the initiation 
of the transcription process (Grzegorski et al. 2014).  
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A series of clones transfected with sgGPR120-Cas9 plasmid were then screened for 
genomic disruptions in GPR120 gDNA by Sanger sequencing. Clones demonstrating 
mutations were then examined for GPR120 protein expression by western blotting. 
Clones 13, 14 and 15 were GPR120 null, whilst β-actin expression was retained. 
Subsequently, these clones were brought forward for functional studies. All functional 
assays were performed on 3 separate GPR120 knockout clones to validate the findings 
observed.  
At physiological concentrations of 10-6M, the insulinotropic response of ALA, DHA, 
GSK137647 and Compound A were abolished, indicating their specificity for GPR120. 
At super physiological concentrations of 10-4M, a slight insulinotropic effect was 
observed by DHA, GSK137647 and Compound A, which may suggest slight affinity for 
another LCFA sensing receptor, such as GPR40.  
Omega-3 fatty acid agonist EPA was shown to be none specific for GPR120 activation in 
pancreatic beta cells as identical secretory effects were observed in the wild type and 
GPR120 null cells. As anticipated, the synthetic GPR120/GPR40 dual agonist GW9508 
demonstrated insulinotropic capabilities on both the wild type and GPR120 knockout 
cells. The secretory response omitted by GW9508 was substantially impaired at all 
concentrations, with a 54% reduction observed at the top concentration tested, suggesting 
that the biological effects are partly driven by GPR120.  
All endogenous GPR120 agonists (ALA, DHA, EPA) augmented intracellular Ca2+ 
concentrations in wild type BRIN-BD11 cells, with EPA omitting a lesser effect. When 
assessed using GPR120 null cells, the effects observed by ALA and EPA were abolished, 
with a reduced effect observed upon DHA treatment. The effects demonstrated by DHA 
suggest involvement of another Gαq mediating receptor, such as GPR40. Interestingly, 
EPA demonstrated insulinotropic activity but ablated intracellular Ca2+ activity in 
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GPR120 knockout cells, suggesting that the insulinotropic response observed may be 
generated by a non-Gαq dependent receptor, such as GPR40.  
In conclusion, the specificity of putative LCFA GPR55 and GPR120 agonists were 
assessed using respective receptor knockout cell lines, generated by CRISPR/Cas9 gene 
editing. GPR55 agonists O-1602, Abn-CBD, AM251 and PEA demonstrated GPR55-
dependent insulin secretion through intracellular Ca2+ modulation. GPR120 agonists 
ALA, DHA, GSK137647 and Compound A were shown to be GPR120 specific and 
augmented intracellular calcium induced insulin release. Abn-CBD (GPR55) and ALA 
(GPR120) were the most specific and potent agonists identified and subsequently present 
therapeutic potential for the treatment of type 2 diabetes. Moreover, the knockout cell 
lines developed in this study are robust and reliable models that will greatly facilitate 
future research exploring the mechanistic function and specificity of GPR55 and GPR120 
agonists in pancreatic beta cells.   
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Figure 5.1: Genomic deletion of GPR55 using CRISPR/Cas9 gene editing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific targeting and genomic deletion of GPR55 in BRIN-BD11 cells using 
CRISPR/Cas9 gene editing. (A)  Schematic of px458 construct used. (B)  sgRNA and 
PAM sequences (underlined) and predicted genomic DNA cleavage sites (indicated by 
arrow) encoding GPR55 exon 1. (C)  Dual luciferase assay demonstrating sgGPR55 
cutting efficiency compared to non-specific control (sgNSC). Values are mean ± SEM 
(C: n=8) *** p<0.001, compared to non-specific control. 
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Figure 5.2: Single cell isolation with FACS for clonal GPR55 knockout cell line 
development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase contrast photomicrograph and sorting gate of GFP+ cells 72 h post-lipofection 
with sgGPR55 construct prior to fluorescence-activated cell sorting (FACS). (A) non-
transfected, (B) CRISPR-GFP transfected and (C) single cell CRISPR-GFP FACS  
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Figure 5.3: Genomic disruption of GPR55 in Clone 2 demonstrated by sanger 
sequencing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sanger sequencing analysis displaying (A) Single allele DNA sequencing traces of 
GPR55 knockout clone 2. (B)  Bi-allelic genomic deletion of the GPR55 start codon. 
 
Wild type 
A 
 
Allele 1 
Allele 2 
B 
 
203 
 
GPR55 GIP R GLP-1 R
0.0
0.5
1.0
1.5
Wild Type
GPR55 KO
XF
o
ld
 C
h
a
n
g
e
 t
o
 w
il
d
 t
y
p
e
0
150
300
450
600
750
900
Glucose     Glucose    Alanine      Arginine        KCL       CaCL.H20      Tol           GLP-1          GIP            IBMX          PMA
(5.6mM)     (16.7mM)      (10mM)   (10mM)      (30mM)     (7.68mM)    (0.2mM)     (10mM)    (10mM)    (10mM)       (10mM)
*
*
***
***
*****
**
***
***
***
***
***
***
******
*** ******
******
Wild type
GPR55 KO
In
s
u
li
n
 s
e
c
re
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
Figure 5.4: Characterisation of clonal GPR55 knockout BRIN-BD11 cell line 
developed by CRISPR/Cas9 gene editing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterisation of the clonal GPR55 knockout BRIN-BD11 cells. (A) Receptor mRNA 
expression by qPCR. (B) Western blotting demonstrating GPR55 protein expression in 
wild type and GPR55 knockout BRIN-BD11 cells. (C) Acute insulin secretory response 
of wild type and GPR55 knockout BRIN-BD11 cells to a range of insulinotropic 
modulators at 5.6 mM glucose. Values are mean ± SEM (A: n=3, B; n=2, C: n=8), * 
p<0.05, **p<0.01, *** p<0.001, compared to 5.6 mM glucose control 
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Figure 5.5: Acute effect of Abn-CBD and AM251 on insulin secretion from wild 
type and GPR55 knockout clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of (A) Abn-CBD (10-7-10-4 M) and (B) AM251 (10-7-10-4 M) on insulin 
secretion wild type and GPR55 knockout clonal pancreatic BRIN-BD11 cells at 16.7 mM 
glucose. Results are the mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001, compared 
to glucose control. +p<0.05, compared to wild type cells. 
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Figure 5.6: Acute effect of O-1602 and PEA on insulin secretion from wild type 
and GPR55 knockout clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of (A) O-1602 (10-7-10-4 M) and (B) PEA (10-7-10-4 M) on insulin secretion 
wild type and GPR55 knockout clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001, compared to glucose 
control. +p<0.05, ++p<0.01, +++p<0.001 compared to wild type cells. 
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Figure 5.7: Acute effect of OEA on insulin secretion from wild type and GPR55 
knockout clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of (A) OEA (10-7-10-4 M) on insulin secretion wild type and GPR55 
knockout clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. Results are the mean 
± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001, compared to glucose control.  
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Figure 5.8: Acute effect of GPR55 agonists on intracellular Ca2+ release from wild 
type pancreatic BRIN-BD11 cells. 
Wild type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GPR55 agonists (10-4 M) on intracellular Ca2+ release from pancreatic 
BRIN-BD11 cells at 16.7 mM glucose. Results are the mean ± SEM (n=8). *p<0.05, 
***p<0.001, compared to glucose control.  
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Figure 5.9: Acute effect of GPR55 agonists on intracellular Ca2+ release from 
clonal GPR55 knockout pancreatic BRIN-BD11 cells. 
GPR55 KO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GPR55 agonists (10-4 M) on intracellular Ca2+ release from pancreatic 
BRIN-BD11 cells at 16.7 mM glucose. Results are the mean ± SEM (n=8). ***p<0.001, 
compared to glucose control.  
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Figure 5.10: Acute effect of GPR55 agonists on cAMP production in wild type and 
clonal GPR55 knockout BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GPR55 agonists (10-4 M) and GLP-1 (10-5 M) on cAMP production in 
(A) wild type and (B) clonal GPR55 knockout BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=4). ***p<0.001, compared to glucose control. 
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Figure 5.11: Effects of GPR55 agonists on insulin mRNA expression in wild type 
and GPR55 knockout BRIN-BD11 cells at 5.6 mM and 16.7 mM glucose. 
 
 
  
   
  
  
  
  
 
 
 
 
  
 
 
 
 
 
 
 
qPCR analysis demonstrating insulin mRNA expression in wild type (A, B) and GPR55 
knockout (C, D) BRIN-BD11 cells upon agonist treatment (10-4 M) for 4 h at 5.6 mM and 
16.7 mM glucose. Values are mean ± SEM (n=3). * p<0.05, ** p<0.01, *** p<0.001, 
compared to glucose control. 
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Figure 5.12: Genomic deletion of GPR120 using CRISPR/Cas9 gene editing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Specific targeting and genomic deletion of GPR120 in BRIN-BD11 cells using 
CRISPR/Cas9 gene editing. (A)  Schematic of px458 construct used. (B)  sgRNA and 
PAM sequences (underlined) and predicted genomic DNA cleavage sites (indicated by 
red arrow) encoding GPR120 exon 1. (C)  Dual luciferase assay demonstrating sgGPR120 
cutting efficiency compared to non-specific control (sgNSC). Values are mean ± SEM 
(C: n=8) *** p<0.001, compared to non-specific control. 
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Figure 5.13: Single cell isolation with FACS for clonal GPR120 knockout cell line 
development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase contrast photomicrograph and sorting gate of GFP+ cells 72 h post-lipofection 
with sgGPR120 construct prior to fluorescence-activated cell sorting (FACS). (A) non-
transfected, (B) CRISPR-GFP transfected and (C) single cell CRISPR-GFP FACS  
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Figure 5.14: Genomic and protein expression of GPR120 in Clone 5 demonstrated 
by Sanger sequencing and western blotting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GPR120 expression: (A) DNA sequencing traces of wild type and sgGPR120 transfected 
clone 5. (B)  Genomic disruption of the GPR120 start codon. (C) Western blotting 
illustrating GPR120 protein expression in wild type and clone 5 transfected cells. 
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Figure 5.15: Identification of sgGPR120 transfected BRIN-BD11 cell clones with 
null GPR120 protein expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of clonal GPR120 knockout BRIN-BD11 cells with (A) sanger sequencing 
to screen for genomic mutations in GPR120 coding DNA and (B) western blotting to 
examine GPR120 protein expression.  
A 
 
 
Wild type 
Cut 
Site 
 
Example - Clone 13 
 
B 
 
215 
 
0
100
200
300
400
500 Wild Type
GPR120 KO
***
***
+++
  Non-treated            10-7M       10-6M        10-5M      10-4M
***
+++
***
++++++
Concentration of ALA (M)
In
s
u
li
n
 s
e
c
re
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
100
200
300
400
500 Wild Type
GPR120 KO
***
*
***
+++
  Non-treated            10-7M       10-6M        10-5M      10-4M
***
+++
***
+++
+++
Concentration of DHA (M)
In
s
u
li
n
 s
e
c
re
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
Figure 5.16: Acute effect of ALA and DHA on insulin secretion from wild type and 
GPR120 knockout clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of (A) ALA (10-7-10-4 M) and (B) DHA (10-7-10-4 M) on insulin secretion 
wild type and GPR120 knockout clonal pancreatic BRIN-BD11 cells at 16.7 mM glucose. 
Results are the mean ± SEM (n=8). *p<0.05, ***p<0.001, compared to glucose control. 
++p<0.01, +++p<0.001, compared to wild type cells. 
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Figure 5.17: Acute effect of EPA and GW9508 on insulin secretion from wild type 
and GPR120 knockout clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of (A) EPA (10-7-10-4 M) and (B) GW9508 (10-7-10-4 M) on insulin 
secretion wild type and GPR120 knockout clonal pancreatic BRIN-BD11 cells at 16.7 
mM glucose. Results are the mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001, 
compared to glucose control. ++p<0.01, compared to wild type cells. 
A 
 
B 
 
217 
 
0
100
200
300
400
500 Wild Type
GPR120 KO
***
*
***
+++
  Non-treated            10-7M       10-6M        10-5M      10-4M
***
+++
***
+++
+++
Concentration of GSK137647 (M)
In
s
u
li
n
 s
e
c
re
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
100
200
300
400
500 Wild Type
GPR120 KO
***
*
***
+++
  Non-treated            10-7M       10-6M        10-5M      10-4M
***
+++
***
+++
+++
Concentration of Compound A (M)
In
s
u
li
n
 s
e
c
re
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
Figure 5.18: Acute effect of GSK137647 and Compound A on insulin secretion 
from wild type and GPR120 knockout clonal pancreatic BRIN-BD11 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of (A) GSK137647 (10-7-10-4 M) and (B) Compound A (10-7-10-4 M) on 
insulin secretion wild type and GPR120 knockout clonal pancreatic BRIN-BD11 cells at 
16.7 mM glucose. Results are the mean ± SEM (n=8). *p<0.05, ***p<0.001, compared 
to glucose control. +++p<0.001, compared to wild type cells. 
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Figure 5.19: Acute effect of endogenous GPR120 agonists on intracellular Ca2+ 
release from wild type pancreatic BRIN-BD11 cells. 
Wild type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of endogenous GPR120 agonists on intracellular Ca2+ release from wild 
type pancreatic BRIN-BD11 cells at 16.7 mM glucose. Results are the mean ± SEM 
(n=8). *p<0.05, **p<0.01, ***p<0.001, compared to glucose control.  
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Figure 5.20: Acute effect of endogenous GPR120 agonists on intracellular Ca2+ 
release from clonal GPR120 knockout pancreatic BRIN-BD11 cells. 
GPR120 KO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of endogenous GPR120 agonists on intracellular Ca2+ release from clonal 
GPR120 knockout pancreatic BRIN-BD11 cells at 16.7 mM glucose. Results are the 
mean ± SEM (n=8). *p<0.05, ***p<0.001, compared to glucose control.  
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Figure 5.21: Acute effect of synthetic GPR120 agonists on intracellular Ca2+ release 
from wild type pancreatic BRIN-BD11 cells. 
Wild type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of synthetic GPR120 agonists on intracellular Ca2+ release from wild type 
pancreatic BRIN-BD11 cells at 16.7 mM glucose. Results are the mean ± SEM (n=8). 
**p<0.01, ***p<0.001, compared to glucose control.  
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Figure 5.22: Acute effect of synthetic GPR120 agonists on intracellular Ca2+ release 
from clonal GPR120 knockout pancreatic BRIN-BD11 cells. 
GPR120 KO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of synthetic GPR120 agonists on intracellular Ca2+ release from clonal 
GPR120 knockout pancreatic BRIN-BD11 cells at 16.7 mM glucose. Results are the 
mean ± SEM (n=8). **p<0.01, ***p<0.001, compared to glucose control. 
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Chapter 6 
 
Investigating the metabolic actions of 
GPR120 agonist monotherapy and 
combinational therapy (Sitagliptin) on 
glycaemic control and lipid homeostasis in-
vivo 
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6.1: Summary 
 
Novel long chain fatty acid (LCFA) GPCRs have been identified with potential to 
counteract defective insulin release, insulin resistance and low beta cell mass. The present 
study aims to evaluate the metabolic effects and GPR120 agonist monotherapy and 
combinational therapy (Sitagliptin) in the maintenance of glucose and lipid homeostasis.  
Acute metabolic actions and potency of oral GPR120 agonist treatments were assessed in 
high fat fed (HFF) induced diabetic obese mice, with hormone release and glucose 
lowering effects determined. Long term effects investigated once daily oral 
administration of ALA alone and in combination with Sitagliptin was performed in HFF 
mice (n=8), with glycaemic control, bodyweight, food intake, insulin, DPP-IV activity, 
CRP, amylase and lipid profiles assessed. Following 21-day administration, effects 
towards glucose tolerance, insulin sensitivity, DEXA and islet morphology analysis were 
examined.  
Orally administered GPR120 agonists ALA, GW9508, GSK137647 and Compound A 
(0.1µmol/kg BW) improved glucose tolerance (p<0.001), increased plasma insulin 
(p<0.001), GLP-1 (p<0.05) and GIP (p<0.05) in HFF mice, with glucose-lowering effects 
enhanced in combination with DPP-IV inhibitor (Sitagliptin) (p<0.05). ALA 
monotherapy (32%; p<0.05) and combinational therapy with Sitagliptin (67%; p<0.001) 
demonstrated the most potent acute glucose lowering effect, with complimentary changes 
in insulin secretion (p<0.01-p<0.001). Daily administration of ALA alone and in 
combination with Sitagliptin reduced non-fasting plasma glucose (83-88%; p<0.001) 
with corresponding increases in circulating insulin (29-33%; p<0.001). ALA reduced 
bodyweight (7%; p<0.05) and attenuated cumulative food intake (p<0.05).  
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Following 21-day administration, ALA alone and with Sitagliptin improved glucose 
tolerance (p<0.01-p<0.001) by 37% and 47%, respectively and insulin sensitivity by 36-
42% (p<0.05). Sitagliptin (16%; p<0.05), ALA (20%; p<0.001) alone and ALA in 
combination with Sitagliptin (19%; p<0.05) reduced fat mass, whilst ALA with 
Sitagliptin restored bone mineral content (BMC) (p<0.01). Sitagliptin (65%; p<0.001), 
ALA (57%; p<0.001) alone and ALA in combination with Sitagliptin (57%; p<0.001) 
improved hypertriglyceridaemia and reduced total cholesterol (21-27%; p<0.001). ALA 
monotherapy reduced LDL cholesterol by 17% (p<0.05), whilst ALA in combination 
with Sitagliptin restored elevated CRP concentrations (p<0.05). ALA improved beta cell 
area by 4% (p<0.001) and increased beta cell proliferation (p<0.001). 
The present study reveals the therapeutic potential of targeting GPR120 with ALA 
monotherapy and combinational therapy (Sitagliptin) and for the treatment of type 2 
diabetes, CVD risk and obesity related diseases.  
 
6.2: Introduction 
 
In recent years, research has intensified on the involvement of free fatty acid (FFA) 
molecules and their ability to activate novel G-protein coupled receptors (GPCRs), with 
the potential to counteract defective insulin secretion and low beta cell mass in obesity 
and type 2 diabetes (Vangaveti et al. 2010, Moran et al. 2016). Islet GPCRs have been 
shown to have a pivotal role in islet cell function, including the regulation of hormone 
release and cellular proliferation, which elucidates the potential of GPCRs as novel 
therapeutic targets (McKillop et al. 2013, Moran et al. 2014, McKillop et al. 2016).  
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FFA sensing GPCR signalling pathways result in an array of downstream signalling, with 
alterations in intracellular Ca+, cAMP production and mitogen activated protein kinase 
phosphorylation, depending on the intracellular G-protein subunit activated (Amisten et 
al. 2013). Long chain fatty acid (LCFA) sensing GPCRs have been heavily reported to 
play a key role in energy metabolism and glucose homeostasis, namely GPR40 (FFAR1), 
GPR41 (FFAR3), GPR43 (FFAR2) and GPR120 (FFAR4) (Stoddart et al. 2008). 
Research on the functionality of LCFA receptors is advancing rapidly, with the potent 
GPR40 agonist TAK-875 (Fasiglifam) recently undergoing stage III clinical trials, before 
its withdrawal due to signs of liver toxicity (Marcinak et al. 2017).   
GPR120 (FFAR4) is a class A (rhodopsin) GPCR that exhibits 10% sequence homology 
with GPR40 (FFAR1), with both demonstrating high affinity for saturated and 
unsaturated LCFA molecules (Vangaveti et al. 2010, Hirasawa et al. 2005).  Although 
the signalling mechanism of GPR120 remains largely unknown, studies have 
demonstrated the involvement of phospholipase C, IP3 and intracellular Ca
2+ upon Gαq 
phosphorylation in the pancreatic beta cell (Sanchez-Reyes et al. 2014, Moran et al. 
2014). However, other underexplored signalling pathways may also have a regulatory 
role in pancreatic islet cells, including extracellular signal-regulated kinase (ERK), 
phosphoinositide (PI)-3-kinase and Akt (Hara et al. 2011, Sanchez-Reyes et al. 2014, 
Moran et al. 2014).     
Abundant expression of GPR120 has been identified in the lungs, pro-inflammatory 
macrophages, adipose tissue, endocrine-pancreas and intestines (Moore et al. 2009, 
Amisten et al. 2013). Interestingly, single nucleotide polymorphisms in the GPR120 gene 
have been shown to modulate circulating insulin concentrations and insulin sensitivity in 
response to omega-3 fatty acid supplements, including docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) (Vallee Marcotte et al. 2017). With respect to the 
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gastrointestinal (GI) tract, studies have demonstrated that agonising GPR120 modulates 
GLP-1, GIP and CCK secretion from enteroendocrine L-cells and K-cells (Hirasawa et 
al. 2005, Ikoubov et al. 2007, Sankoda et al. 2017).   
GPR120 is activated by micromolar concentrations of circulating omega-3 fatty acid 
molecules, including docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and α-
linolenic acid (ALA) (Shimpukade et al. 2012, Watson et al. 2012). In addition, numerous 
synthetic agonists have been developed with high affinity for GPR120 activation, 
including GW9508, Compound A and GSK137647 (Mizuta et al. 2015, Oh et al. 2010, 
Sparks et al. 2014). The parent omega-3 fatty acid ALA cannot be synthesised and must 
be acquired from dietary components, such as plants, fish and seeds (Biondeau et al. 
2015). Once consumed, ALA is broken down into DHA and EPA through the action of 
the enzyme delta-6-desaturase (Shi et al. 2016). The activity of fatty acid desaturation 
enzymes is altered with diabetic complications, including elevated circulating insulin 
concentrations (Brenner 2003).   
Recent studies demonstrated a range of endogenous (ALA, DHA, EPA) and synthetic 
(GW9508) GPR120 agonists to enhance glucose stimulated insulin release from clonal 
beta cells, isolated mouse islets and mice (Moran et al. 2014). In addition, acute and 
chronic administration of ALA has been shown to promote GLP-1 secretion in rats 
(Tanaka et al. 2008). Furthermore, administration of ALA has been shown to omit potent 
anti-inflammatory effects, through the downregulation of inflammatory COX-2, iNOS 
and TNF-alpha gene expression mediated by blocking of NF-kappaB and MAPK 
activation (Ren & Chung 2007). Positive effects of ALA towards insulin resistance have 
been heavily documented in both pre-clinical studies using rodents and clinical human 
intervention studies. In an 8-week clinical study, obese participants that received an oral 
dose of ALA displayed enhanced peripheral insulin sensitivity (Wang et al. 2013). 
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ALA supplementation has been demonstrated to counteract oxidative stress by quenching 
a range of reactive oxygen species (ROS) (Li et al. 2013). As this molecule is soluble in 
both lipid and aqueous portions of the cell, its biological functionality is not limited by 
cellular environments (Li et al. 2013). In addition, several studies have also revealed the 
lipid modulating characteristics of ALA, including the lowering of circulating 
triglycerides, control of hypertension and protection against LDL oxidation (Bradberry et 
al. 2013). Subsequently, ALA supplementation may act as a possible protective agent 
against risk factors associated with cardiovascular disease (CVD) (Bradberry et al. 2013). 
Type 2 diabetes is one of the most prevalent metabolic diseases strongly linked with 
increased risk of CVD (Martin-Timon et al. 2014). The risk is derived from 
counterregulatory bodily functions that coexist with CVD risk factors and complications, 
including obesity, hypertension and dyslipidaemia (Bradberry et al. 2013). In general, the 
incidence of thrombotic and macrovascular disease is greatly increased in patients with 
type 2 diabetes. Pro-inflammatory cytokines and inflammation play a key role in the 
lipotoxic and glucotoxic induced mitochondrial injury, oxidative stress, beta cell 
apoptosis and insulin resistance in type 2 diabetes (Lathief & Inzucchi 2013). Whilst, the 
parent omega-3 fatty acid, ALA has the potential to counteract inflammation and 
adiposity (Todric et al. 2006).  
Although the anti-inflammatory and lipid lowering properties of GPR120 and ALA are 
well known, the present study aims to evaluate the glucoregulatory and anti-obesity 
effects of ALA supplementation in high fat fed (HFF) induced diabetic obese mice. Due 
to the hypothesised role of GPR120 in the modulation of incretin release from 
enteroendocrine cells, ALA combinational therapy using the DPP-IV inhibitor 
(Sitagliptin) was utilised to prolong the circulating half-life of incretin hormones. Acute 
glucose lowering parameters of ALA monotherapy and combinational therapy 
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(Sitagliptin) were assessed, including glucose tolerance, insulin secretion, incretin 
secretion, DPP-IV activity and agonists specificity. In addition, chronic analysis assessed 
the effects of 21-day oral administration of ALA monotherapy and combinational therapy 
on bodyweight, food intake, non-fasting plasma glucose, insulin secretion/content, insulin 
sensitivity, lipid profile, pancreatic islet morphology, amylase activity, C-reactive protein 
and DEXA analysis.   
 
6.3: Materials and methods 
Development of high fat fed induced diabetic obese mice was outlined previously in 
Section 2.9.2. Materials and methods used to assess the metabolic actions of GPR120 
agonist-based therapies are outlined in Sections 2.10 and 2.11. Materials and 
methodologies for DPP-IV activity analysis and ELISAs used for biochemical analysis 
are detailed in Sections 2.12 and 2.13, respectively. 
 
6.4 Results 
 
6.4.1: Effect of a high fat fed diet for 4 months on glucose tolerance in Swiss TO mice 
To confirm the diabetic phenotype, Swiss TO mice, subjected to a high fat fed diet for 
four months, were challenged with an oral glucose tolerance test. Using AUC data, the 
glycaemic control of the high fat fed mice was impaired by 47% (p<0.001), compared to 
the lean control (Fig. 6.1A), with glucose stimulated insulin release impaired by 48% 
(p<0.001; Fig. 6.1D). In addition, mice subjected to the high fat diet demonstrated an 
average weight gain of 18% (p<0.001), compared to the lean control (Fig. 6.1E).   
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6.4.2: Acute effect of GPR120 agonist monotherapy and combinational therapy 
(Sitagliptin) on glucose tolerance and insulin secretion in high fat fed diabetic mice 
An oral glucose tolerance test (OGTT) was performed to assess the acute glucose 
lowering properties of GPR120 agonists (ALA. GW9508, GSK137647, Compound A) in 
fasted, HFF mice. Agonists were assessed alone or in combination with the DPP-IV 
inhibitor (Sitagliptin). The GPR120 antagonist AH-7614 was utilised to determine 
agonist specificity in-vivo. Oral administration of all GPR120 agonists improved glucose 
tolerance (p<0.05-p<0.001) (Fig. 6.2-6.9 A), with AUC data showing decreases in 
glucose with ALA (32%; p<0.05), GW9508 (16%), Compound A (26%; p<0.05) and 
GSK137647 (18%; p<0.05) (Fig. 6.2-6.9 B). In combination with Sitagliptin, synthetic 
GPR120 agonist GW9508 exhibited a further 22% (p<0.01) improvement on glucose 
excursion, whilst the endogenous agonist ALA demonstrated an additive 35% (p<0.05) 
effect in combination (Fig. 6.2-6.9 B). The GPR120 antagonist impaired the glucose 
lowering properties of ALA (31%), GW9508 (6%), Compound A (77%; p<0.05) and 
GSK137647 (89%; p<0.05) (Fig. 6.2-6.9 B). The acute glucose lowering effect of the 
GPR120/GPR40 dual agonist GW9508 was also impaired by 31% in the presence of the 
GPR40 antagonist (GW1100). 
These effects on blood glucose control were accompanied by relative changes in insulin 
secretion. Agonising GPR120 with ALA (23%; p<0.01), GW9508 (21%; p<0.05), 
Compound A (17%; p<0.05) and GSK137647 (35% p<0.001) increased plasma insulin 
when assessed with AUC data (Fig. 6.2-6.9). ALA in combination with Sitagliptin 
demonstrated an additive 16% (p<0.05) insulinotropic effect compared to agonist 
monotherapy (Fig. 6.2-6.9). The GPR120 antagonist AH-7614 abolished the 
insulinotropic effect of ALA and GW9508 (Fig. 6.3B, 6.5B), whilst the effects of 
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Compound A and GSK137647 were impaired by 30% (p<0.001) and 76% (p<0.001), 
respectively (Fig. 6.7B, 6.9B). 
 
6.4.3: Acute effect of GPR120 agonist monotherapy and combinational therapy 
(Sitagliptin) on incretin secretion and DPP-IV activity in high fat fed diabetic mice 
In response to an oral glucose tolerance test, all GPR120 agonists increased GLP-1 
secretion by 20-25% (p<0.05-p<0.01) (Fig. 6.10). ALA (41%; p<0.01), GW9508 (30%; 
p<0.05) and GSK137647 (31%; p<0.01) stimulated GIP secretion, whilst Compound had 
no significant effect (Fig. 6.11). GSK137647 (p<0.01) and ALA (p<0.01) reduced DPP-
IV activity, with activity further diminished when administered in combination with 
Sitagliptin (p<0.001) (Figure 6.12).    
  
6.4.4: Chronic effect of once daily oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on body weight, non-fasting plasma glucose, 
insulin, pancreatic insulin content, circulating incretin concentrations, DPP-IV 
activity and food intake 
Once daily oral administration of Sitagliptin, ALA alone and combination with Sitagliptin 
demonstrated no significant effect towards bodyweight in HFF mice when measured 
every consecutive 3 days (Fig. 6.13A, B). However, when assessed by percentage weight 
change, ALA alone and in combination with Sitagliptin influenced a 7% (p<0.05) 
reduction in bodyweight (Fig. 6.13C).  
HFF-induced hyperglycaemia was reduced by Sitagliptin (56%; p<0.01), ALA alone 
(83%; p<0.001) and ALA in combination with Sitagliptin (88%; p<0.001) during the 21-
day treatment period (Fig. 6.14). Administration of ALA and Sitagliptin in HFF mice 
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resulted in a greater reduction (32%; p<0.05) of glucose when compared to Sitagliptin 
alone. 
Corresponding increases in plasma insulin concentrations were observed upon treatment 
with Sitagliptin (24%; p<0.001), ALA alone (29%; p<0.001) and ALA in combination 
with Sitagliptin (33%; p<0.001) (Fig. 6.15A, B). ALA or Sitagliptin administration 
resulted in a similar insulin response to combination therapy. Terminal pancreatic tissue 
analysis demonstrated that insulin content was reduced by 70% (p<0.01) in HFF-induced 
diabetic mice. Treatment with Sitagliptin and ALA alone in HFF mice increased insulin 
content by 48% (p<0.05), whilst ALA in combination with Sitagliptin had no effect (Fig. 
6.15C).  
HFF mice treated with Sitagliptin and ALA alone and ALA in combination with 
Sitagliptin demonstrated no effect in circulating total-GLP-1 (Fig. 6.16) and total-GIP 
(Fig. 6.17). DPP-IV activity was elevated by 42% (p<0.01) in HFF-induced diabetic mice, 
whilst administration of Sitagliptin alone and ALA in combination with Sitagliptin 
reduced DPP-IV activity by 26-34% (p<0.05) (Fig. 6.18).  
When assessed by consecutive 3-day measurements, no significant changes in food intake 
were identified upon treatment with Sitagliptin, ALA alone and ALA in combination with 
Sitagliptin (Fig. 6.19). However, upon the assessment of cumulative food intake, ALA 
monotherapy reduced food intake at day 21 (p<0.05), whilst Sitagliptin monotherapy and 
ALA combination with Sitagliptin demonstrated no change in food intake (Fig. 6.20A). 
Cumulative energy intake demonstrated that HFF-induced diabetic mice consumed 
higher energy intake from days 3-21 (p<0.01-p<0.001), compared to lean control (Fig. 
6.20B). Corresponding to food intake analysis, ALA treated mice demonstrated reduced 
cumulative energy intake at day 21 (p<0.05) (Fig. 6.20B). 
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6.4.5: Chronic effect of once daily oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on glucose tolerance and insulin sensitivity 
Administration of Sitagliptin, ALA alone and ALA in combination with Sitagliptin for 
21 days improved glucose tolerance (p<0.05-p<0.001), as assessed by an oral glucose 
tolerance test (Fig. 6.21A). Overall, using AUC data, Sitagliptin, ALA and ALA in 
combination with Sitagliptin improved glucose tolerance by 37-47% (p<0.01-p<0.001), 
with ALA combinational therapy demonstrating the most potent effect (47%; p<0.001) 
(Fig. 6.21C). Corresponding insulin secretory responses were observed in response to the 
glucose lowering effects observed by ALA (p<0.001) from 15-60 min, whilst Sitagliptin 
alone having no effect on insulin release (Fig. 6.21B). ALA alone augmented insulin 
release by 18% (p<0.01), whilst ALA in combination with Sitagliptin demonstrated an 
additive insulin secretory response of 51% (p<0.001) (Fig. 6.21B, D). In addition, 21-day 
oral administration of ALA alone and ALA in combination with Sitagliptin lowered blood 
glucose (p<0.05-p<0.01) following exogenous insulin injection, compared to non-treated 
HFF mice (Fig. 6.22A). Overall, using AOC data, HFF mice treated with ALA and ALA 
in combination with Sitagliptin demonstrated enhanced glucose lowering capabilities by 
36-42% (p<0.05) upon insulin injection, whilst Sitagliptin alone had no effect (Fig. 
6.22B).   
 
6.4.6: Chronic effect of once daily oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on DEXA measurements, lipid profile, plasma 
C-reactive protein and amylase activity 
Post 21-day oral administration, Sitagliptin, ALA alone and ALA in combination with 
Sitagliptin demonstrated reductions in bodyweight 11-14% (p<0.05) in HFF-induced 
diabetic mice, as measured by DEXA analysis (Fig. 6.23A). HFF mice demonstrated 
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increased fat mass by 32% (p<0.001), whilst administration of Sitagliptin, ALA alone and 
ALA in combination with Sitagliptin reduced fat mass by 16-20% (p<0.05-p<0.01) in 
HFF mice (Fig. 6.23B). No effects on lean mass was observed in all groups (Fig. 6.23C).   
DEXA analysis revealed that HFF mice demonstrated reduced total bone mineral content 
(p<0.05; Fig. 6.24A) and femur bone mineral content (p<0.05; Fig. 6.24A) compared to 
lean controls. Administration of Sitagliptin alone and ALA in combination with 
Sitagliptin increased total bone mineral content by 10-11% (p<0.01), whilst ALA alone 
had no effect (Fig. 6.24A). When localised to the femur, Sitagliptin reduced bone mineral 
content (p<0.05), whilst ALA monotherapy and combinational therapy increased bone 
mineral content by 9-13% (p<0.05-p<0.01) (Fig. 16.25A). All groups had no effect on 
total bone mineral density nor femur bone mineral density (Fig. 6.24B; 6.25B). 
Lipid profile analysis on terminal plasma revealed that HFF-induced diabetic mice 
exhibited increased triglycerides (p<0.001), total cholesterol (p<0.001) and LDL 
cholesterol (p<0.001) concentrations, with no change in HDL cholesterol, compared to 
lean mice (Fig. 6.26, 6.27). Administration of Sitagliptin alone (65%; p<0.001), ALA 
(57%; p<0.001) alone and ALA in combination with Sitagliptin (57%; p<0.001) 
improved hypertriglyceridemia and reduced total cholesterol (21-27%; p<0.001).  (Fig. 
6.26). Sitagliptin treated HFF mice demonstrated reduced HDL cholesterol (5%; p<0.05) 
and increased LDL cholesterol (17%; p<0.01). ALA demonstrated no effect on HDL 
cholesterol, however, ALA monotherapy reduced LDL cholesterol by 17% (p<0.05) (Fig. 
6.27B).  
Mice subjected to a HFF diet displayed elevated plasma CRP concentrations by 37% 
(p<0.05), compared to lean control. Administration of ALA in combination with 
Sitagliptin reduced plasma CRP by 46% (p<0.05), whereas ALA and Sitagliptin alone 
had no effect (Fig. 6.28A). HFF mice demonstrated elevated plasma amylase activity by 
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18% (p<0.01), whilst administration of Sitagliptin, ALA alone and ALA in combination 
with Sitagliptin all reduced amylase activity by 12-16% (p<0.01) (Fig. 6.28B). 
 
6.4.7: Chronic effect of once daily oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on islet morphology 
Immunohistochemistry was utilised to examine insulin and glucagon expression in lean, 
HFF and treated mouse pancreatic islets (Fig. 6.29). HFF mice revealed increased islet 
size by 62% (p<0.001), whilst treatment with Sitagliptin and ALA alone resulted in no 
change to islet size. Treatment with ALA in combination with Sitagliptin reduced islet 
size by 65% (p<0.001) (Fig. 6.28A, 6.29). Mice subjected to a HFF diet demonstrated 
major islet abnormalities, including reduced insulin-positive beta cell percentage (p<0.05; 
Fig.6.30B) and increased glucagon-positive alpha cell percentage (p<0.05; Fig.6.30D). 
However, complimentary to islet size, HFF mice demonstrated increased beta cell mass 
(p<0.05; Fig.6.30C) and alpha cell mass (p<0.01; Fig.6.30E). Administration of ALA 
alone increased percentage beta cell area (p<0.001; Fig.6.30B) and beta cell mass 
(p<0.05; Fig.6.30C), whilst reducing percentage alpha cell area (p<0.01; Fig.6.30D) and 
alpha cell mass (p<0.05; Fig.6.30E). ALA in combination with Sitagliptin reduced 
percentage alpha cell area (p<0.05; Fig.6.30D) and alpha cell mass (p<0.05; Fig.6.30E). 
Administration of Sitagliptin alone to HFF mice demonstrated no effects towards islet 
morphology (Fig.6.30).  
Administration on ALA in HFF mice increased beta cell proliferation by 3.1% (p<0.001), 
as assessed by Ki-67 immunohistochemistry (Fig 6.31). In addition, abundant expression 
of both GPR120 and insulin was demonstrated on islets from lean and HFF mice (Fig. 
6.32), with areas of double-immunofluorescent staining between both GPR120 and 
insulin observed (Fig. 6.32G, H).  
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6.5: Discussion 
 
Novel therapeutics that improve defective insulin secretion and beta cell mass are 
required, with recent interest focusing on the role of long chain fatty acid sensing GPCRs 
(Vangaveti et al. 2010, Moran et al. 2016). The functional role of many of the 293 GPCRs 
on the pancreatic islet remains largely unknown (Amisten et al. 2013). However, recent 
studies have demonstrated several LCFA GPCRs to exhibit therapeutic potential for the 
treatment of type 2 diabetes, CVD and obesity related diseases (Stoddart et al. 2008). 
Namely, GPR119, GPR55, GPR40, GPR41, GPR43 and GPR120 have been shown to 
regulate glucose homeostasis mediated through enhanced hormone release and cellular 
proliferation (Stoddart et al. 2008, Marcinak et al. 2017).  
Previous studies have demonstrated insulinotropic and anti-inflammatory properties of 
GPR120 (FFAR4) with a range of endogenous (ALA, DHA, EPA) and synthetic 
(GW9508, GSK137647, Compound A) agonists (Moran et al. 2014). Recently, novel 
synthetic agonists (GSK137647, Compound A) have been developed with high 
specificity for GPR120, thus enabling accurate characterisation of the receptor by 
diminishing the risk of off-target receptor activation (Oh et al. 2010, Sparks et al. 2014). 
The present study firstly investigates the acute metabolic actions and compares the 
potency of several naturally occurring and synthetic GPR120 agonists in HFF-induced 
diabetic obese mice. HFF mice have been extensively reported to be a robust model of 
obesity and type 2 diabetes with characteristics including weight gain, glucose 
intolerance, insulin resistance, dyslipidaemia, hyperinsulinemia, hyperglucagonemia and 
alterations to pancreatic islet morphology (Heydemann 2016).  To confirm the diabetic 
phenotype prior to analysis, HFF mice challenged to an oral glucose tolerance test 
displayed glucose intolerance and defective insulinotropic actions.  
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Oral administration of GPR120 agonists (ALA, GW9508, GSK137647, Compound A) 
improved glucose excursion and insulin release when given in combination with glucose 
to the diabetic animal model, thus demonstrating the glucoregulatory role of GPR120 
activation in the pancreatic islet. Complimentary studies have also demonstrated the acute 
glucose lowering and insulinotropic actions of GPR120 activation in streptozotocin-
induced diabetic mice (Moran et al. 2014).  
To investigate the specificity of putative GPR120 agonists, the high affinity GPR120 
antagonist (AH7614) was employed to block the respective receptor. The glucose 
lowering and insulinotropic effects of ALA, GSK137637 and Compound A were greatly 
diminished in the presence of the GPR120 antagonist, demonstrating their selectivity 
towards GPR120. In contrast, the effect omitted by the synthetic GPR120/GPR40 dual 
agonist GW9508 was impaired by 37% in the presence of the GPR120 antagonist, 
suggesting that the glucose lowering and insulinotropic responses observed were only 
partly driven by GPR120. 
Conflicting results have been reported of the effect of GPR120 activation on GLP-1 
secretion (Tanaka et al. 2008, Paulsen et al. 2014). In the present acute study, ALA, 
GW9508, GSK137647 and Compound A were shown to induce GLP-1 secretion, whilst 
only ALA and GSK137647 stimulated GIP secretion. Interestingly, ALA and 
GSK137647 enhanced both GLP-1 and GIP secretion and omitted the most potent glucose 
lowering and insulinotropic effects. To prolong the bioactivity of endogenously released 
incretins, the DPP-IV inhibitor Sitagliptin was examined in combination with the 
GPR120 agonists (Drucker et al. 2007). Under these conditions, GPR120 agonists 
exhibited enhanced glucose lowering capabilities by stimulating incretin (GLP-1, GIP) 
and insulin secretion through GPR120 activation, supplemented with prolonged incretin 
action through DPP-IV inhibition. Although ALA and GSK137647 slightly attenuated 
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DPP-IV activity, the activity of DPP-IV was completely abolished when administered in 
combination with Sitagliptin. ALA demonstrated the greatest additive effect towards both 
glucose tolerance and insulin secretion when administered in combination with 
Sitagliptin, further elucidating its role in incretin release.  
Upon assessment of acute GPR120 agonist potency and efficacy, the second phase of this 
study investigated the effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) in HFF-induced diabetic obese mice. In the study, 
ALA alone and in combination with Sitagliptin demonstrated marked improvements on 
the prognosis of the diabetic animal model, surpassing the capabilities of Sitagliptin 
alone. A range of beneficial effects were demonstrated, including improvements towards 
glucose tolerance, circulating insulin, insulin sensitivity, weight loss, hyperlipidaemia 
and islet morphology.  
Administration of ALA reduced bodyweight by 7%, implicating the involvement of ALA 
in energy homeostasis and bodyweight management. With respect to glucose tolerance, 
ALA alone and in combination (Sitagliptin) improved glycaemic control beyond the 
capabilities on Sitagliptin only, with ALA combinational therapy omitting the most potent 
effect. These effects on blood glucose control were accompanied by relative changes in 
insulin secretion with ALA combination (Sitagliptin) proving most potent towards 
circulating insulin concentrations. As anticipated, Sitagliptin alone and in combination 
with ALA reduced DPP-IV activity. DPP-IV inhibition however countered the inhibitory 
effects of ALA on feeding activity. Further studies are required to fully understand the 
mechanism but inhibition of DPP-IV-mediated degradation of PYY(1-36) to the active 
form PYY(3-36) seems likely (Batterham & Bloom 2003).  
Post 21-day oral administration of Sitagliptin, ALA alone and ALA in combination with 
Sitagliptin improved glucose tolerance when subjected to an OGTT. Interestingly, ALA 
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combinational therapy (Sitagliptin) demonstrated the greatest insulin secretory effect in 
response to the glucose challenge, with insulinotropic actions enhanced from 15-60 min, 
suggesting involvement of the incretin hormones.  Complimentary to previous findings, 
ALA based therapies attenuated insulin resistance (Oh et al. 2010), whilst Sitagliptin 
alone had no effect. 
DEXA analysis revealed reduced bone mineral content in HFF mice. Interestingly, the 
actions of Sitagliptin appeared to restore total bone mineral content, whilst ALA restored 
bone mineral content when analysis was localised to the femur. Consistently, ALA 
combinational therapy restored bone mineral content for each analysis. Preservation of 
bone quality and strength is strongly linked with GLP-1 and GIP receptor activation, 
which may implicate the mechanism of action for ALA and Sitagliptin based therapies 
on bone mineral content restoration (Irwin & Flatt 2015).  
Terminal plasma analysis demonstrated that Sitagliptin, ALA alone and ALA in 
combination with Sitagliptin greatly improved total cholesterol and triglyceride 
concentrations. Interestingly, Sitagliptin alone attenuated HDL cholesterol, however, 
increased LDL cholesterol. Previous studies have demonstrated omega-3 fatty acids DHA 
and EPA to reduce triglycerides but elevate LDL cholesterol (Bradberry 2013). In 
contrast, administration of the parent omega-3 fatty (ALA) reduced LDL cholesterol and 
diminished hypertriglyceridemia, revealing the regulatory role of ALA in cardiovascular 
health. In this study, administration of ALA in combination with Sitagliptin restored 
elevated C-reactive protein concentrations in HFF mice, which further implicates the 
beneficial effects of ALA based therapies on CVD risk and obesity related diseases. In 
harmony with these findings, previous have also demonstrated the cardioprotective 
effects of omega-3 fatty acids (Clearfield 2005, Bahadursingh et al. 2009). 
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HFF mice demonstrated elevated circulating amylase activity due to pancreatic islet cell 
damage (Vasudevan et al. 2018). Administration of Sitagliptin, ALA alone and ALA in 
combination with Sitagliptin all restored amylase activity, implicating pancreatic 
cytoprotection. Terminal analysis revealed that HFF mice demonstrated major islet 
abnormalities, including increased islet size and alpha percentage area with reduced 
percentage beta cell area. Due to an increase in islet size, HFF islets displayed increased 
alpha and beta cell mass. Administration of ALA increased beta cell area and beta cell 
mass, whilst reducing alpha cell area and mass. Interestingly, ALA in combination with 
Sitagliptin reduced islet size, alpha cell area and alpha cell mass, however, no effects were 
observed towards the beta cell population. Thus, revealing the beneficial effects of this 
treatment in the restoration of non-diabetic islet architecture. When exploring the positive 
effects observed by ALA administration, Ki-67 staining revealed that ALA increased beta 
cell proliferation, which contributes to the increase in beta cell population. Furthermore, 
upon exploring the expression of GPR120 lean and HFF islets, abundant regions of co-
localisation between GPR120 and insulin were observed, which further implicates the 
importance of GPR120 in beta cell function. 
In conclusion, oral administration of GPR120 agonist monotherapy and combinational 
therapy (Sitagliptin) improved glycaemic control in HFF-induced diabetic obese mice, 
with positive effects towards CVD risk and obesity related diseases also observed. 
Biological effects included attenuated plasma glucose with increased insulin and incretin 
secretion. In addition, long term administration of ALA improved glucose tolerance, 
insulin sensitivity and hyperlipidaemia, whilst restoring CRP, amylase activity and islet 
cell morphology. Beneficial effects observed were predominantly enhanced in the 
presence of the DPP-IV inhibitor Sitagliptin, with particular benefits observed in the 
restoration of islet morphology. These findings promote GPR120 agonist monotherapy 
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and combinational therapy (Sitagliptin) as a novel therapeutic approach for the treatment 
of type 2 diabetes and obesity related diseases.   
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Figure 6.1: Effect four-month high fat fed diet on glucose tolerance and insulin secretion in 18 h fasted Swiss TO mice.  
 
 
 
 
 
 
 
 
 
 
 
Swiss TO mice were subjected to a high fat fed (HFF) diet for four months to induce an insulin resistance and glucose intolerance. To confirm the diabetic 
phenotype of the model, animals were subjected to an oral glucose tolerance test (18 mmol/kg bw) with (A, C) glucose tolerance, (B, D) insulin secretory 
response and (E) bodyweight determined.  Results are the mean ± SEM (n=6). *p<0.05, **p<0.01, ***p<0.001 compared to lean control. 
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Figure 6.2: Acute effect of ALA on plasma glucose in 18 h fasted high fat fed diabetic 
mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of ALA on plasma glucose (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with ALA (0.1µmol/kg 
bw) and either the GPR120 antagonist AH7614 (0.1µmol/kg bw) or Sitagliptin (50 mg/kg 
bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  *p<0.05, **p<0.01, 
***p<0.001, compared to HFF glucose control. +p<0.05, compared to agonist alone. 
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Figure 6.3: Acute effect of ALA on plasma insulin in 18 h fasted high fat fed diabetic 
mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of ALA on plasma insulin (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with ALA (0.1µmol/kg 
bw) and either the GPR120 antagonist AH7614 (0.1 µmol/kg bw) or Sitagliptin (50 mg/kg 
bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  *p<0.05, **p<0.01, 
***p<0.001, compared to HFF glucose control. +p<0.01, ++p<0.05, +++p<0.001, 
compared to agonist alone. 
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Figure 6.4: Acute effect of GW9508 on plasma glucose in 18 h fasted high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
Acute effect of GW9508 on plasma glucose (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with GW9508 
(0.1µmol/kg bw) and either the GPR120 antagonist AH7614 (0.1µmol/kg bw), GPR40 
antagonist GW1100 (0.1µmol/kg bw) or Sitagliptin (50 mg/kg bw) to HFF mice (n = 6). 
Values are presented as mean ± SEM.  *p<0.05, **p<0.01, ***p<0.001, compared to 
HFF glucose control. ++p<0.01, compared to agonist alone. 
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Figure 6.5: Acute effect of GW9508 on plasma insulin in 18 h fasted high fat fed 
diabetic mice. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of GW9508 on plasma insulin (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with GW9508 
(0.1µmol/kg bw) and either the GPR120 antagonist AH7614 (0.1µmol/kg bw), GPR40 
antagonist GW1100 (0.1µmol/kg bw) or Sitagliptin (50 mg/kg bw) to HFF mice (n = 6). 
Values are presented as mean ± SEM.  *p<0.05, **p<0.01, ***p<0.001, compared to 
HFF glucose control. +++p<0.001, compared to agonist alone. 
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Figure 6.6: Acute effect of GSK137647 on plasma glucose in 18 h fasted high fat fed 
diabetic mice. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of GSK137647 on plasma glucose (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with GSK137647 
(0.1µmol/kg bw) and either the GPR120 antagonist AH7614 (0.1µmol/kg bw) or 
Sitagliptin (50 mg/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, ***p<0.001, compared to HFF glucose control. +p<0.05, ++p<0.01, 
compared to agonist alone. 
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Figure 6.7: Acute effect of GSK137647 on plasma insulin in 18 h fasted high fat fed 
diabetic mice. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of GSK137647 on plasma insulin (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with GSK137647 
(0.1µmol/kg bw) and either the GPR120 antagonist AH7614 (0.1µmol/kg bw) or 
Sitagliptin (50 mg/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, ***p<0.001, compared to HFF glucose control. +++p<0.001, 
compared to agonist alone. 
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Figure 6.8: Acute effect of Compound A on plasma glucose in 18 h fasted high fat 
fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
Acute effect of Compound A on plasma glucose (A) and respective AUC (B). Glucose 
(18 mmol/kg bw) was administered orally alone or in combination with GSK137647 
(0.1µmol/kg bw) and either the GPR120 antagonist AH7614 (0.1µmol/kg bw) or 
Sitagliptin (50 mg/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, ***p<0.001, compared to HFF glucose control. +p<0.05, compared 
to agonist alone. 
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Figure 6.9: Acute effect of Compound A on plasma insulin in 18 h fasted high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of Compound A on plasma insulin (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with Compound A 
(0.1µmol/kg bw) and either the GPR120 antagonist AH7614 (0.1µmol/kg bw) or 
Sitagliptin (50 mg/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, compared to HFF glucose control. +++p<0.001, compared to agonist 
alone. 
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Figure 6.10: Acute effects of GPR120 agonists on total plasma GLP-1 in 18 h fasted 
high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effects of GPR120 agonists on total plasma GLP-1 (A) and respective AUC (B). 
Glucose (18 mmol/kg bw) was administered orally alone or in combination with GPR120 
agonists (0.1µmol/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, ***p<0.001, compared to HFF glucose control.  
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Figure 6.11: Acute effects of GPR120 agonists on total plasma GIP in 18 h fasted 
high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GPR120 agonists on total plasma GIP (A) and respective AUC (B). 
Glucose (18 mmol/kg bw) was administered orally alone or in combination with GPR120 
agonists (0.1µmol/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, ***p<0.001, compared to HFF glucose control.  
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Figure 6.12: Acute effects of GPR120 agonists and Sitagliptin on DPP-IV activity in 
18 h fasted high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GPR120 agonists on DPP-IV activity (A) and respective AUC (B). 
Glucose (18 mmol/kg bw) was administered orally alone or in combination with GPR120 
agonists (0.1µmol/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, ***p<0.001 compared to HFF glucose control.  
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Figure 6.13: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (sitagliptin) on bodyweight in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
  
  
   
 
 
 
  
Chronic effect of ALA alone and in combination with Sitagliptin on (A) bodyweight, (B) 
respective AUC and (C) percentage weight change. Bodyweight measurements were 
obtained before and during ALA (0.1 µmol/kg bw) and Sitagliptin (50 mg/kg bw) 
therapies (indicated by the black bar). Values are presented as mean ± SEM (n = 8).  
*p<0.05, **p<0.01, compared to HFF control.  
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Figure 6.14: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (Sitagliptin) for 21 days on plasma glucose in high fat 
fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
 
 
  
Chronic effect of ALA alone and in combination with Sitagliptin on (A) plasma glucose 
and (B) respective AUC. Parameters were obtained before and during ALA (0.1µmol/kg 
bw) and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). Values are 
presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared to HFF 
control. +p<0.05, compared to ALA alone. 
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Figure 6.15: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (Sitagliptin) for 21 days on plasma insulin 
concentrations in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
   
  
 
  
 
 
Chronic effect of ALA alone and in combination with Sitagliptin on (A) plasma insulin, 
(B) respective AUC and (C) pancreatic insulin content. Parameters were obtained before 
and during ALA (0.1µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies (indicated by 
the black bar). Insulin content was determined after 21-day treatment. Values are 
presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared to HFF 
control. +++p<0.001, compared to ALA alone. 
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Figure 6.16: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (Sitagliptin) for 21 days on circulating total-GLP-1 in 
high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
   
  
  
  
  
  
 
Chronic effect of ALA alone and in combination with Sitagliptin on (A) total-GLP-1 and 
(B) respective AUC. Parameters were obtained before and during ALA (0.1 µmol/kg bw) 
and Sitagliptin (50 mg/kg bw) therapies. Values are presented as mean ± SEM (n = 6). 
*p<0.05, compared to HFF control. 
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Figure 6.17: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (Sitagliptin) for 21 days on circulating total-GIP in high 
fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
  
  
  
 
Chronic effect of ALA alone and in combination with Sitagliptin on (A) total-GIP and 
(B) respective AUC. Parameters were obtained before and during ALA (0.1 µmol/kg bw) 
and Sitagliptin (50 mg/kg bw) therapies. Values are presented as mean ± SEM (n = 6).  
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Figure 6.18: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (Sitagliptin) for 21 days on DPP-IV activity in high fat 
fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
   
  
 
  
  
 
  
Chronic effect of ALA alone and in combination with Sitagliptin on (A) DPP-IV activity 
and (B) respective AUC. Parameters were obtained before and during ALA (0.1 µmol/kg 
bw) and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). Values are 
presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, compared to HFF control. 
++p<0.05, compared to ALA alone. 
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Figure 6.19: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (Sitagliptin) for 21 days on food intake in high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
   
  
 
  
 
 
  
Chronic effect of ALA alone and in combination with Sitagliptin on (A) food intake and 
(B) respective AUC. Parameters were obtained before and during ALA (0.1µmol/kg bw) 
and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). Values are presented 
as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared to HFF control. 
+p<0.05, compared to ALA alone. 
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Figure 6.20: Chronic effect of once daily oral administration of ALA monotherapy 
and combinational therapy (Sitagliptin) for 21 days on cumulative food and energy 
intake in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
 
 
  
Chronic effect of ALA alone and in combination with Sitagliptin on (A) food intake and 
(B) energy intake. Parameters were obtained before and during ALA (0.1µmol/kg bw) 
and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). Values are presented 
as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared to HFF control.  
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Figure 6.21: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on glucose tolerance and insulin secretion in 
high fat fed diabetic mice. 
  
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
Oral glucose tolerance test (18 mmol/kg bw) was conducted on HFF mice following 21-
day treatment with ALA (0.1µmol/kg bw) and/or Sitagliptin (50 mg/kg bw). (A, C) 
Plasma glucose and (B, D) plasma insulin were determined. Results are mean ± SEM 
(n=6).  *p<0.05, **p<0.01, ***p<0.001, compared to HFF glucose control. ++p<0.01, 
+++p<0.001, compared to ALA alone. 
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Figure 6.22: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on insulin sensitivity in high fat fed diabetic 
mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Insulin sensitivity (40U/kg bodyweight; dissolved in 0.9% saline, i.p. injection) test was 
conducted following 21-day treatment with ALA alone (0.1 µmol/kg bw) or in 
combination with Sitagliptin (50 mg/kg bw) to HFF diabetic mice. (A) Blood glucose and 
(B) respective AOC are shown. Results are mean ± SEM (n=8).  *p<0.05, **p<0.01, 
compared to HFF control. +p<0.05, compared to ALA alone. 
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Figure 6.23: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on bodyweight, fat mass and lean mass as 
measured by DEXA in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of ALA (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) bodyweight, (B) fat mass and (C) lean 
mass in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).  *p<0.05, 
**p<0.01, ***p<0.001, compared to HFF control. +p<0.05, compared to ALA alone. 
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Figure 6.24: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on total bone mineral content and bone mineral 
density as measured by DEXA in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of ALA (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) bone mineral content, (B) bone 
mineral density in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).  
*p<0.05, **p<0.01, compared to HFF control. ++p<0.01, compared to ALA alone. 
A 
 
B 
 
265 
 
Lean HFF Sitagliptin ALA ALA + Sitagliptin
0.00
0.02
0.04
0.06
***
***
* **
+++
*
++ *
F
e
m
u
r 
b
o
n
e
 m
in
e
ra
l
c
o
n
te
n
t 
(g
)
Lean HFF Sitagliptin ALA ALA + Sitagliptin
0.00
0.05
0.10
0.15
***F
e
m
u
r 
b
o
n
e
 m
in
e
ra
l
d
e
n
s
it
y
 (
g
/c
m
2
)
Figure 6.25: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on total bone mineral content and bone mineral 
density as measured by DEXA in the femur of high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of ALA (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) bone mineral content, (B) bone 
mineral density in the femur of HFF diabetic mice. Values are presented as mean ± SEM 
(n = 8).  *p<0.05, **p<0.01, compared to HFF control. ++p<0.01, compared to ALA 
alone. 
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Figure 6.26: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on plasma triglycerides and total cholesterol in 
high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of ALA (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) plasma triglyceride, (B) total 
cholesterol in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).   
***p<0.001, compared to HFF control. +p<0.05, +++p<0.001, compared to ALA alone. 
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Figure 6.27: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on plasma HDL cholesterol and LDL cholesterol 
in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of ALA (0.1µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on plasma (A) triglycerides and (B) total 
cholesterol in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).  *p<0.05, 
**p<0.01, ***p<0.001, compared to HFF control. +p<0.05, +++p<0.001, compared to 
ALA alone. 
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Figure 6.28: Chronic effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on plasma C-reactive protein and amylase 
activity in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of ALA (0.1µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on plasma (A) C-reactive protein and (B) 
amylase activity in HFF diabetic mice. Values are presented as mean ± SEM (n = 6).  
*p<0.05, **p<0.01, compared to HFF control.  
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Figure 6.29: Distribution of islet insulin and glucagon, following 21-day oral administration of ALA monotherapy and combinational therapy 
(Sitagliptin) in high fat fed diabetic mice.  
 
  
 
 
 
 
 
 
Representative images for distribution of DAPI (blue), insulin (red) and glucagon (green) in pancreatic islets of HFF mice at x40 magnification, following 
21-day treatment of (A-D) lean control, (E-H) HFF, (I-L) Sitagliptin, (M-P) ALA and (Q-T) ALA + Sitagliptin. 
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Figure 6.30: Effect of 21-day oral administration of ALA monotherapy and 
combinational therapy (Sitagliptin) on islet morphology in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohistochemistry demonstrating the effect of ALA monotherapy and combinational 
therapy (Sitagliptin) on (A) islet size, (B) beta cell area, (C) beta cell mass, (D) alpha cell 
area and (E) alpha cell mass in HFF mice.  Values are mean ± SEM (n = 8), with 30 islets 
per group.  *p<0.05, **p<0.01, ***p<0.001, compared to HFF. +p<0.05, +++p<0.001, 
compared to ALA alone. (Representative images as per Fig 6.29). 
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Figure 6.31: Effect of 21-day oral administration of ALA on beta cell proliferation 
(Ki-67) in high fat fed diabetic mice. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative images for DAPI (blue), insulin (green) and Ki-67 (red) in pancreatic islets 
of HFF mice at x40 magnification, following 21-day treatment with (A-D) HFF control 
and (E-H) ALA. Values are mean ± SEM (n = 8), with 50 islets per group.  ***p<0.001, 
compared to HFF. Positive Ki-67 staining indicated by arrows. 
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Figure 6.32: Distribution of GPR120 and insulin in pancreatic islets from lean and 
high fat fed mice. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohistochemistry demonstrating the distribution of DAPI (blue), GPR120 (green) 
and insulin (red) in HFF (A, C, E, G) and lean (B, D, F, H) pancreatic islets at x40 
magnification. Areas of double immunofluorescent staining indicated by white arrows. 
Images are representative of several tissue sections. 
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Chapter 7 
 
Assessing the therapeutic actions of GPR55 
agonist monotherapy and combinational 
therapy (Sitagliptin) on glucose intolerance, 
dyslipidaemia and bodyweight control in-
vivo 
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7.1: Summary 
 
Recent studies have recognised GPR55 as a novel anti-diabetic target through 
enhancement of beta cell function and beta cell mass. The present study aims to evaluate 
the metabolic actions and therapeutic efficacy of GPR55 agonist monotherapy and 
combinational therapy (Sitagliptin) in islet and enteroendocrine cell function. 
Acute glucose lowering effects of agonist monotherapy and combinational therapy (DPP-
IV inhibitor) were investigated in HFF-induced diabetic mice, followed by biochemical 
assessment of plasma glucose and glucoregulatory hormone release. Chronic effect of 21-
day oral administration of Abn-CBD (0.1 µmol/kg bw) monotherapy and combinational 
therapy with Sitagliptin (50 mg/kg bw) were assessed in HFF mice (n=8). Biochemical 
and anthropometric assessments of plasma glucose, circulating insulin, DPP-IV activity, 
CRP, amylase, lipids, body weight and food intake were conducted. Glucose tolerance, 
insulin sensitivity, DEXA scanning and islet morphology analysis were performed post 
21-day administration.  
Abn-CBD (31%; p<0.01) and AM251 (28%; p<0.01) improved glucose tolerance in HFF 
mice. Plasma insulin concentrations were enhanced by 27-39% (p<0.001), with further 
increases in GLP-1 (p<0.05-p<0.001) and GIP (p<0.05) release. When accompanied with 
DPP-IV inhibition (Sitagliptin), glucose lowering capabilities of Abn-CBD were 
enhanced by 22% (p<0.05). Chronic administration of Abn-CBD alone (54%; p<0.001) 
and in combination with Sitagliptin (57%; p<0.001) attenuated plasma glucose and 
enhanced circulating insulin concentrations by 18 and 24% (p<0.001), respectively. Abn-
CBD and Abn-CBD in combination with the DPP-4 inhibitor reduced bodyweight by 9% 
(p<0.05-p<0.01). Post 21-day administration, Abn-CBD alone (23%; p<0.01) and with 
Sitagliptin (47%; p<0.01) improved glucose tolerance, whilst enhancing insulin 
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sensitivity by 42-43% (p<0.05). Abn-CBD increased islet area (43%; p<0.05), beta cell 
mass (p<0.001) and beta cell proliferation (3.5%; p<0.001), whilst Abn-CBD in 
combination with Sitagliptin reduced islet area (44%; p<0.05). Abn-CBD alone reduced 
plasma triglycerides by 34% (p<0.001) and both total cholesterol and LDL cholesterol by 
15% (p<0.01). Abn-CBD in combination with Sitagliptin further reduced triglycerides 
(p<0.001) and total cholesterol (p<0.001) by 22% and 10%, respectively. Abn-CBD in 
combination with Sitagliptin reduced fat mass by 22% (p<0.05) and restored elevated 
CRP concentrations (48%; p<0.05).  
These findings promote Abn-CBD monotherapy and combinational therapy (Sitagliptin) 
as a novel therapeutic approach for the treatment of glucose intolerance, bodyweight 
control and dyslipidaemia in patients with type 2 diabetes. 
 
7.2: Introduction 
 
The endocannabinoid system (ECS) has been shown to exhibit a wide range of 
physiological functions upon activation with small lipid-based retrograde 
neurotransmitter molecules (Reggio 2010). The ECS is responsible for the 
pharmacological effects of cannabis, whilst also mediating effects towards appetite, pain-
sensation, memory, mood and energy metabolism (Donvito et al. 2018, Manzanares et al. 
2006, McKillop et al. 2013). The physiological functions of the CB1 and CB2 
cannabinoid receptors have been extensively reported, with functionality primarily 
associated within the brain, central nervous system and peripheral nervous system 
(Svizenska et al. 2018). Recently, GPR55 has been identified as a novel endocannabinoid 
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receptor and has been hypothesised to be responsible for the non CB1/CB2 physiological 
effects omitted by cannabinoid ligands (Morales & Reggio 2017). 
G-protein coupled receptor 55 (GPR55) was first identified and cloned in 1999 
(Sawzdargo et al. 1999). Later studies revealed GPR55 to be a cannabinoid receptor due 
to similar amino acid sequence identity in the binding sites of the receptor (Baker et al. 
2006). Initial characterisation of GPR55 focused on its function in blood pressure control 
upon activation with cannabinoid ligands (Johns et al. 2007). Although several 
cannabinoids were shown to demonstrate blood pressure lowering properties, these 
actions were shown to be independent of GPR55 activation (Johns et al. 2007). At present, 
the entire physiological function of GPR55 remains unclear, with GPR55 knockout mice 
displaying no specific phenotype (Johns et al. 2007). However, studies have demonstrated 
the receptor to play a role in energy metabolism, whilst exhibiting pharmacological 
potential for metabolic diseases (McKillop et al. 2013, McKillop et al. 2016, Liu et al. 
2016) 
Activation of GPR55 is mediated by a range of natural and synthetic ligands, including 
endocannabinoids, phytocannabinoid plant components and long chain fatty acid 
molecules (McKillop et al. 2013, Tudurí et al. 2017). Lysophosphatidylinositol (LPI) has 
been generally accepted as the endogenous ligand of GPR55, however, one recent study 
utilising GPR55 knockout mice demonstrated LPI to act through a GPR55-independent 
mechanism in pancreatic islets (Tudurí et al. 2017, Liu et al. 2016). Interestingly, 
increased circulating concentrations of LPI is associated with obesity and type diabetes 
with concentrations correlating with BMI and fat percentage (Moreno-Navarrete et al. 
2012). Furthermore, increased plasma LPI concentrations have also been shown to be a 
prognostic indicator of cardiac arrest and ovarian cancer (Arifin & Falasca 2016). Due to 
the undefined specificity of LPI and its correlation with poor prognosis of obesity and 
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inflammatory related diseases, studies have favoured LPI as a prognostic biomarker rather 
than a therapeutic agent (Kim et al. 2017).   
GPR55 is expressed widely throughout the body, with abundant expression in the brain, 
intestines, osteoblasts and endocrine-pancreas (Ryberg et al. 2009, McKillop et al. 2013, 
Sawzdargo et al. 1999). Recent results from the genome wide association study (GWAS) 
revealed that a variant of the GPR55 gene displayed the phenotype of type 2 diabetes and 
coronary artery calcification (Divers et al. 2017). The variant displayed a single 
nucleotide polymorphism (SNP) on an intronic region of the GPR55 gene at chromosome 
2q37.1 (Divers et al. 2017). 
Current research is now heavily investigating the therapeutic potential of GPR55 in the 
treatment of type 2 diabetes and other obesity related diseases (Tudurí et al. 2017). 
GPR55 has been shown to demonstrate insulinotropic actions in clonal pancreatic beta 
cells upon activation with a range of endogenous (OEA, PEA) and synthetic (Abn-CBD, 
AM251) agonists (McKillop et al. 2013). In the same study, antagonising the receptor 
impaired the stimulatory effect of the agonists, with Abn-CBD omitting the potent and 
selective properties (McKillop et al. 2013).   
Chronic administration of Abn-CBD was previously reported to induce glucose lowering 
and insulinotropic effects in multiple low dose streptozotocin mice, with further 
improvements towards insulin sensitivity, glucose tolerance and lipid balance also 
observed (McKillop et al. 2016). In addition, immunohistochemical analysis revealed 
abundant GPR55 expression in mouse and human pancreatic islet cells (McKillop et al. 
2013, Liu et al. 2016). Interestingly, GPR55 expression was demonstrated to be solely 
expressed in beta cells in rodent rodents, however, one recent study identified moderate 
GPR55 expression in alpha cells of human islets also (Liu et al. 2016).  
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Previous reports resulted in discrepancies over the specificity of Abn-CBD in the 
pancreatic islet, particularly with respect to insulin-producing beta cells (McKillop et al. 
2013, Ruz-Maldonado et al. 2018). Recently, the insulinotropic actions of Abn-CBD in 
mouse islets were demonstrated to be independent of GPR55 activation when assessed 
using isolated GPR55 knockout islets (Ruz-Maldonado et al. 2018). However, the same 
report revealed the proliferative effects of Abn-CBD in beta cells to be GPR55-dependent 
using the same model (Ruz-Maldonado et al. 2018). The use of knockout tissues to 
determine specificity may be unreliable as numerous compensatory pathways may be 
introduced. Studies using a clonal GPR55 knockout beta cell line, developed using 
innovative CRISPR/Cas9 gene editing, revealed that Abn-CBD induced insulin release is 
predominately GPR55-dpenednatnt, with potential synergistic activity with other 
cannabinoid receptors such as GPR18 (Chapter 5). 
Chronic administration of Abn-CBD has also been shown to confer cardioprotection in 
diabetic rats by alleviating defective ventricle function and myocardial oxidative stress, 
through the restoration of impaired nitric oxide (NO) and adiponectin (ADN) 
concentrations (Matouk et al. 2018).  
Given the known insulinotropic and cardioprotective function of Abn-CBD, the present 
study aims to evaluate the glucoregulatory and anti-obesity effects of Abn-CBD in high 
fat fed (HFF) induced diabetic obese mice. Due to abutment expression of GPR55 
incretin-releasing enteroendocrine cells, Abn-CBD combinational therapy using the DPP-
IV inhibitor (Sitagliptin) was explored and utilised to prolong the circulating half-life of 
incretin hormones (Drucker et al. 20017). Acute glucose lowering parameters of Abn-
CBD monotherapy and combinational therapy (Sitagliptin) were assessed, including 
glucose tolerance, insulin secretion, incretin secretion, DPP-IV activity and agonist 
specificity. In addition, chronic analysis assessed the effects of 21-day oral administration 
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of Abn-CBD monotherapy and combinational therapy on bodyweight, food intake, non-
fasting plasma glucose, insulin secretion/content, insulin sensitivity, lipid profile, 
pancreatic islet morphology, amylase activity, C-reactive protein and DEXA analysis.   
 
7.3: Materials and methods 
Development of high fat fed induced diabetic obese mice were outlined previously in 
Section 2.9.2. Materials and methods used to assess the metabolic actions of GPR55 
agonist-based therapies are outlined in Sections 2.10 and 2.11. Materials and 
methodologies for DPP-IV activity analysis and ELISAs used for biochemical analysis 
are detailed in Sections 2.12 and 2.13, respectively. 
 
7.4: Results 
 
7.4.1: Effect of four-month high fat fed diet on glucose tolerance in Swiss TO mice 
To confirm the diabetic phenotype, Swiss TO mice subjected to a high fat fed diet for 
four months were challenged with an oral glucose tolerance test. Using AUC data, the 
glycaemic control of the high fat fed mice was impaired by 47% (p<0.001), compared to 
the lean control (Fig. 7.1A), with glucose stimulated insulin release impaired by 48% 
(p<0.001; Fig. 7.1D). In addition, mice subjected to the high fat diet demonstrated an 
average weight gain of 18% (p<0.001), compared to the lean control (Fig. 7.1E).   
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7.4.2: Acute effect of GPR55 agonist monotherapy and combinational therapy 
(Sitagliptin) on glucose tolerance and insulin secretion in high fat fed mice 
An oral glucose tolerance test (OGTT) was performed to assess the acute glucose 
lowering properties of GPR55 agonists Abn-CBD and AM251 in fasted, HFF mice. 
Agonists were assessed alone or in combination with the DPP-IV inhibitor (Sitagliptin). 
The GPR55 antagonist CBD was utilised to determine agonist specificity in-vivo. Oral 
administration of both GPR55 agonists improved glucose tolerance (p<0.05-p<0.001) 
(Fig. 7.2, 7.4 A), with AUC data showing decreases in glucose with Abn-CBD (28%; 
p<0.01) and AM251 (31%; p<0.01) (Fig. 7.2, 7.4 B). In combination with Sitagliptin, 
both GPR55 agonists exhibited a further improvement on glucose excursion by 8-22%, 
whilst Abn-CBD demonstrating the most potent glucose lowering effect (50%; p<0.001) 
in combination (Fig. 7.2). The GPR55 antagonist impaired the glucose lowering 
capabilities of Abn-CBD and AM251 by 47% and 2%, respectively (Fig. 7.2, 7.4 B). 
Effects on blood glucose control were accompanied by relative changes in insulin 
secretion. Agonising GPR55 with Abn-CBD (27%; p<0.001) and AM251 (39%; 
p<0.001) increased plasma insulin when assessed with AUC data (Fig. 7.3, 7.5 B). Abn-
CBD combination with Sitagliptin demonstrated an additive 15% insulinotropic effect 
compared to agonist monotherapy (Fig. 7.3, 7.5). The GPR55 antagonist CBD impaired 
the insulinotropic effect of Abn-CBD by 55% (Fig. 7.3B), whilst the effects of AM251 
were greatly diminished by 80% (p<0.001) (Fig. 7.5B). 
 
7.4.3: Acute effect of GPR55 agonist monotherapy and combinational therapy 
(Sitagliptin) on incretin secretion and DPP-IV activity in high fat fed mice 
In response to an oral glucose tolerance test, Abn-CBD and AM251 agonists increased 
GLP-1 secretion (p<0.05-p<0.001) at 15 min (Fig. 7.6). After 15 min, AM251 stimulated 
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GIP secretion (p<0.01), whilst Abn-CBD had no significant effect (Fig. 7.7). Overall, 
using AUC data for the 30 min treatment period, both Abn-CBD (p<0.001) and AM251 
(p<0.05) stimulated GLP-1 release, whilst Abn-CBD (p<0.05) and AM251 (p<0.05) also 
augmented GIP secretion. (Fig. 7.7B). DPP-IV activity was diminished through the 
actions of Sitagliptin only (p<0.001; Fig. 7.8). 
 
7.4.4: Chronic effect of once daily oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on body weight, non-fasting plasma glucose, 
insulin, pancreatic inulin content, circulating incretin concentrations, DPP-IV 
activity and food intake 
Once daily oral administration of Sitagliptin, Abn-CBD alone and combination with 
Sitagliptin demonstrated no significant effect towards bodyweight in HFF mice when 
measured every consecutive 3 days (Fig. 7.9A, B). However, when assessed by 
percentage weight change, Abn-CBD alone and in combination with Sitagliptin 
influenced a 9-10% (p<0.05-p<0.01) reduction in bodyweight (Fig. 7.9C).  HFF-induced 
hyperglycaemia was reduced by Sitagliptin (37%; p<0.01), Abn-CBD alone (54%; 
p<0.001) and Abn-CBD in combination with Sitagliptin (57%; p<0.001) during the 21-
day treatment period (Fig. 7.10). Abn-CBD alone surpassed the glucose lowering 
capabilities of Sitagliptin by 17% (p<0.05).Corresponding increases in plasma insulin 
concentrations were observed upon treatment with Sitagliptin (24%; p<0.001), Abn-CBD 
alone (18%; p<0.001) and Abn-CBD in combination with Sitagliptin (24%; p<0.001) 
(Fig. 7.11A, B). Terminal pancreatic tissue analysis demonstrated that insulin content was 
reduced by 70% (p<0.01) in HFF-induced diabetic mice. Treatment with Sitagliptin alone 
increased insulin content by 48% (p<0.05), whilst Abn-CBD alone and in combination 
with Sitagliptin had no effect (Fig. 7.11C).  
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Chronic administration of Abn-CBD and Abn-CBD in combination with Sitagliptin 
enhanced circulating GLP-1 concentrations by 27% (p<0.05; Fig.7.12) and 30% (p<0.01, 
Fig. 7.13), respectively. No effects on circulating GIP concentrations were observed. 
DPP-IV activity was elevated by 42% (p<0.01) in HFF-induced diabetic mice, whilst 
administration of Sitagliptin and Abn-CBD in combination with Sitagliptin reduced DPP-
IV activity by 26-35% (p<0.05) (Fig. 7.14). When assessed by consecutive 3-day 
measurements, no significant changes in food intake nor cumulative food intake were 
identified upon treatment with Sitagliptin, Abn-CBD alone and Abn-CBD in combination 
with Sitagliptin (Fig. 7.15, 7.16). Cumulative energy intake demonstrated that HFF-
induced diabetic mice consumed higher energy intake from days 3-21 (p<0.01-p<0.001), 
compared to lean control (Fig. 7.16B). Corresponding to food intake analysis, no effects 
towards cumulative food intake were observed with all treatment groups (Fig. 7.16B). 
  
7.4.5: Chronic effect of once daily oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on glucose tolerance and insulin sensitivity 
Administration of Sitagliptin, Abn-CBD alone and Abn-CBD in combination with 
Sitagliptin for 21 days improved glucose tolerance (p<0.05-p<0.001), as assessed by an 
oral glucose tolerance test (Fig. 7.17A). Overall, using AUC data, Sitagliptin, Abn-CBD 
and Abn-CBD in combination with Sitagliptin improved glucose tolerance by 23-47% 
(p<0.01) (Fig. 7.17C). Corresponding insulin secretory responses were observed in 
response to the glucose lowering effects observed by Abn-CBD combinational therapy 
with Sitagliptin (p<0.001) at 15 min, whilst Sitagliptin and Abn-CBD alone having no 
effect on insulin release (Fig. 7.17B). Abn-CBD in combination with Sitagliptin 
demonstrated an additive insulin secretory response of 30% (p<0.01) (Fig. 7.17B, D). In 
addition, 21-day oral administration of Abn-CBD alone and Abn-CBD in combination 
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with Sitagliptin lowered blood glucose (p<0.05-p<0.01) following exogenous insulin 
injection, compared to non-treated HFF mice (Fig. 7.18A). Overall, using AOC data, HFF 
mice treated with Abn-CBD and Abn-CBD in combination with Sitagliptin demonstrated 
enhanced glucose lowering capabilities by 42-43% (p<0.05) upon insulin injection, whilst 
Sitagliptin alone had no effect (Fig. 7.18B).   
 
7.4.6: Chronic effect of once daily oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on DEXA measurements, lipid profile, 
plasma C-reactive protein and amylase activity 
Post 21-day oral administration, Sitagliptin, Abn-CBD alone and Abn-CBD in 
combination with Sitagliptin demonstrated reductions in bodyweight 11-18% (p<0.05-
p<0.01) in HFF-induced diabetic mice, as measured by DEXA analysis (Fig. 7.19A). HFF 
mice demonstrated increased fat mass by 32% (p<0.001), whilst administration of 
Sitagliptin, Abn-CBD alone and Abn-CBD in combination with Sitagliptin reduced fat 
mass by 14-22% (p<0.05) in HFF mice (Fig. 7.19B). No effects towards lean mass was 
observed in all groups (Fig. 7.19C).  DEXA analysis revealed that HFF mice 
demonstrated reduced total bone mineral content (p<0.05; Fig. 7.20A) and femur bone 
mineral content (p<0.05; Fig. 7.21A). Administration of Sitagliptin and Abn-CBD 
increased total bone mineral content by 12% (p<0.01) (Fig. 7.20A). When localised to 
the femur, Sitagliptin reduced bone mineral content (p<0.05), whilst Abn-CBD 
combinational therapy increased bone mineral content by 17% (p<0.01) (Fig. 7.21A). All 
groups had no effect on total bone mineral density nor femur bone mineral density (Fig. 
7.20B; 7.21B). 
Lipid profile analysis on terminal plasma revealed that HFF-induced diabetic mice 
exhibited increased triglycerides (p<0.001), total cholesterol (p<0.001) and LDL 
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cholesterol (p<0.001) concentrations, with no change in HDL cholesterol (Fig. 7.22, 
7.23). Administration of Sitagliptin, Abn-CBD alone and Abn-CBD in combination with 
Sitagliptin lowered triglycerides by 34-65% (p<0.001) and total cholesterol 
concentrations by 15-25% (p<0.001) (Fig. 7.22). Sitagliptin treated HFF mice 
demonstrated reduced HDL cholesterol (5%; p<0.05) and increased LDL cholesterol 
(17%; p<0.01). Abn-CBD alone demonstrated no effect towards HDL cholesterol, 
however, reduced LDL cholesterol by 15% (p<0.01). Abn-CBD in combination with 
Sitagliptin reduced HDL cholesterol by 7% (p<0.05), whilst having no effect on LDL 
cholesterol (Fig. 7.23).  
Mice subjected to a HFF diet displayed elevated plasma CRP concentrations by 37% 
(p<0.05), compared to lean control. Administration of Abn-CBD in combination with 
Sitagliptin reduced plasma CRP by 48% (p<0.05), whereas Abn-CBD and Sitagliptin 
alone had no effect (Fig. 7.24A). HFF mice demonstrated elevated plasma amylase 
activity by 18% (p<0.01), whilst administration of Sitagliptin and Abn-CBD in 
combination with Sitagliptin reduced amylase activity by 10-12% (p<0.05-p<0.01) (Fig. 
7.24B). 
 
7.4.7: Chronic effect of once daily oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on islet morphology  
Immunohistochemistry was utilised to examine insulin and glucagon expression in lean, 
HFF and treated mouse pancreatic islets (Fig. 7.25). HFF mice revealed increased islet 
size by 62% (p<0.001). Treatment with Abn-CBD alone increased islet size by 43% 
(p<0.05) whilst Abn-CBD in combination with Sitagliptin reduced islet size by 44% 
(p<0.01) (Fig. 7.26A). Mice subjected to a HFF diet demonstrated major islet 
abnormalities, including reduced insulin-positive beta cell percentage (p<0.05; 
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Fig.7.26B) and increased glucagon-positive alpha cell percentage (p<0.05; Fig.7.26D). 
However, complimentary to islet size, HFF mice demonstrated increased beta cell mass 
(p<0.05; Fig.7.26C) and alpha cell mass (p<0.01; Fig.7.26E). Administration of Abn-
CBD alone increased beta cell mass (p<0.001; Fig.7.26C) and alpha cell mass (p<0.01; 
Fig.7.26E). All treatment groups demonstrated no effects towards percentage beta and 
alpha cell area (Fig.7.26B, D).  
Administration on Abn-CBD in HFF mice increased beta cell proliferation by 3.5% 
(p<0.001), as assessed by Ki-67 immunohistochemistry (Fig 7.27). In addition, abundant 
expression of both GPR55 and insulin was demonstrated on islets from lean and HFF 
mice (Fig. 7.28), with areas of double-immunofluorescent staining between both GPR55 
and insulin observed (Fig. 7.28D, H).  
 
7.5: Discussion 
 
It has been estimated that 34% current FDA approved drugs are mediating through 
GPCRs, with characterisation and specific targeting of novel GPCRs revealing a 
promising approach for future drug discovery (Hauser et al. 2018). In particular, research 
has intensified on the potential pharmacological capabilities of novel endocannabinoid 
receptors in metabolic control, with the CB1 inverse agonist Rimonabant once used as an 
anti-obesity drug (Sam et al. 2011).  Recently, the novel endocannabinoid receptor 
GPR55 has been identified as a potential therapeutic target for the treatment of obesity 
and type 2 diabetes (Tuduri et al. 2017). Interestingly, pre-clinical studies have 
demonstrated GPR55 activation to omit insulinotropic and glucoregulatory effects in 
clonal beta cells, diabetic mice and human islets (McKillop et al. 2013, Liu et al. 2016). 
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However, further investigations are warranted to fully understand the functionality of 
GPR55 activation and evaluate its potential as a novel therapeutic target.  
The present study investigates the acute and chronic effects of GPR55 agonist 
monotherapy and combinational therapy with the DPP-IV inhibitor Sitagliptin in HFF-
induced diabetic obese mice. The acute metabolic actions of potent GPR55 agonists Abn-
CBD and AM251 on glucose excursion, insulin release, incretin release and DPP-IV 
activity were investigated. Oral administration of Abn-CBD and AM251 improved 
glucose tolerance and insulin secretion when administered in combination with glucose 
to HFF mice, revealing the glucoregulatory role of GPR55 activation in an obese insulin 
resistant model of type 2 diabetes. This compliments previous reports which 
demonstrated glucose lowering and insulinotropic actions of GPR55 agonists in multiple 
low dose streptozotocin-induced diabetic mice (McKillop et al. 2016). Cannabidiol 
(CBD) was employed to antagonise the GPR55 receptor and demonstrate agonist 
specificity in-vivo. In harmony with previous findings using GPR55 knockout cells 
generated by CRISPR/Cas9 gene editing (Chapter 5), the glucose lowering effect and 
insulinotropic response of Abn-CBD was abolished upon GPR55 antagonism, suggesting 
that the actions of Abn-CBD are GPR55-dependent in-vitro and in-vivo. Although the 
GPR55 antagonist abolished the insulinotropic response of AM251, an attenuated glucose 
lowering effect was still observed, suggesting that the actions of AM251 are only partly 
driven by GPR55 in the beta cell. 
Abundant GPR55 expression has been extensively reported in the intestines, with 
previous studies demonstrating its role in inflammatory responses and motility (Schicho 
& Storr 2012, Shore & Reggio 2015). The present study revealed, for the first time, that 
Abn-CBD and AM251 augments both GLP-1 and GIP secretion from enteroendocrine 
cells; greatly encouraging GPR55 as an anti-diabetic target. Upon the discovery of the 
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incretin secretory effect of GPR55 activation, the DPP-IV inhibitor Sitagliptin was 
administered in combination with Abn-CBD and AM251 to prolong the circulating half-
life of the incretin hormones (Drucker et al. 2007). As anticipated, the actions of 
Sitagliptin when administered alone or in combination with the GPR55 agonists abolished 
DPP-IV activity, whilst Abn-CBD and AM251 alone had no effect. When accompanied 
with DP-IV inhibition through Sitagliptin, Abn-CBD and AM251 demonstrated enhanced 
glucose lowering and insulinotropic capabilities, through GPR55- induced incretin 
release, supplemented with prolonged incretin action through DPP-IV inhibition. Abn-
CBD demonstrated the most potent glucoregulatory effects in combination with 
Sitagliptin. 
21-day oral administration Abn-CBD alone and in combination with Sitagliptin greatly 
improved glycaemic control and dyslipidaemia in HFF mice and surpassed the 
capabilities of Sitagliptin monotherapy. Abn-CBD based therapies demonstrated a range 
of anti-diabetic effects, including improvements towards glycaemic control, GSIS, 
bodyweight, insulin sensitivity, dyslipidaemia and islet architecture. Oral administration 
of Abn-CBD alone and in combination with Sitagliptin reduced bodyweight by 9% in the 
obese animal model, whilst terminal DEXA analysis also revealed reduced bodyweight 
and fat mass with all treatment groups. Interestingly, the CB1 endocannabinoid receptor 
shares structural similarities with GPR55 and has been previously shown to regulate 
bodyweight, thus clearly revealing the pivotal role of the endocannabinoid system in 
bodyweight management (Bergholm et al. 2013). With respect to glucose control, Abn-
CBD alone and in combination with Sitagliptin improved glucose control beyond the 
capabilities of Sitagliptin alone, clearly implicating the therapeutic efficacy of GPR55 
activation. In response to the glucose lowering effect, relative changes in plasma insulin 
concentrations were also observed, with Sitagliptin based therapies demonstrating the 
most potent insulinotropic effect. Sitagliptin alone and in combination with Abn-CBD 
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augmented pancreatic insulin content, whilst Abn-CBD alone had no effect, indicating 
the role of prolonged incretin action on insulin production. Correspondingly, Sitagliptin 
alone and in combination with Abn-CBD reduced circulating DPP-IV activity, 
complimenting previous findings (Drucker et al. 2007). 
Although marked reductions in bodyweight were demonstrated by Abn-CBD alone and 
in combination with Sitagliptin, no effects towards cumulative food intake nor cumulative 
energy intake were observed, thus indicating an alternative mechanism of weight loss 
which warrants further investigation. Interestingly, inverse agonism of the structurally 
related CB2 receptor has also been shown to reduce bodyweight in humans (Sam et al. 
2011). Post 21-day oral administration of Sitagliptin and Abn-CBD in combination with 
Sitagliptin improved glucose tolerance when subjected to an OGTT. Interestingly, Abn-
CBD combinational therapy (Sitagliptin) demonstrated the greatest insulin secretory 
effect in response to the glucose challenge, elucidating the beneficial effects of Abn-CBD 
combinational therapy (Sitagliptin) on the restoration of beta cell function.  In addition, 
Abn-CBD alone and in combination with Sitagliptin improved insulin sensitivity in HFF 
mice; a novel finding which may be partly driven by the anti-inflammatory properties 
associated with GPR55 activation (Stancic et al. 2015).  
Lipid profile analysis post 21-day treatment demonstrated that Abn-CBD, Sitagliptin and 
Abn-CBD in combination with Sitagliptin improved dyslipidaemia with marked 
reductions on plasma triglycerides and total cholesterol. Interestingly, Sitagliptin reduced 
HDL cholesterol and increased LDL cholesterol. In contrast, Abn-CBD alone attenuated 
LDL cholesterol and had no effect on HDL cholesterol, corresponding with previous 
studies, which demonstrate the cardioprotective effects of Abn-CBD in type 2 diabetes 
(Su & Vo 2007, Matouk et al. 2018). In addition, Abn-CBD in combination with 
Sitagliptin ameliorated plasma C-reactive protein concentrations; a biomarker that 
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correlates with CVD risk and cardiovascular health (Bahadursingh et al. 2009, Clearfield 
2005).  
Complimentary with previous studies (McKillop et al. 2013, Ruz‐Maldonado et al. 2018), 
expression analysis of GPR55 in lean and HFF islets revealed abundant regions of co-
localisation between GPR55 and insulin, which further implicates the importance of 
GPR55 in beta cell function. As anticipated, examination of islet architecture revealed 
that HFF mice demonstrated major islet abnormalities, including increased islet size and 
alpha percentage area with reduced percentage beta cell area. Interestingly, Abn-CBD 
greatly increased islet area, with further increases of beta and alpha cell mass observed. 
Previous studies have demonstrated the proliferative and anti-apoptotic effect of Abn-
CBD in beta cells, which is likely to account for the effects observed (Ruz‐Maldonado et 
al. 2018, Chapter 4). In harmony with this, Ki-67 staining revealed that Abn-CBD 
increased beta cell proliferation. Although normal islet architecture was restored, Abn-
CBD in combination with Sitagliptin greatly reduced islet area to non-diabetic islet 
specifications. Complimentary with enhanced GSIS post 21-day treatment and reduced 
plasma amylase activity, these findings suggest that Abn-CBD accompanied with DPP-
IV inhibition improves beta cell function and promotes islet cell regeneration.  
Collectively, the present study demonstrates that oral administration of GPR55 agonist 
monotherapy and combinational therapy with Sitagliptin emit potent glucoregulatory and 
anti-obesity properties in HFF diabetic mice. Biochemical analysis demonstrated that 
acute and chronic administration of GPR55 agonists regulate glucose homeostasis 
through both insulin and incretin secretion and through the restoration of islet 
morphology. In addition, long term administration of Abn-CBD improved bodyweight, 
dyslipidaemia and plasma CRP concentrations. Overall, revealing the efficacy of GPR55 
290 
 
as novel therapeutic target for the treatment of type 2 diabetes and obesity related 
disorders.
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Figure 7.1: Effect four-month high fat fed diet on glucose tolerance and insulin secretion in 18 h fasted Swiss TO mice.  
 
 
 
 
 
 
 
 
 
 
 
Swiss TO mice were subjected to a high fat fed (HFF) diet for four months to induce an insulin resistance and glucose intolerance. To confirm the diabetic 
phenotype of the model, animals were subjected to an oral glucose tolerance test (18 mmol/kg bw) with (A, C) glucose tolerance, (B, D) insulin secretory 
response and (E) bodyweight determined.  Results are the mean ± SEM (n=6). *p<0.05, **p<0.01, ***p<0.001 compared to glucose control. 
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Figure 7.2: Acute effect of Abn-CBD on plasma glucose in 18 h fasted high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of Abn-CBD on plasma glucose (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with Abn-CBD 
(0.1µmol/kg bw) and either the GPR55 antagonist CBD (0.1µmol/kg bw) or Sitagliptin 
(50 mg/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  *p<0.05, 
**p<0.01, ***p<0.001, compared to HFF glucose control. +p<0.05, compared to agonist 
alone. 
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Figure 7.3: Acute effect of Abn-CBD on plasma insulin in 18 h fasted high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Acute effect of Abn-CBD on plasma insulin (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with Abn-CBD 
(0.1µmol/kg bw) and either the GPR55 antagonist CBD (0.1 µmol/kg bw) or Sitagliptin 
(50 mg/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  ***p<0.001, 
*p<0.05, compared to HFF glucose control. 
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Figure 7.4: Acute effect of AM251 on plasma glucose in 18 h fasted high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Acute effect of AM251 on plasma glucose (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with AM251 (0.1 µmol/kg 
bw) and either the GPR55 antagonist CBD (0.1µmol/kg bw) or Sitagliptin (50 mg/kg bw) 
to HFF mice (n = 6). Values are presented as mean ± SEM.  *p<0.05, **p<0.01, 
***p<0.001, compared to HFF glucose control.  
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Figure 7.5: Acute effect of AM251 on plasma insulin in 18 h fasted high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effect of AM251 on plasma insulin (A) and respective AUC (B). Glucose (18 
mmol/kg bw) was administered orally alone or in combination with AM251 (0.1 µmol/kg 
bw) and either the GPR55 antagonist CBD (0.1µmol/kg bw) or Sitagliptin (50 mg/kg bw) 
to HFF mice (n = 6). Values are presented as mean ± SEM.  **p<0.01, ***p<0.001, 
compared to HFF glucose control. +++p<0.001, compared to agonist alone. 
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Figure 7.6: Acute effects of GPR55 agonists on total plasma GLP-1 in 18 h fasted 
high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acute effects of GPR55 agonists on total plasma GLP-1 (A) and respective AUC (B). 
Glucose (18 mmol/kg bw) was administered orally alone or in combination with GPR55 
agonists (0.1 µmol/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, ***p<0.001, compared to HFF glucose control.  
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Figure 7.7: Acute effects of GPR55 agonists on total plasma GIP in 18 h fasted high 
fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GPR55 agonists on total plasma GIP (A) and respective AUC (B). 
Glucose (18 mmol/kg bw) was administered orally alone or in combination with GPR55 
agonists (0.1µmol/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01, compared to HFF glucose control.  
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Figure 7.8: Acute effects of GPR55 agonists and Sitagliptin on DPP-IV activity in 18 
h fasted high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute effects of GPR55 agonists on DPP-IV activity (A) and respective AUC (B). 
Glucose (18 mmol/kg bw) was administered orally alone or in combination with GPR55 
agonists (0.1 µmol/kg bw) to HFF mice (n = 6). Values are presented as mean ± SEM.  
*p<0.05, **p<0.01 ***p<0.001, compared to HFF glucose control.  
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Figure 7.9: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (sitagliptin) on bodyweight in high fat fed 
diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
  
  
   
 
 
 
  
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) bodyweight, 
(B) respective AUC and (C) percentage weight change. Bodyweight measurements were 
obtained before and during Abn-CBD (0.1 µmol/kg bw) and Sitagliptin (50 mg/kg bw) 
therapies (indicated by the black bar). Values are presented as mean ± SEM (n = 8).  
*p<0.05, **p<0.01, compared to HFF control.  
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Figure 7.10: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (Sitagliptin) for 21 days on plasma glucose 
in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
 
 
  
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) plasma 
glucose and (B) respective AUC. Parameters were obtained before and during Abn-CBD 
(0.1 µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). 
Values are presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared 
to HFF control. +p<0.05, compared to Abn-CBD alone. 
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Figure 7.11: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (Sitagliptin) for 21 days on plasma insulin 
concentrations in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
   
  
 
  
 
 
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) plasma 
insulin, (B) respective AUC and (C) pancreatic insulin content. Parameters were obtained 
before and during Abn-CBD (0.1 µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies 
(indicated by the black bar). Insulin content was determined after 21-day treatment. 
Values are presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared 
to HFF control. +p<0.05, +++p<0.001, compared to Abn-CBD alone. 
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Figure 7.12: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (Sitagliptin) for 21 days on circulating 
total-GLP-1 in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
   
  
   
  
  
  
 
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) total-GLP-
1 and (B) respective AUC. Parameters were obtained before and during Abn-CBD (0.1 
µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies. Values are presented as mean ± 
SEM (n = 6). *p<0.05, **p<0.01, compared to HFF control. 
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Figure 7.13: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (Sitagliptin) for 21 days on circulating 
total-GIP in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
   
  
  
  
  
  
 
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) total-GIP 
and (B) respective AUC. Parameters were obtained before and during Abn-CBD (0.1 
µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies. Values are presented as mean ± 
SEM (n = 6). *p<0.05, compared to HFF control. 
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Figure 7.14: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (Sitagliptin) for 21 days on DPP-IV 
activity in high fat fed-induced diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
   
  
 
  
  
 
  
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) DPP-IV 
activity and (B) respective AUC. Parameters were obtained before and during Abn-CBD 
(0.1 µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). 
Values are presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, compared to HFF 
control. +p<0.05, compared to Abn-CBD alone. 
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Figure 7.15: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (Sitagliptin) for 21 days on food intake in 
high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
   
  
 
  
 
 
  
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) food intake 
and (B) respective AUC. Parameters were obtained before and during Abn-CBD 
(0.1µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). 
Values are presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared 
to HFF control. +p<0.05, compared to Abn-CBD alone. 
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Figure 7.16: Chronic effect of once daily oral administration of Abn-CBD 
monotherapy and combinational therapy (Sitagliptin) for 21 days on cumulative 
food and energy intake in high fat fed diabetic mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
 
 
  
Chronic effect of Abn-CBD alone and in combination with Sitagliptin on (A) food intake 
and (B) energy intake. Parameters were obtained before and during Abn-CBD (0.1 
µmol/kg bw) and Sitagliptin (50 mg/kg bw) therapies (indicated by the black bar). Values 
are presented as mean ± SEM (n = 8).  *p<0.05, **p<0.01, ***p<0.001, compared to HFF 
control. +p<0.05, compared to Abn-CBD alone. 
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Figure 7.17: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on glucose tolerance and insulin secretion 
in high fat fed diabetic mice. 
  
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
Oral glucose tolerance test (18 mmol/kg bw) was conducted on HFF mice following 21-
day treatment with Abn-CBD (0.1µmol/kg bw) and/or Sitagliptin (50 mg/kg bw). (A, C) 
Plasma glucose and (B, D) plasma insulin were determined. Results are mean ± SEM 
(n=6).  *p<0.05, **p<0.01, ***p<0.001, compared to HFF glucose control. ++p<0.01, 
+++p<0.001, compared to Abn-CBD alone. 
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Figure 7.18: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on insulin sensitivity in high fat fed diabetic 
mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Insulin sensitivity (40U/kg bodyweight; dissolved in 0.9% saline, i.p. injection) test was 
conducted following 21-day treatment with Abn-CBD alone (0.1 µmol/kg bw) or in 
combination with Sitagliptin (50 mg/kg bw) to HFF diabetic mice. (A) Blood glucose and 
(B) respective AOC are shown. Results are mean ± SEM (n=8).  *p<0.05, **p<0.01, 
compared to HFF control. +p<0.05, compared to Abn-CBD alone. 
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Figure 7.19: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on bodyweight, fat mass and lean mass as 
measured by DEXA in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of Abn-CBD (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) bodyweight, (B) fat mass and (C) lean 
mass in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).  *p<0.05, 
**p<0.01, ***p<0.001, compared to HFF control. +p<0.05, compared to Abn-CBD 
alone. 
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Figure 7.20: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on total bone mineral content and bone 
mineral density as measured by DEXA in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of Abn-CBD (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) bone mineral content, (B) bone 
mineral density in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).  
*p<0.05, **p<0.01, compared to HFF control.  
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Figure 7.21: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on total bone mineral content and bone 
mineral density as measured by DEXA in the femur of high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of Abn-CBD (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) bone mineral content, (B) bone 
mineral density in the femur of HFF diabetic mice. Values are presented as mean ± SEM 
(n = 8).  *p<0.05, **p<0.01, compared to HFF control. +p<0.05, +++p<0.001, compared 
to Abn-CBD alone. 
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Figure 7.22: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on plasma triglycerides and total 
cholesterol in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of Abn-CBD (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on (A) plasma triglyceride, (B) total 
cholesterol in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).   
***p<0.001, compared to HFF control. +++p<0.001, compared to Abn-CBD alone. 
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Figure 7.23: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on plasma HDL cholesterol and LDL 
cholesterol in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of Abn-CBD (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on plasma (A) triglycerides and (B) total 
cholesterol in HFF diabetic mice. Values are presented as mean ± SEM (n = 8).  *p<0.05, 
**p<0.01, ***p<0.001, compared to HFF control. +p<0.05, ++p<0.01, +++p<0.001, 
compared to Abn-CBD alone. 
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Figure 7.24: Chronic effect of 21-day oral administration of Abn-CBD monotherapy 
and combinational therapy (Sitagliptin) on plasma C-reactive protein and amylase 
activity in high fat fed diabetic mice.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Chronic effect of 21-day oral administration of Abn-CBD (0.1 µmol/kg bw) alone and in 
combination with Sitagliptin (50 mg/kg bw) on plasma (A) C-reactive protein and (B) 
amylase activity in HFF diabetic mice. Values are presented as mean ± SEM (n = 6).  
*p<0.05, **p<0.01, compared to HFF control.  
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Figure 7.25: Distribution of islet insulin and glucagon, following 21-day oral administration of Abn-CBD monotherapy and combinational 
therapy (Sitagliptin) in high fat fed-induced diabetic mice.  
 
  
 
 
 
 
 
 
Representative images for distribution of DAPI (blue), insulin (red) and glucagon (green) in pancreatic islets of HFF mice at x40 magnification, following 
21-day treatment of (A-D) lean control, (E-H) HFF, (I-L) Sitagliptin, (M-P) Abn-CBD and (Q-T) Abn-CBD + Sitagliptin. 
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Figure 7.26: Effect of 21-day oral administration of Abn-CBD monotherapy and 
combinational therapy (Sitagliptin) on islet morphology in high fat fed diabetic mice.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohistochemistry analysis demonstrating the effect of Abn-CBD monotherapy and 
combinational therapy (Sitagliptin) on (A) islet size, (B) beta cell area, (C) beta cell mass, 
(D) alpha cell area and (E) alpha cell mass in HFF mice.  Values are mean ± SEM (n = 
8), with 30 islets per group.  *p<0.05, **p<0.01, ***p<0.001, compared to HFF. +p<0.05, 
+++p<0.001, compared to Abn-CBD alone. (Representative images as per Figure 7.25) 
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Figure 7.27: Effect of 21-day oral administration of Abn-CBD on beta cell 
proliferation (Ki-67) in high fat fed diabetic mice. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative images for DAPI (blue), insulin (green) and Ki-67 (red) in pancreatic islets 
of HFF mice at x40 magnification, following 21-day treatment with (A-D) HFF control 
and (E-H) Abn-CBD. Values are mean ± SEM (n = 8), with 50 islets per group.  
***p<0.001, compared to HFF. Positive Ki-67 staining indicated by arrows. 
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Figure 7.28: Distribution of GPR55 and insulin in pancreatic islets from lean and 
HFF mice. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohistochemistry demonstrating the distribution of DAPI (blue), GPR55 (green) 
and insulin (red) in HFF (A-D) and lean (E-H) pancreatic islets at x40 magnification. 
Areas of double immunofluorescent staining indicated by white arrows. Images are 
representative of several tissue sections. 
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8.1: Limitations of current anti-diabetic therapeutics 
 
The primary objective for all anti-diabetic therapies is to maintain glucose homeostasis 
whilst attenuating micro- and macro-vascular complications correlated with the disease 
(Lebovitz 2011). First line treatments routinely fail to maintain glycaemic control with 
long-term patient response rates declining over time; warranting combinational 
therapeutic approaches to retain normoglycemia (Turner et al. 1999, Cahn & Cefalu 
2016). Moreover, current therapies overlook chronic complications of diabetes including 
obesity, CVD risk and kidney disease (Molenaar et al. 2008, Trudeau & Gilbert 2018). 
According to ADA/EASD guidelines, metformin monotherapy is the current first line of 
treatment; however, 20-30% of patients have reported adverse effects with this approach, 
including gastrointestinal tract discomfort, nausea and vomiting (American Diabetes 
Association 2015, Schommers et al. 2017). In addition, second line therapeutics such as 
sulphonylureas, meglitinides and TZDs have been shown to favour weight gain, 
hypoglycaemia, increase ischemic complications and accelerate beta cell exhaustion (Del 
Prato & Pulizzi 2006, Chaudhury et al. 2017).  
The pathophysiology of type 2 diabetes is a multifactorial process that involves numerous 
organs in the body, whilst many current therapies exploit single glucoregulatory 
responses, such as insulin secretion, insulin resistance or hepatic glucose production 
(Bailey 2000). Moreover, current oral therapies fail to counteract reduced beta cell mass 
and impaired beta cell function, ultimately leading to beta cell exhaustion and poor 
disease prognosis (Cernea & Raz 2011). In recent years, incretin mimetics with increased 
plasma stability and DPP-IV inhibitors have been identified as promising classes of anti-
diabetic drugs due to their ability to maintain glucose homeostasis and enhance beta cell 
proliferation (Siddigui 2009, Vanderheiden et al. 2016). Incretin-based therapies omit the 
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risk of hypoglycaemia and have been shown to display a range of additional beneficial 
effects towards cognitive function and cardio-protection (Groeneveld et al. 2016). 
 
8.2: GPCR targeting therapeutics 
 
It has been estimated that 108 independent GPCRs are the primary target of 475 FDA 
approved drugs, accounting for approximately 34% of all drugs (Hauser et al. 2017). 
However, it has been estimated that around 700 FDA approved drugs stimulate GPCR 
activation (Sriram & Insel 2018). Reports conclude that 321 GPCR ligands are 
undergoing clinical trials, whilst 66 (20%) of these agents are targeting novel GPCRs 
with no pre-approved drug (Hauser et al. 2017). Subsequently, the number of biological 
drugs, selective agonists and allosteric modulators have increased (Hauser et al. 2017). 
Disease indications for GPCR agonist therapies have primarily shifted towards obesity, 
diabetes, Alzheimer’s disease and other neurological disorders (Hauser et al. 2017, 
Sriram & Insel 2018).  Currently, 56% (224) of non-olfactory GPCRs have not yet been 
explored in clinical trials and present untapped therapeutic potential for the treatment of 
metabolic, genetic and immune system disorders (Hauser et al. 2017, Sriram & Insel 
2018). 
Non-olfactory GPCRs (e.g.  incretin, cannabinoid and free fatty acid receptors) have 
presented therapeutic interest due to their regulation by a diverse range of ligands 
including peptides, fatty acids and monatomic ions (Reimann & Gribble 2016). With 
respect to obesity and type 2 diabetes, research has intensified on the exploitation of 
incretin receptors (GLP-1, GIP) due to the effectiveness of the endogenous incretin 
hormones on glucose homeostasis, bodyweight management and islet cell regeneration 
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(Siddigui 2009, Vanderheiden et al. 2016). The incretin GPCRs are expressed in the gut-
brain-pancreatic axis and are key regulators of postprandial metabolism and food intake 
(Reimann & Gribble 2016). GLP-1 mimetics liraglutide and exenatide are current 
pharmaceuticals that act through incretin GPCRs, whilst once weekly GLP-1 mimetics 
(e.g. Semaglutide) have also become available (Madsbad 2009, Andreadis et al. 2018). 
Interestingly, pre-clinical trials using hybrid peptides that simultaneously target multiple 
glucoregulatory GPCRs have shown promise in diabetic animal models (Gault et al. 
2013). 
Aside from peptide hormones, fatty acid receptors have been shown to play a pivotal role 
in lipid and glucose homeostasis with recent studies revealing GPCR-dependent effects 
on islet and enteroendocrine cell secretions (McKillop et al. 2013, Moran et al. 2014, 
Moran et al. 2016) (Table 8.1). Moreover, several fatty acid ligands have undertaken 
clinical trials for metabolic, inflammatory and immune system disorders. GPR40 
(FFAR1) is a long chain fatty acid sensing receptor that has shown promise for the 
treatment of type 2 diabetes with Fasiglifam (TAK875) passing both stage I and stage II 
clinical trials (Marcinak et al. 2017). Although Fasiglifam demonstrated effective 
glucose-dependent insulinotropic responses surpassing the capabilities of the current 
sulphonylurea Glimepiride, stage III trials proved unsuccessful due to signs of 
hepatotoxicity (Marcinak et al. 2017).   
In addition, the long chain fatty acid sensing cannabinoid receptor GPR119 has been 
shown to act as a lipid biosensor and modulates both lipid and glucose homeostasis 
(Moran et al. 2014, Reimann & Gribble 2016, Ritter et al. 2016). Several GPR119 
agonists have progressed into clinical trials for the treatment of type 2 diabetes (Reimann 
& Gribble 2016, Ritter et al. 2016). BMS-903452 (Bristol-Myers Squibb) and ZYG-19 
(Zydus Cadila) have successfully completed phase I clinical trials with MBX-2982 
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(Metabolex) also completing phase II clinical trials and exhibiting potent anti-diabetic 
effects towards glycaemic control and weight loss (Ritter et al. 2016). Although, GPR119 
agonists have yet to reach stage III clinical trials, results from early studies reveal the 
therapeutic potential of novel endocannabinoid GPCRs, including GPR55 and GPR18.  
Cannabinoid (GPR55, GPR119) and free fatty acid (GPR40, GPR41, GPR43, GPR120) 
receptors are abundantly expressed in the pancreatic beta cells and enteroendocrine L-, 
K- and I-cells of the gut, with effects towards insulin, GLP-1, GIP, CCK, leptin and PYY 
release stimulated upon activation (Moran et al. 2016). Pre-clinical studies using clonal 
beta cells and diabetic mice have demonstrated the effects of fatty acid agonists towards 
islet cell proliferation and the regeneration of beta cell mass (McKillop et al.2016, Ruz-
Maldonado et al. 2018). Although many GPCRs have been previously shown to regulate 
glycaemic control (Reimann & Gribble 2016), GPR55 and GPR120 have been identified 
with promising anti-diabetic potential (McKillop et al. 2013, Moran et al. 2014). GPR55 
and GPR120 are both abundantly expressed in islet and enteroendocrine cells and 
stimulate insulin secretion upon activation (Moran et al. 2016). The known anti-
inflammatory effects (Oh et al. 2014, Stancic et al. 2015) accompanied with hypothesised 
involvement on incretin release (Martin et al. 2012, Tuduri et al. 2017) warrants further 
investigation into the glucoregulatory role and therapeutic efficacy of GPR55 and 
GPR120. 
 
8.3: Activation of GPR120 in pancreatic islets 
 
In chapter 3, the antidiabetic potential of GPR120 activation with respect to islet cell 
function was assessed by utilising a range of endogenous (ALA, DHA, EPA) and 
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synthetic (GW9508, Compound A, GSK137647) agonists (Fig. 8.1). Previously, GPR120 
expression was determined in both pancreatic islets and clonal beta cells (Moran et al. 
2014). The insulinotropic actions of the endogenous omega-3 fatty acids have been well 
documented using rodent models, however interspecies variation and involvement of 
GPR40 may have also contributed to the effects observed (Houthuijzen 2016). The 
present study compared the potency of the endogenous and synthetically-derived 
selective GPR120 agonists. Insulinotropic responses were observed in BRIN-BD11 cells 
to the endogenous ligands, with ALA emitting the most potent effect. Although less 
potent than ALA, recently developed selective agonists (Compound A, GSK137647) 
augmented insulin release with effects abolished upon simultaneous GPR120 antagonism. 
ALA was the most potent agonist tested with the degradation profile of ALA possibly 
contributing to the effects observed (Kaur et al. 2014). Upon cleavage by delta-6 
desaturase, ALA is broken down to form DHA and EPA which are other GPR120 agonists 
that may synergistically agonise GPR120 (Kaur et al. 2014). The insulinotropic effect 
observed using rodent BRIN-BD11 cells was replicated on human 1.1B4 cells, ruling out 
interspecies variation, particularly as minor structural differences exist between rodent 
and human GPR120.  
Literature has documented that GPR120 activation is coupled with Gαq downstream 
receptor signalling which utilises PLCβ and IP3 secondary messenger pathways, however, 
conflicting studies have also indicated the involvement of cAMP in beta cells (Moran et 
al. 2014, Stone et al. 2014,). Understanding the downstream signalling mechanism of 
GPR120 in the beta cell is essential to evaluate the efficacy of GPR120 targeting 
therapeutics. The present study revealed that intracellular calcium modulation was the 
primary mechanism of insulin release upon GPR120 activation, whilst the response was 
abolished upon IP3
 receptor blocking, further eliciting PLCβ and IP3 signalling. The other 
arm of PLCβ signalling was subsequently investigated and for the first time, the present 
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study revealed that GPR120 induces ERK1/2 phosphorylation in beta cells; a key MAPK 
phosphoprotein that regulates insulin synthesis and beta cell proliferation (Lawrence et 
al. 2008, Stewart et al. 2015).  
Many current therapies fail to counteract reduced beta cell mass and enhanced alpha cell 
area in type 2 diabetic islets (Siddigui 2009, Sabir et al. 2018). The present study 
demonstrated that GPR120 activation induces beta cell proliferation and alpha cell 
apoptosis, thus indicating the beneficial effects of GPR120 in beta cell regeneration. 
Moreover, both GPR120 and insulin expression were upregulated in hyperglycaemia 
upon agonist treatment. Previous findings reported that GPR120 downregulation in type 
2 diabetes contributes to the onset of high fat diet complications, including weight gain 
and hyperglycaemia (Ichimura et al. 2012).  Chapter 3 demonstrated that GPR120 
expression is glucose-dependent and is upregulated upon agonist treatment; a property of 
the receptor that may be exploited by future GPR120-targeting therapeutics. Overall, 
GPR120 activation augments insulin biosynthesis, insulin release and islet cell 
regeneration. 
  
8.4: Activation of GPR55 in pancreatic islets 
 
This research study investigated the effect of GPR55 activation on islet cell function using 
a range of endogenous (OEA, PEA) and synthetic (Abn-CBD, AM251, O-1602) agonists 
(Chapter 4; Fig. 8.1). Studies have demonstrated the expression of GPR55 in rodent and 
human islets with abundant expression in beta cells (McKillop et al. 2013, Ruz-
Maldonado et al. 2018). Interestingly, GPR55 is lowly expressed in human alpha cells 
with some studies implicating that it is null expressed in rodent alpha cells (McKillop et 
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al. 2013). Complimentary with previous reports, the present study demonstrated the 
insulinotropic effects of endogenous and synthetic GPR55 agonists in rodent beta cells 
(McKillop et al. 2013). This response was retained when assessed using human 1.1B4 
cells, validating the use of rodent models for assessment of GPR55 function.  
Upon activation, GPR55 couples to both Gαq and Gα12/13 subunits (Shi et al. 2017). 
Initial studies have suggested that GPR55 is primarily driven by intracellular Ca2+ 
modulation, therefore, downstream PLCβ signalling mechanisms were assessed in this 
study (McKillop et al. 2013). As anticipated, GPR55 activation increased intracellular 
Ca2+ levels and had no effect on cAMP, ruling out GPR119 agonism which couples to Gs 
and modulates adenylyl cyclase signalling (Hassing et al. 2016). Investigating the 
diacylglycerol (DAG) branch of PLCβ signalling revealed that GPR55 activation 
attenuates the phosphorylation of apoptotic MAPK signalling (JNK, p38) (Hou et al. 
2008, Zhou et al. 2014). Interestingly, previous studies have demonstrated 
cardioprotective effects of Abn-CBD mediated by ERK1/2 signalling in other cell types 
(Su & Vo 2007, Matouk et al. 2017, Matouk et al. 2018), however, the present study in 
beta cells have indicated that only JNK and P38 are regulated by Abn-CBD treatment. 
Moreover, GPR55 activation enhanced beta cell proliferation, increased insulin 
biosynthesis and reduced beta cell apoptosis, with opposing effects demonstrated in alpha 
cells, thus revealing the effects of GPR55 in beta cell regeneration.  
Previous findings demonstrated that Abn-CBD augments beta cell proliferation in a 
GPR55-dependent manner, however, the mechanism of action remains unclear (Ruz-
Maldonado et al. 2018). These studies suggest that intracellular Ca2+, JNK and p38 
signalling downstream of GPR55 activation may be key modulators in beta cell 
regeneration and insulin release. These proliferative effects accompanied with 
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insulinotropic and glucose-lowering actions present GPR55 as a promising therapeutic 
target for type 2 diabetes. 
 
8.5: Specificity of putative GPR120 and GPR55 agonists in islets 
 
Currently, the specificity of GPR120 and GPR55 agonists remains poorly understood 
(Moran et al. 2016, Tuduri et al. 2017, Ruz-Maldonado et al. 2018). Long chain fatty acid 
sensing GPR40 and GPR120 share similar sequence homology and can be activated by 
similar ligands (Yonezawa et al. 2013). Whereas, GPR55 shares structural similarities 
with other cannabinoid receptors (e.g. GPR119 and GPR18) and can be activated by the 
same endocannabinoid ligands (Fine & Rosenfeld 2013, Irving et al. 2017). Many studies 
have used antagonists to assess agonist specificity, however, adverse antagonist 
bioactivity and selectivity may influence findings. In addition, studies using knockout 
mice typically incorporate multiple cells types which can lead to induction of 
complimentary compensatory pathways (Barbaric et al. 2007). Chapter 5 involves the 
development of two independent (GPR120 and GPR55) knockout beta cell lines using 
revolutionary CRISPR/Cas9 gene editing. The major advantage of CRISPR/Cas9 is its 
ability to generate complete gene knockout rather than gene knockdown, which enables 
absolute characterisation of a given gene (Ran et al. 2013, Boettcher & McManus 2015). 
Insulin secretory analysis using both wild type and GPR120 knockout cells revealed that 
ALA was completely GPR120-dependent whilst DHA, Compound A and GSK137647 
were only GPR120-dependent at normal physiological concentrations (10-6 M). 
Complimentary studies utilising GPR120 knockout mice concluded that DHA-induced 
glucagon release from islets is driven by GPR120, whilst other studies revealed that ALA-
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induced GLP-1 release is GPR120-dependent (Martin et al. 2012, Suckow et al. 2014). 
As anticipated, the effect of dual-agonist GW9508 was substantially impaired, in support 
of previous evidence demonstrating the pharmacology of this agonist (Briscoe et al. 
2006). Moreover, EPA was shown to be GPR120-independent and suggests involvement 
of another free fatty acid receptor, such as GPR40 (Yonezawa et al. 2013).  Gαq signalling 
downstream of GPR120 activation resulting in intracellular Ca2+ modulation was then 
assessed in both wild type and GPR120 knockout cells. In harmony with insulin secretory 
analysis, ALA, GSK137647 and Compound A demonstrated GPR120-dependent effects 
on intracellular Ca2+ production, which implicates that these long chain fatty acid agonists 
are acting through GPR120.  
Upon assessment of GPR55 agonists on insulin release and intracellular Ca2+ production 
from both wild type and GPR55 knockout cells, it was revealed that Abn-CBD, AM251, 
PEA and O-1602 were partly driven by GPR55. Thus, corresponding with previous 
research utilising the GPR55 antagonist (Cannabidiol) (McKillop et al. 2013). 
Contrastingly, OEA-induced insulin release was independent of GPR55. No changes in 
cAMP production were observed in wild type or knockout cells, suggesting that GPR55 
signalling is primarily modulated through Gαq activation and release of Ca2+ from 
intracellular stores (Putney & Tomita 2012). However, Gα12/13 activation may also 
contribute to the actions of GPR55 and warrants further investigation (Shi et al. 2017). 
Evaluation of the specificity of agonists is essential to characterise the biological function 
of a given GPCR. Overall, the present study identified ALA (GPR120) and Abn-CBD 
(GPR55) as the most potent and receptor-specific modulators of insulin release. 
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8.6: Biological effect of GPR55/GPR120 agonist monotherapy and combinational 
therapy 
 
The therapeutic efficacy of GPR55 and GPR120 activation in high fat fed-induced 
diabetic mice was investigated by examining the effect of several GPR55/GPR120 
agonists on glucose tolerance and glucoregulatory hormone release (Fig. 8.1). GPR120 
(ALA, GW9508, GSK137647, Compound A) and GPR55 (Abn-CBD, AM251) agonists 
improved glucose excursion and enhanced GSIS in glucose intolerant obese mice. 
Complimentary findings also previously reported acute glucose lowering and 
insulinotropic actions of GPR55 and GPR120 activation in lean mice (McKillop et al. 
2013, Moran et al. 2014).  Previous studies have demonstrated abundant GPR55 and 
GPR120 expression in enteroendocrine cells of the gut with other studies showing 
GPR120 to modulate GLP-1 release (Martin et al. 2012, Simcocks et al. 2014).  The 
present study revealed for the first time that GPR55 and GPR120 activation induces both 
GLP-1 and GIP secretion in high fat fed mice. Moreover, the glucose lowering and 
insulinotropic effects observed were enhanced in combination with DPP-IV inhibition 
(Sitagliptin), with Abn-CBD (GPR55) and ALA (GPR120) emitting the most potent 
effects. In accordance with this, previous GPCR agonist combinational studies have also 
shown promising anti-diabetic effects such as the GPR40 agonist (AS-2575959), which 
enhanced insulin and GLP-1 concentrations when in combination with Sitagliptin 
(Tanaka et al. 2014). 
Chronic oral administration of Abn-CBD and ALA for 21 days improved glucose 
homeostasis and dyslipidaemia in high fat fed mice. Biological effects included decreased 
non-fasting glucose, bodyweight and DPP-IV activity accompanied with enhanced non-
fasting insulin and insulin sensitivity. In support of these findings, previous studies also 
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demonstrated the glucoregulatory effects of Abn-CBD using streptozotocin-induced 
diabetic mice and potentiation of GSIS by ALA in lean mice (Moran et al. 2014, 
McKillop et al. 2016).   
Following 21-day treatment, both Abn-CBD and ALA based therapies substantially 
reduced bodyweight in the obese mouse model, whilst LDL cholesterol, triglycerides and 
CRP concentrations were greatly improved. Thus, revealing anti-obesity and 
cardioprotective effects that may be partly driven by anti-inflammatory responses linked 
with fatty acid GPCR activation (Oh et al. 2014). Notably, Abn-CBD emitted the most 
potent effects towards weight loss, whilst ALA demonstrated the greatest improvement 
towards GSIS and glycaemic control; highlighting the prospective applications of GPR55 
and GPR120 targeting therapeutics.  
Treatment of ALA and Abn-CBD therapies restored pancreatic islet architecture in high 
fat fed-induced diabetic mice by enhancing beta cell proliferation and beta cell mass. The 
proliferative effects observed may be modulated indirectly of GPCR activation through 
incretin hormone secretion. Complimentary studies demonstrated the proliferative effect 
of Abn-CBD in murine islets to be GPR55-dependent (Ruz-Maldonado et al. 2018). 
Whilst both therapeutic approaches in the present study improved islet cell regeneration, 
Abn-CBD monotherapy induced a vast increase in islet size; a potential characteristic of 
GPR55 that may be exploited in novel pharmaceutical development. These studies 
suggest that GPR55 and GPR120 agonist monotherapy and combinational therapy with 
Sitagliptin are effective therapeutic approaches and may have future clinical applications 
for the treatment of type 2 diabetes and other obesity related diseases (Fig. 8.1). 
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8.7: Future studies 
 
GPR55 and GPR120 have been shown to regulate a range of physiological responses 
involved in the maintenance of glucose and lipid homeostasis and are presented as 
promising therapeutic targets. To build on the growing body of evidence that demonstrate 
the efficacy of GPR55- and GPR120-targerting agents, future studies are required to 
further explore the mechanistic function and specificity of GPCR agonist-based therapies. 
The use of GPCR knockout mice would greatly aid the investigation of agonist action in-
vivo. Moreover, GPCR knockout murine islets accompanied with already established 
clonal knockout cell lines (Chapter 5) could be utilised to further explore agonist 
specificity and compensatory pathways in response to GPCR ablation. Global receptor 
knockout mice could be used to evaluate the importance of GPR55 and GPR120 on 
energy metabolism, glucoregulatory hormone release and islet cell regeneration.  
Studies have revealed that GPR55 and GPR120 improved insulin sensitivity in HFF 
insulin resistant mice (Oh et al. 2014, Chapter 6, 7), which may be partly driven by the 
anti-inflammatory effects emitted by the agonists (Oh et al. 2014, Stancic et al. 2015). 
Whilst the insulinotropic properties of GPR55 and GPR120 are well documented 
(McKillop et al. 2013, Moran et al. 2014, Moran et al. 2016), agonist effects on insulin 
action remains poorly understood and may have major impact on the development of 
future GPCR-based therapies. Therefore, future studies could investigate the effects of 
GPCR agonism towards insulin sensitivity and glucose uptake using peripheral cell lines 
such 3T3 and c2c12. Moreover, effects towards insulin sensitivity could be further 
validated in-vivo using knockout animal models.  
Due to the known safety and previous clinical analysis of both endogenous omega-3 ALA 
and Sitagliptin, it would be interesting to implement a placebo-controlled crossover trial 
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in type 2 diabetic patients to assess the acute glucoregulatory effect of GPR120-targeting 
agents in humans. Moreover, it would be of interest to compare the effects observed with 
conventional therapies currently in use. As previous clinical trials with synthetic GPR40 
agonists have been conducted (Tanaka et al. 2014, Marcinak et al. 2017), it would also 
be of interest for pharmaceutical companies to consider a clinical trial that utilised a 
synthetic GPR120 agonist (e.g. GSK137647) based on the growing body of pre-clinical 
evidence supporting its therapeutic efficacy (Sparks et al. 2014, Chapter 6). Moreover, a 
clinical trial could be utilised to assess the biosynthesis and degradation of omega-3 fatty 
acids as they remain poorly understood in patients with type 2 diabetes. It would be of 
interest to assess the circulation and breakdown of omega-3 molecules in both healthy 
and type 2 diabetic patients. Initial biochemical assessment could investigate circulating 
ALA, DHA, EPA concentrations and other desaturase enzymes involved in their 
degradation. 
Collectively, the studies in the thesis demonstrate that both GPR55 and GPR120 play a 
key role in metabolic hormone release and glucose homeostasis. Similar to the effects of 
incretin mimetics and DPP-IV inhibitors, GPR55 and GPR120 agonist monotherapies and 
combinational therapies have potential to emerge as a leading therapeutic approach for 
the treatment of type 2 diabetes and other obesity related diseases.    
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Table 8.1: Summary of GPCRs located in intestinal and pancreatic endocrine cells 
that have been assessed in clinical trials for the treatment of type 2 diabetes. 
Receptor Natural ligands Target cell types/tissues Effect of GPCR agonism 
GLP1R GLP-1, oxyntomodulin Pancreatic beta and delta 
cells, brain, vagus nerve 
↑ insulin, ↓ glucagon, ↓ 
gastric emptying 
GIPR GIP Pancreatic alpha, beta and 
delta cells, adipose tissue 
↑ insulin, ↑ glucagon, ↑ fat 
storage 
GCGR Glucagon, oxyntomodulin Pancreatic beta cells, liver, 
adipose tissue, brain 
↑ insulin, ↑ energy 
expenditure, ↓ food intake 
GPR119 Oleoylethanolamide, 
monooleoylglycerol 
Enteroendocrine cells, 
pancreatic alpha and beta 
cells 
↑ GLP-1, ↑ GIP, ↑ insulin 
(possible ↑ glucagon) 
FFAR1 
(GPR40) 
Long-chain NEFA Enteroendocrine cells, 
pancreatic beta cells 
↑ GLP-1, ↑ GIP, ↑ insulin 
 
(Adapted from Reimann & Gribble 2016)  
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Figure 8.1: Therapeutic action of GPR55 and GPR120 monotherapy and combinational therapy (Sitagliptin) for the treatment of type 2 diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from Siddiqui 2009, Chapters 3-7) 
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